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Abstract 
 
 
The anti-CD20 monoclonal antibody, rituximab, has very significantly altered 
management and prognosis in patients with various B-cell malignancies, including 
follicular lymphoma.  However, some patients respond less well to rituximab or 
become resistant to it.  A better understanding of the mechanisms of action of 
rituximab in cancer patients and reasons for treatment failure could lead to optimal 
use of the drug and the design of more effective monoclonal antibodies in the 
future. 
 
It has been suggested that constitutional polymorphisms in immune effector 
mechanisms may explain some inter-individual differences in rituximab 
effectiveness.  Particularly, a polymorphism in the Fc receptor IIIA has been 
found in several small studies to be correlated with clinical response to rituximab.  
A large, multicentre trial in newly diagnosed, advanced stage but asymptomatic 
follicular lymphoma randomised patients to receive up-front rituximab 
monotherapy or to watchful waiting.  This cohort of patients provided an excellent 
opportunity to examine the possible effect of this, and other polymorphisms. 
 
Patient samples were tested by PCR and restriction enzyme digestion for this 
polymorphism in Fc receptor IIIA (FCGR3A-V158F), and linked with the cleaned 
clinical database.  Other constitutional polymorphisms in Fc receptors and the 
complement pathway have been suggested to play a role in rituximab response.  
Additional work determined polymorphism status for the same patient cohort for 
FCGR2A-H131R, FCGR2B-I232T, C1QA-Gly70GGG/GGA and C3-R102G.  In 
summary, there was no convincing evidence of a large effect of any of the 
polymorphisms studied.  In particular, the FCGR3A-158V allele, considered by 
many to predict rituximab response on the basis of in vitro work and small, 
published series, was found to have no effect in this larger study.  This has 
implications for future antibody design and usage, and interpretation of small 
pharmacogenetic response studies in general.   
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Introduction 
Follicular lymphoma 
Epidemiology 
Non-Hodgkin lymphoma (NHL) comprises a group of heterogeneous malignancies 
of lymphocyte origin with distinct clinicopathological features.  Various attempts at 
classification have been made in the past 5 decades; the World Health 
Organisation (WHO) classification published in 2001 and updated in 2008 has 
provided a reliable classification system, with around 50 subtypes of NHL 
identified.1   NHL can be broadly categorised as aggressive or indolent based on 
clinical features and rate of progression; 80-90% are of B-cell origin with T-cell and 
natural killer (NK) cell-derived tumours being less common.   
NHL is the 5th most common cancer in the UK with 12,793 people diagnosed in 
2011, representing 4% of all cancer diagnoses.2 Follicular NHL (FL) is the most 
common of the indolent lymphomas (although marginal zone lymphoma diagnoses 
have increased to similar levels) and the second most common type overall, 
representing 20-25% of NHL cases (the most common type being diffuse large B 
cell lymphoma (DLBCL)).2 There are geographical and racial variations with the 
highest incidence reported in Northern America, Australasia and Northern Europe, 
and the lowest in South-Eastern Asia.3 In the United States, the incidence of B-cell 
lymphomas is higher in whites than blacks.4 The incidence of FL increases with 
age with a median age at diagnosis of 59 years. Unlike most NHL subtypes, there 
is a slight female preponderance with a female to male ratio of between 1.1 and 
1.7:1.5,1 The cause and risk factors of FL are unclear, although environmental and 
occupational exposures, such as exposure to solvents and chemical, have been 
implicated in the aetiology of the disease. 
Histology and pathogenesis 
FL is a clonal proliferation of B cells of germinal centre origin.1  Morphologically, 
the normal lymph node architecture is replaced by a neoplastic infiltrate exhibiting 
a follicular or nodular pattern reminiscent of germinal centres.  FL can be graded 
histologically by the number of centroblasts and presence or absence of 
centrocytes.1 Grade 1 and 2 FL has less than 15 centroblasts per high power field. 
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Grade 3 FL has more than 15 centroblasts per high power field; while centrocytes 
are still present in FL 3A, FL 3B is entirely composed of centroblasts.  FL 3B is 
considered to be an aggressive lymphoma and patients are managed similarly to 
those with DLBCL.6 
FL typically expresses B-lineage antigens including CD20, germinal centre 
markers CD10 and bcl-6, and bcl-2.1 CD20 is a membrane-embedded, non-
glycosylated phosphoprotein, virtually specifically found on B-cells and expressed 
in the majority of B-cell lymphoproliferative disorders (figure 1).  It acts as a Ca2+-
permeable cation channel, involved in the regulation of B-cell activation, 
proliferation and differentiation.7 CD10 is a membrane-associated neutral 
endopeptidase expressed by a wide variety of normal human cells, including 
follicular centre cells. It is differentially expressed by neoplastic lymphocytes 
leading to its use in accurate lymphoma diagnosis.7 Bcl-6 (B-cell CLL/lymphoma 6) 
is a nuclear zinc finger transcription factor which functions as a transcriptional 
repressor and is necessary for germinal centre formation.7 It has been suggested 
that bcl-6 allows germinal centre B-cells to tolerate the physiologic DNA breaks 
required for immunoglobulin class switch recombination and somatic hyper-
mutation without inducing a p53-dependent apoptotic response, by suppressing 
p53 expression. Deregulated bcl-6 expression may contribute to 
lymphomagenesis, in part, by functional inactivation of p53.8 Bcl-2 (B-cell 
leukaemia/lymphoma 2) is part of a family of pro- and anti-apoptotic proteins 
governing the permeability of the outer mitochondrial membrane and the release 
of cytochrome c to the cytoplasm.9 Bcl-2 is an inhibitor of apoptosis expressed 
normally on rapidly dividing cells, including T-cells, pro-B cells and mature B-cells.  
Bcl-2 is down regulated in normal germinal centre B-cells (where apoptosis forms 
part of the developmental pathway in order to select only cells producing 
antibodies with high avidity) but over-expressed in NHL and various other cancers.   
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Figure 1: Schematic representation of a CD20 molecule. The larger of the two 
extracellular loops includes the rituximab-binding site. Figure from Cheson et al, 201010 
The chromosomal translocation t(14;18)(q32.3;q21.3) is present in a large majority 
of patients and can be viewed as the initial genetic hit in the pathogenesis of FL.11 
Juxtaposition of the BCL2 gene and the immunoglobulin heavy-chain (IgH) 
enhancer leads to deregulation of BCL2 and constitutive expression of the Bcl-2 
protein.  Bcl-2 over-expression alone is insufficient for FL development; t(14;18) 
has been detected at low levels in the peripheral blood of healthy individuals, the 
majority of which never develop overt follicular lymphoma.12 Bcl-2 expressing FL 
cells fail to undergo apoptosis in the germinal centres and, therefore, are more 
likely to accumulate secondary chromosomal alterations and complete neoplastic 
transformation.  The pathogenesis of t(14;18)-negative FL remains largely unclear. 
Natural history 
FL is generally held to be an indolent but incurable malignancy with an inexorable 
drop-off seen on survival curves and a median overall survival (OS) of 7-10 years.  
The natural history is extremely variable with some patients remaining well for 
many years with minimal therapeutic intervention and others experiencing rapid 
progression and death despite aggressive therapy.  Typically, patients relapse 
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after initial treatment but respond to further therapy, with recurrent progressions 
and progressively shorter remissions. Prior to the advent of rituximab, 
improvements in OS were already being seen in successive trials from the South 
West Oncology Group (SWOG), and in single-institution series, likely due to the 
availability of more therapeutic agents for treatment at relapse and improved 
supportive care (Figure 2).13,14,15  However, the anti-CD20 monoclonal antibody 
rituximab has revolutionised treatment in FL and other B-cell malignancies since 
the pivotal phase II study resulted, in 1997, in rituximab being the first FDA 
approved monoclonal antibody for the treatment of cancer.16  It is highly likely that 
further improvements in overall survival will be proven for those diagnosed in the 
rituximab era.   However, there is still no curative treatment for most patients, 
many questions remain about the optimum timing and combinations of therapies, 
and not every patient responds to rituximab. 
 
 
Figure 2: Overall survival in patients with advanced stage follicular lymphoma 
treated with multi-agent chemotherapy on South West Oncology Group (SWOG) 
trials in three different time periods.  Successive improvements are seen between 
patients treated with CHOP (1974-1983), ProMACE (1988-1994) and CHOP + rituximab 
(1998-2000). Graph from Fisher et al, 200513 
 
FL most commonly presents with painless lymphadenopathy, which may wax and 
wane and even enter spontaneous remission.  The majority of patients present 
with generalised adenopathy (stage III) and the bone marrow is involved (stage IV) 
in more than half, i.e. advanced stage disease.11 Systemic (“B”) symptoms (fever, 
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night sweats, weight loss in excess of 10%) are infrequent at presentation but can 
be observed in later stages of the disease. Some patients present due to bulky 
intra-abdominal nodes which may compress adjacent structures. Primary 
mediastinal involvement and isolated splenic enlargement are uncommon.   
Transformation to an aggressive lymphoma is associated with a poor outcome; the 
rate of transformation varies in different series but is around 3% per year.17 
 
Management 
There is a wide range of treatment options in FL, from expectant management to 
allogeneic stem cell transplantation.  Many chemotherapeutic and 
immunotherapeutic agents have efficacy in FL, which is also highly radio-sensitive. 
A curative treatment option is lacking, with the possible exception of allogeneic 
transplantation in a small minority of patients.  However, most patients live with the 
disease for years, some for decades.  Treatment therefore aims to maximise life 
expectancy whilst minimising treatment toxicity and optimising quality of life.  
There are many good quality published trials and yet many questions still remain 
about the optimum timing and combination of therapies.  As new agents become 
available, choice in management will likely further broaden. 
The choice of initial management is heavily dependent upon the clinical picture 
and patient co-morbidities and general health.  Prognostic markers provide useful 
information but thus far have limited value in guiding initial treatment choice. The 
Follicular Lymphoma International Prognostic Index (FLIPI) stratifies patients into 3 
groups with clearly different outcomes, based on the presence or absence of five 
adverse features: age 60 years or older, haemoglobin concentration less than120 
g/l, serum lactate dehydrogenase (LDH) above the upper limit of normal, stage III-
IV, and greater than four involved nodal areas.  The 5-year OS from the original 
publication prior to the availability of rituximab (retrospective data on patients 
diagnosed between 1985 and 1992) was 91%, 78% and 52%, in the low, 
intermediate and high-risk groups, respectively.18  Prognostic discrimination has 
been confirmed by a number of investigators in the rituximab era.19,20  More 
recently, the FLIPI2 was devised based on prospective data from patients treated 
in the rituximab era, combining the factors age, serum β2-microglobulin, 
haemoglobin concentration, bone marrow involvement and tumour burden.21  The 
low, intermediate and high-risk groups included 20%, 53% and 27% of patients 
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and had 5 year OS of 98%, 88% and 77%, respectively.  A group of patients with a 
very poor outcome, in whom more aggressive therapy might be warranted, cannot 
therefore be identified at diagnosis. 
Management of limited stage disease 
In the small proportion of patients presenting with limited stage disease (stage I 
and stage II with contiguous nodes), many consider radical radiotherapy to be the 
treatment of choice with the potential to cure around half the patients.22,23,24  The 
delivered dose of radiotherapy can be reduced to 24Gy from the previous standard 
30-40Gy without compromising long-term outcomes;25 in a recent trial comparing 
24Gy with 4Gy more events were observed in the low-dose arm and such a 
reduction cannot be recommended in the setting of potentially curable disease.26  
The general consensus is that radiation fields can be limited to involved nodes 
with modest extension.27  That said, observation alone might be suitable 
management and some series with careful patient selection suggest similar long-
term outcome to radiotherapy; information from randomised trials is lacking.28  
There are also advocates of combined-modality therapy but data is limited for 
these approaches.29  Patients with limited stage disease would, of course, be 
expected to respond to immunotherapy with rituximab but the long-term benefit is 
unknown.  The idea of combining radiation therapy with rituximab is attractive as 
radiotherapy at low doses has been shown to increase CD20 expression on B 
cells in vitro.30 
Management of advanced stage disease 
As the presentation and prognosis varies greatly for individual patients, so too do 
management options. A significant proportion of new patients are asymptomatic, 
having been diagnosed incidentally or following investigation of modest, 
untroublesome lymphadenopathy.  Expectant management (“watchful waiting”) 
has been employed in these patients with good long-term outcome; in a single-
institution study of patients diagnosed over three decades ago the reported 10 
year survival was 73%.31 Systemic therapy may still not be necessary in those with 
a single site of troublesome disease as radiotherapy can treat these areas very 
effectively, although not with curative intent in the setting of advanced disease. 
Initial watchful waiting has been cemented as the standard of care in newly 
diagnosed, asymptomatic patients with low-bulk disease by three randomised 
Introduction 
 16 
trials comparing this approach with immediate chemotherapy with, respectively, 
single-agent chlorambucil, predimustine or interferon, and aggressive combined 
modality therapy.32,33,34   No difference was found in overall survival and patients 
were able to delay the initiation of therapy (with its attendant toxicities) by an 
average of 2-3 years (figure 3).  Indeed, in the BNLI study, 19% had neither died 
of lymphoma nor required chemotherapy for it at 10 years, rising to 40% for those 
diagnosed aged 70 or more.32  With the advent of rituximab with its favourable 
toxicity profile, this question is being re-addressed and forms the basis of the trial 
from which the samples were obtained for this study (see page 51).  Patients were 
managed with watchful waiting alone or with up-front single-agent rituximab; 
preliminary results have been presented showing a significant increase in 
progression free survival (PFS) and time to next treatment (TTNT) for those 
receiving rituximab.35  Longer-term effects on responses to further lines of therapy 
and OS are not yet known and thus watchful waiting remains standard 
management, although early quality of life data may support the initial use of 
rituximab36 and it is a reasonable treatment option.   
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Figure 3:  Overall survival in 309 patients with advanced stage, asymptomatic 
follicular lymphoma. Patients were treated on a randomised British National Lymphoma 
Investigation trial comparing initial observation (“watchful waiting”) with immediate 
systemic therapy with oral chlorambucil and overall survival was virtually identical. Graph 
from Ardeshna et al, 200332 
 
When treatment is required for advanced disease, the choice of approaches is 
wide, from single-agent regimens to combination immunochemotherapy, with the 
option of maintenance or consolidation therapy and the potential for autologous or 
allogeneic stem cell transplantation. There is good evidence that the initial regimen 
should include rituximab; several large randomised trials have shown significant 
improvements in response rates, PFS and, of great importance, OS using R-
chemotherapy compared with chemotherapy alone.37,38  However, there is no gold 
standard chemotherapeutic regimen to combine with rituximab.  Whilst differences 
may exist in response and PFS there is no evidence of improved OS for any first-
line therapy.   Patients are likely to require multiple lines of therapy over the course 
of their disease and therefore, ultimately, receive many different agents.  In the 
UK, R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone) or R-CHOP 
(R-CVP plus doxorubicin) are often viewed as standard first-line therapy.  Prior to 
the advent of rituximab, there was no evidence that the use of intensive 
anthracycline-containing combination chemotherapy regimens conferred a survival 
advantage over single-agent alkylators.39  In recent trials of immunochemotherapy 
there is a suggestion that patients who received anthracyclines had better PFS 
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than those who did not; however, this has not yet been compared in a randomised 
fashion.37,38   Improvements in response must be balanced again the increased 
toxicity seen with anthracyclines as well as the inability to use them at a 
subsequent stage in the disease, such as at a time of high-grade transformation.  
Other first-line options include R-bendamustine, which has been shown to be 
highly effective with a more favourable side-effect profile than R-CHOP.40  
Fludarabine alone or in combination has achieved excellent results41 but is 
associated with increased risks of opportunistic infection and may impede 
mobilisation of stem cells for autologous transplantation at a later date.  Rituximab 
monotherapy and the anti-CD20 radiolabelled monoclonal antibody 131I 
tositumomab (Bexxar) have been used as single agents in phase II trials with 
promising results.42,43   
It is possible to prolong remissions in those responding to induction therapy using 
rituximab maintenance, given every two or three months for 2 years.  In the 
PRIMA trial, those achieving at least a partial response to first line therapy were 
randomised to rituximab maintenance or observation; with a median follow up of 3 
years the PFS was significantly different at 75% and 58% respectively (figure 4).44 
As yet no difference has emerged in OS.  The side-effect profile of rituximab is 
good compared with most chemotherapeutic agents; therefore the theory that 
more severe side-effects can be delayed is attractive.  Fears of a high frequency 
of severe infections due to profound B-cell depletion have been shown to be 
unfounded. However, prolonged rituximab therapy is associated with an excess 
infection risk compared with observation following (immuno) chemotherapy 
induction.  For example, in the PRIMA trial, the improved PFS in the maintenance 
arm came at the expense of a two-fold increase in infection risk, and a quadrupled 
risk of grade 3/4 infection (4% vs. 1%).  Only one patient death in the 501 patients 
in the maintenance arm was felt to be possibly related to the treatment (fulminant 
hepatitis in the absence of antiviral therapy).44  The number of cases of the fatal 
JC viral infection Progressive Multifocal Leucoencephalopathy (PML) attributable 
to rituximab is difficult to gauge, as haematological diseases are themselves a risk 
factor, but is in the order of 1 in 100000 patients treated.     
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Figure 4: Progression-free survival on the PRIMA study.  1018 patients with advanced 
stage follicular lymphoma requiring up-front therapy, who responded to induction 
immunochemotherapy, were randomised to a 2-year period of rituximab maintenance or 
observation.  The group allocated to maintenance therapy had significantly improved 
progression free survival. Graph from Morschauser et al, 200844 
Similarly, the FIT trial randomised those responding to induction chemotherapy to 
observation or a single treatment with the radiolabelled monoclonal antibody 90Y-
Ibritumomab tiuxetan (Zevalin®).  Again, significant improvement in PFS was seen 
with consolidation but not in OS.45  The majority of patients on this trial did not 
receive rituximab as part of their induction as it predated its routine use, and it is 
not known if similar results would be achieved in patients treated with rituximab-
containing induction regimens. 
Treatment of relapsed disease 
Although immunochemotherapy has improved outcomes, most patients are 
expected to relapse and require a succession of therapies over many years.  The 
overall aim of therapy is similar to that at diagnosis – to optimise OS and quality of 
life.  The options for management again include observation for those with low-
bulk relapse, radiotherapy to particular sites of troublesome disease, 
radioimmunotherapy with 90Y-Ibritumomab tiuxetan, and chemotherapy combined 
with rituximab.  Many patients initially treated with rituximab have disease which 
remains sensitive to this agent after relapse.  Rituximab maintenance can again be 
used after relapse in an attempt to prolong the period of remission,46 although the 
degree of benefit from repeated periods of rituximab maintenance after successive 
relapses is unclear.  Newer agents are being evaluated alone and in combinations, 
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including bortezomib and lenalidomide, bcl-2 inhibitors and drugs which target 
intracellular pathways such as spleen tyrosine kinase (Syk), Bruton’s tyrosine 
kinase, the mammalian target of rapamycin (mTOR) and PI3-kinase.  In the pre-
rituximab era, high dose therapy with autologous stem cell rescue was of proven 
benefit in relapsed/refractory patients with chemosensitive disease who were fit 
enough to undergo the procedure.47  The place of autografting has not been 
clearly defined in the rituximab era.  Allogeneic stem cell transplantation holds the 
possibility of cure but myeloablative conditioning carries a transplant-related 
mortality (TRM) of around 30%.  Whilst non-myeloablative conditioning has 
achieved encouraging results, the TRM is still at least 10%.48   
Some people will respond repeatedly to regimens containing rituximab and it is 
possible that in this way their disease can be managed as a chronic disorder over 
many decades.  It is hoped that new antibodies will improve on the response rates 
and duration and offer alternatives in relapsing patients who have lost rituximab 
responsiveness.  Much effort has gone into understanding the mechanisms of 
action of rituximab and the reasons for suboptimal response in patients in the hope 
that this will lead to the development of new antibodies in FL and, indeed, many 
other cancers. 
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Fc receptors 
Antibodies contain Fab (fragment, antigen-binding) and Fc (fragment, 
crystallisable) domains.  Activation of immune effector cells occurs after binding of 
their Fc receptors to antibodies via the Fc region; Fc receptors (FcR) bind IgG 
antibodies.  FcRs are members of the immunoglobulin superfamily.  They have 
an IgG-binding α-chain with an extracellular portion composed of either two 
(FcgRII and FcgRIII) or three (FcgRI) Ig-like domains.  Different classes of FcR 
differ in cell distribution and affinity for IgG subclasses (table 1). 
The FCGR gene cluster is located on the long arm of chromosome 1 (1q21-23) 
and consists of 8 genes (figure 5).49  FcRI is a high affinity receptor which binds 
monomeric IgG, coded by three genes (FCGR1A, FCGR1B and FCGR1C); 
however only FcγRIa is capable of binding IgG and the function of FcγRIb and 
FcγRIc is poorly characterized. FcRII and FcRIII are low-affinity, bind only 
complexed or multimeric IgG and are important in initiating ADCC. The FcRs can 
be classified by their effect, being either activating or inhibitory.  The activating 
receptors contain an intracellular tyrosine-based activation motif (ITAM) for signal 
transduction. An ITAM is a specific sequence of amino acids (YXXL) occurring 
twice in close succession; phosphorylation of the tyrosine (Y) residue leads to a 
signalling cascade. FcRIIb is an inhibitory receptor, containing an inhibitory motif 
(ITIM) in the cytosolic domain.  Activating and inhibitory receptors are often co 
expressed on the same cell and the balance of the two signals determines the 
degree of cellular activation.  FcRIIIa binds only IgG1 and IgG3 isotypes; FcRIIa 
also binds IgG2.  Polymorphisms in FcRs can influence the level of receptor 
expression, affinity for specific IgG isotypes or receptor function in terms of down-
stream signalling.49   
Several common SNPs and copy number variant regions exist at the FcR locus.  
Such genetic variation is characteristic of regions involved in immunity, likely 
because such diversity reduces the risk of population-destruction by a particular 
pathogen.  This diversity has been very well described at the MHC locus.  FcR 
polymorphisms have been implicated in the risk and severity of a variety of 
infectious and autoimmune diseases.50,51,52  In very simplistic terms, FcR alleles 
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which somehow confer a lower threshold for activation would increase 
susceptibility to autoimmune disease but may provide for a better response to 
infection.  Such SNPs may be postulated to enhance (or reduce inhibition of) 
response to monoclonal antibodies. 
 
Receptor FcRIa FcRIIa FcRIIb FcRIIc FcRIIIa FcRIIIb 
Alias CD64 CD32 CD32 CD32 CD16a CD16b 
Gene FCGR1A FCGR2A FCGR2B FCGR2C FCGR3A FCGR3B 
Expression 
Macrophages
monocytes 
neutrophils 
Macrophages 
neutrophils 
platelets 
Macrophages
monocytes 
B-cells 
Macrophages 
neutrophils 
Macrophages 
monocytes 
NK cells 
Neutrophils 
Variant  H131R 
I232T 
−386G>C 
−343G>C 
−120T>A 
Q57X 
−386G>C 
−120T>A 
CNV 
V158F NA1/2 
Effect   
232T ↓ 
inhibitory 
activity 
-386C ↑ 
promoter 
activity 
Transcription
al repression 
-120A ↑ 
promoter 
activity 
Non-
functional 
protein 
-386C ↑ 
promoter 
activity 
-120A ↑ 
promoter 
activity 
158V ↑affinity 
IgG1 & IgG3 
NA1 
↑affinity 
IgG1 & 
IgG3 
IgG 
subclass 
specificity 
3>1>4>>2 
R131: 3>1>>2,4 
H131:3>1,2>>4 
3>1>4>>2  1,3>>2,4 1,3>>2,4 
Table 1: The FcR family.  Encoding genes are shown, together with allelic variants with 
known functional impact49,53 
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Rituximab mechanisms of action   
Rituximab has become a mainstay in the therapy of B-cell malignancies, including 
FL, although its mechanisms of action are incompletely understood.  There is 
evidence to support the importance of a variety of mechanisms; much of this 
evidence comes from in vitro work and in vivo murine models and may or may not 
relate to the situation in patients.  Rituximab is not effective for all patients and 
various factors may contribute to clinical resistance to rituximab.  Understanding 
the mechanisms of action of rituximab and reasons for variability in clinical 
response will hopefully lead to improvements in anti-CD20 monoclonal antibody 
therapy, and, indeed, inform the development of effective antibodies for use in a 
variety of cancers and other indications. 
At the time of early interest in monoclonal antibody therapy for human cancers, 
CD20 was identified as an ideal target for such therapy.  CD20 is found on most B-
cell neoplasms, its expression is normally restricted to mature-B and pre-B cells, it 
is not shed from the cell surface, does not internalize upon antibody binding and is 
not found free in the circulation (thus an antibody would not be neutralized before 
binding to its target cell).  CD20 is a 297 amino acid protein which spans the cell 
membrane four times. It is not known to have a natural ligand and its normal 
function is incompletely understood.  Once the B-cell receptor (BCR) has been 
stimulated by antigen, it seems that CD20 collaborates and acts as a calcium 
channel.54  CD20 knockout mice were found to be without obvious phenotype;54 
recently a case was reported of a girl with a homozygous mutation resulting in 
absence of CD20 expression.  She presented with recurrent respiratory infections; 
although B cell development appeared normal she had impaired antibody 
responses.55 
Transient partial responses with few side effects were observed in lymphoma 
patients treated with a murine antibody to CD20.56  Rituximab is a chimeric IgG1 
antibody containing murine variable regions and human constant regions 
produced in vitro from a transfected Chinese hamster ovary cell line.  The human 
constant regions allow for effective interaction with human complement and 
effector cells.57  Potential mechanisms of action for rituximab include antibody-
dependent cell-mediated cytotoxicity (ADCC), phagocytosis, complement-
dependent cytotoxicity (CDC), and direct signalling leading to apoptosis.  Other 
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suggested mechanisms include a vaccinal effect eliciting a T-cell response and 
complement-enhanced ADCC (CR3-ADCC).  These mechanisms will now be 
discussed in turn; it is likely that more than one mechanism is at work and it may 
be that different mechanisms predominate in different clinical situations (figure 5). 
 
Figure 5:  Possible mechanisms of action of rituximab.  CD20 molecules are 
represented by twin blue cylinders with extracellular loop including rituximab binding site 
and intracellular domains.  ADCC= Antibody dependent cellular cytotoxicity; CDC= 
Complement dependent cytotoxicity; CR3 ADCC= complement-enhanced ADCC. 
 
Fc receptor-dependent mechanisms 
FcRs are found on a variety of immune effector cells including natural killer (NK) 
cells and macrophages.  ADCC depends on the activation of NK cells via the Fc-
FcR interaction leading to the release of substances toxic to the target cell such 
as perforin and granzyme, as well as cytokines which recruit other immune cells.  
Phagocytosis of pathogens is initiated by FcRs on macrophages binding antibody 
that is bound to antigen.  Fc-FcR interactions may also effect target cell death by 
cross linking antibodies leading to intracellular signalling and apoptosis. 
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ADCC 
In vitro studies have used chromium release cytotoxicity assays to investigate 
ADCC in fresh lymphoma cells and lymphoma cell lines.57,58,59  Purified human 
effector cells cause tumour cell death in the presence of rituximab, with NK cells 
being the prominent effector cells in ADCC in vitro.  However, in vitro detection of 
ADCC often involves much higher ratios of effector to target cells than would be 
found in vivo.  Further evidence for the importance of Fc-FcR interactions comes 
from murine models.  Uchida et al demonstrated that mouse-anti mouse CD20 
antibody depleted normal B cells in vivo, but not in mice lacking the FcR common  
chain, implying a critical role for FcRs.  Furthermore, they showed that the 
depletion of B cells by rituximab was just as effective in mice with congenital 
deficiencies in the complement components C3, C4 or C1qa.  B-cell depletion still 
occurred in mice with defective or deficient NK cells or T-cells but not in those 
rendered macrophage deficient, implying a central role for 
monocytes/macrophages, whether by ADCC or phagocytosis.53  In a mouse 
lymphoma model, Clynes et al irradiated athymic nude mice and injected them 
subcutaneously with Raji human lymphoma cell line.  They observed response to 
rituximab in wild type mice but not in those lacking the FcR common  chain.  In 
mice lacking the inhibitory FcRIIb but with other FcRs intact, the response to 
rituximab was increased, providing evidence that the interaction of rituximab with a 
variety of FcRs on a variety of effector cells is central to determining the 
effectiveness of therapy (FcRIIb not being expressed on NK cells).60  They 
obtained similar results in mouse models of breast cancer treated with the anti-
HER2 (Human Epidermal growth factor Receptor 2) antibody trastuzumab and 
melanoma treated with a murine IgG2 antibody TA99.   
Rituximab infusion into lymphoma patients has been shown to result in NK cell 
activation,61 but the strongest evidence that ADCC is involved in clinical response 
comes from correlative studies linking outcome to FcR polymorphism status.  
FcRIIIa has either a phenylalanine (F) or a valine (V) at position 158.  FcRIIIa-
158V has a higher affinity for IgG1 in vitro than FcRIIIa-158F,62,63 and patients 
with at least one V allele have a greater degree of NK cell activation following 
rituximab infusion.61  Several studies have described significant improvements in 
response to rituximab and PFS in VV lymphoma patients compared to FF.64,65  
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This has been interpreted as highlighting the importance of Fc-FcR interactions in 
rituximab response and suggests that ADCC is of critical importance with NK cells, 
the principal cells expressing FcRIIIa, being key contributors to in vivo response.  
The H131R polymorphism in FcRIIa has also been linked to outcomes following 
rituximab therapy.65  However, not all studies have found these polymorphisms to 
be clinically relevant and those which did often included small patient numbers.  
The studies are discussed in further detail later in this introduction, when the 
individual polymorphisms are discussed. 
Phagocytosis 
A central role for macrophages which is FcR dependent has been found in normal 
and malignant B cell depletion in murine models.66,67  Macrophages can 
phagocytose rituximab-opsonised cells in vitro.58,68  Another IgG1 monoclonal 
antibody, SGN35 (anti-CD30), has been found to cause FcR-dependent 
phagocytosis by macrophages in vitro, but not ADCC or CDC; response to SGN35 
in murine models was lost if the mice were macrophage depleted but maintained if 
NK-cell depleted.69  Leidl et al found that macrophages could phagocytose fresh 
B-Chronic Lymphocytic Leukaemia (CLL) cells (and also cells from FL and mantle 
cell lymphoma patients, but not cells from lymphoma cell lines) in vitro but could 
not induce ADCC.68  They suggest that the principal way by which human 
macrophages contribute to rituximab response is by phagocytosis rather than 
ADCC, although the proportion of rituximab response attributable to macrophages 
in human patients rather than murine models is not clear.   
Direct signalling 
Rituximab can induce death of malignant B-cell lines in vitro in the absence of 
immune effector cells, although not all cell lines are sensitive and this has not 
been clearly demonstrated with primary lymphoma cells.  Most researchers have 
found that detection of signalling changes requires hyper cross-linking of the 
rituximab with anti-rituximab antibody.70,71 The mitochondrial (intrinsic) pathway is 
reported to be employed in apoptosis induced in vitro by hyper cross-linked 
rituximab, with activation of caspase-9, cytochrome c release and mitochondrial 
disruption.72  Of interest, programmed cell death without such hyper cross-linking 
has been found to be independent of caspases.71  In vitro cross-linking of 
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rituximab may not reflect the situation in patients, providing such a strong signal 
that non-physiological changes are induced.  Alternatively, cross-linking may occur 
in vivo, possibly again through Fc-FcR interactions. 
Several clinical observations suggest that rituximab can be effective against 
lymphoma cells without immune effector cells.73 In an early trial of radiolabelled 
anti-CD20 therapy, patients were preloaded with unradiolabelled murine CD20 
antibody IgG2a to improve biodistribution of the experimental therapy.  Some 
subjects experienced reduction in lymphoma tumour burden after this pre-loading 
but before the radiolabelled antibody was given.74 This suggests anti-tumour 
activity form the mouse antibody despite the fact that interaction between murine 
antibody and human FcRs is poor.  Secondly, in a phase I study rituximab was 
administered directly into the cerebrospinal fluid of 10 patients with CNS 
involvement by B-cell lymphoma.  Despite the lack of complement and immune 
effector cells in this compartment, 6 responded clinically, implying a direct effect of 
the drug.75  Finally, the fact that rituximab plus conventional chemotherapy gives 
better clinical responses than either alone would suggest that immune effector 
cells are not critical to the response to combination therapy as they would be 
expected to be depleted by chemotherapy. 
CDC 
Rituximab can bind C1q in vitro and induce CDC of B cell lines and fresh 
lymphoma cells.57,76  The ability of a monoclonal antibody to fix C1q and lyse cells 
probably depends on the density of antigen and proximity to the cell membrane, as 
well as the particular binding site and spatial projection of the antibody.  In 
addition, the ability of different anti-CD20 antibodies to reorganise CD20 
molecules into lipid rafts is linked to their ability to cause CDC, presumably by 
clustering of available epitopes.77  The level of expression of the complement-
defence molecules CD55 and CD59 on tumour cells also contributes to the ability 
of rituximab to lyse cells by CDC in vitro.76  Golay et al showed that sensitivity to 
rituximab-induced CDC of fresh CLL, MCL and PLL cells was dependent upon the 
level of CD20 expression, and also that of CD55 and CD59.  Blocking 
complement-defence molecules in poorly responding CLL cells increased their 
sensitivity to lysis.76  Manches et al also found that CD20, CD55 and CD59 
expression on fresh lymphoma cells could predict in vitro CDC.  They found that 
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different histological types of lymphoma were equally sensitive to ADCC, 
phagocytosis and apoptosis, but differentially lysed by CDC.  CDC sensitivity was 
highest for FL, moderate for DLBCL and MCL and low for small lymphocytic 
lymphoma (SLL), suggesting that it is the degree of CDC which influences the in 
vivo responsiveness of different B-cell neoplasms to rituximab.58  However, in a 
small study of 29 patients with FL, pre-treatment levels of complement-defence 
molecules did not correlate with clinical response to rituximab.78   
Clinical studies in patients with CLL have shown that complement is depleted 
following rituximab infusion,79 and replacement by fresh frozen plasma (FFP) 
infusion might improve response.  Animal model studies supporting a prominent 
role of CDC have used non-immunodeficient mice injected intravenously with 
murine lymphoma cells, engineered to express human CD20, and 
immunodeficient mice xenografted with human lymphoma cell lines.80,81  Mice 
rendered deficient in cellular effectors did not demonstrate any reduction in 
response to rituximab; however, complement depletion with cobra venom factor 
abolished it.  The discrepancy with the results from the mouse models of Uchida et 
al and Clynes et al is intruiging.53,60  Uchida et al measured depletion of normal B 
cells and used murine anti-CD20 antibody, which may have important differences 
to rituximab, e.g. its ability to relocate CD20 antigens into lipid rafts.  Golay et al 
acknowledge several possibilities which may explain the differences in their results 
compared with Clynes et al.  Golay et al depleted NK cells and macrophages 
individually using antibodies or clodronate; ADCC may still be an effective 
mechanism if some cells remained after antibody/clodronate treatment or if the 
other cell type were able to compensate.  However, they favour an explanation 
related to differences in tumour kinetics from the cell lines used.  Xenograft models 
tend to have slow growing tumours, perhaps analogous to patients with bulky but 
indolent disease, whilst the cell line used by Golay is aggressive and grows 
rapidly.  Rituximab therapy was shown to be effective against this rapidly growing 
lymphoma only up until day 15 from inoculation, around the time point of tumour 
detectability by PCR.  The authors propose that this situation is analogous to that 
of minimal residual disease in aggressive lymphoma and suggest that CDC alone 
is sufficient for rituximab efficacy in this situation.80 
The formation of the membrane attack complex and cell lysis is one way in which 
the complement system could contribute to tumour cell death.  Complement 
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components may also enhance phagocytosis by opsonisation, recruit effector cells 
chemotactically and enhance interactions between tumour and effector cells, 
thereby enhancing the action of rituximab by other mechanisms.  In certain 
circumstances complement may be antagonistic to the effects of rituximab.  C3b 
deposition on tumour cells in vitro seems to block Fc:FcR interactions with NK 
cells, thus impairing ADCC.82  Complement has been implicated in enhancing 
“shaving”, a process by which CD20:rituximab complexes are removed from 
tumour cells, allowing them to escape further rituximab attack.79  Finally, a SNP in 
the C1QA gene which leads to lower levels of C1q has been associated with 
prolonged clinical response to rituximab in FL patients, compared with the high-
expressing allele (see below).83 
Vaccinal effect 
Another proposed mechanism by which rituximab may exert some of its tumour 
control is via the generation of a tumour specific T-cell response.  Regardless of 
the major mechanism of rituximab causing cell death, such cell death will liberate 
tumour antigens which can then be taken up and presented by dendritic cells to T-
cells.  Theoretically, rituximab could further favour the generation of such a cellular 
immune response via Fc:FcR interactions with dendritic cells.  Idiotype-specific T-
cells were found in 4 out of 5 FL patients one month after rituximab therapy, but 
not pre-treatment.84  Another study suggesting a vaccinal role looked at a SNP at 
position 276 in C1QA.  The polymorphism is non-coding with either a guanine or 
adenine as the third nucleotide in the codon for glycine at amino acid 70 (C1QA-
Gly70GGG/GGA).  The G allele is associated with higher expression of the 
complement component C1q and increased CDC in vitro, compared with the A 
allele. The A allele has been reported to be over-represented in patients with 
subacute cutaneous lupus erythematosis.85  The high-expressing allele might be 
expected to predict better rituximab responses if CDC were an important 
mechanism of action.  However, the G allele was found to be linked with a shorter 
period of remission in FL patients who respond to rituximab.  The authors of this 
study propose that high levels of C1q lead to opsinization of tumour apoptotic 
bodies and their efficient phagocytosis and removal, limiting the availability of 
tumour antigen for presentation to T-cells.83 
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CR3-enhanced ADCC 
During the classical complement cascade, C3b is generated from cleavage of C3 
and binds to C3 convertase to form C5 convertase, leading to the formation of the 
membrane attack complex.  C3b also acts as an opsonin and can interact with 
different receptors on immune cells, including complement receptor 3 (CR3) (also 
termed Mac-1 and CD11b/CD18) on NK cells, neutrophils and macrophages.  
Synergy of C3b:CR3 interactions with Fc:FcR interactions have been suggested 
by in vitro studies.86  In a melanoma mouse model, CR3 knockout mice were less 
protected by the monoclonal antibody TA99 than wild-type mice.87  Imai et al 
studied EL4-lymphoma cell lines in a mouse model and used an IgG2 anti-GD2 
antibody, which protected the mice from tumour progression and improved 
survival.  Protection by the monoclonal antibody was not lessened in C3 or CR3 
deficient mice, but almost entirely abrogated in mice deficient in FcRI and FcRIII, 
supporting a crucial role for ADCC.  However, at low antibody levels, protection 
was partially lost in C3-deficient mice.  The authors conclude that complement-
mediated enhancement of ADCC was important at limiting antibody 
concentration.88 
Conclusions 
A large body of literature now exists, providing evidence to support the central role 
of a variety of mechanisms of action of rituximab.  Much of this, often conflicting, 
evidence comes from in vitro and mouse models and it is difficult to know how 
easily this transfers to the situation in human patients.  In order to increase the 
body of evidence of clinical importance it is essential to push ahead with 
translational work linked to rigorously-run clinical trials.  The strongest evidence of 
clinical importance is in favour of ADCC, from the correlative studies linking FcR 
polymorphism status with clinical outcome.  As previously mentioned, these 
studies were often small and underpowered, and not all reported the association.  
Nevertheless, they have directed a huge effort in therapeutic antibody 
development aimed at increasing affinity for FcRs and enhancing ADCC. The 
current research aimed to verify or refute these findings in a larger patient cohort 
and increase the body of evidence concerning rituximab mechanism of action in 
patients. 
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It is likely that ADCC, CDC, direct signaling and other mechanisms contribute to 
rituximab’s effects in some patients at some time.  Differences in tumour histology, 
bulk, and localization in the circulation or tissue probably affect the predominant 
mode of action in rituximab responders.  In the next section, reasons for sub-
optimal response to rituximab, and possible strategies to overcome them will be 
discussed. 
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Rituximab resistance 
The term rituximab resistance has been widely used when discussing the range of 
tumour, patient and pharmacokinetic factors which may contribute to rituximab 
treatment failure.  Few indolent lymphomas are truly rituximab-refractory with a 
decrease in tumour size of some degree seen in most patients after rituximab 
monotherapy.16    
Lymphoma-related resistance 
It is known that different histological types of B-cell malignancy have differing 
responses to rituximab monotherapy, with small lymphocytic lymphoma (SLL) and 
CLL having lower response rates than FL,16,89 and MCL having shorter event free 
survival than FL patients.90  These differences may relate to the level of CD20 
expression and that of complement-defence molecules as well as tumour kinetics 
and the predominant location of lymphoma cells (blood or tissues).  Differences in 
active cell survival pathways and membrane lipid content may also contribute to 
different sensitivities.91 
Patient factors  
As previously discussed, the action of rituximab may depend on the availability 
and ability to utilise effector cells and complement components.  Certain 
anatomical sites, for example the central nervous system, may lack certain 
effectors.  Factors which could influence the number and activity of effector cells, 
and the availability of complement components in an individual could alter the 
observed therapeutic response.  The subject of the current research, 
polymorphisms in FcRs and complement components and receptors, are 
discussed more fully elsewhere.  In addition, rituximab effector mechanisms could 
become saturated or exhausted under conditions of high tumour burden.  
Complement may be consumed for other reasons, such as infection or 
inflammation.  Finally, as rituximab is not fully humanised it may stimulate 
formation of human anti-chimeric antibodies.  This has been implicated in lack of 
response to rituximab in auto-immune conditions,92,93 although there is no 
evidence of a significant contribution to therapy resistance in lymphoma.16,94 
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Rituximab concentration 
Serum rituximab concentrations (and hence exposure) have been shown to 
correlate with clinical outcome, with higher concentrations seen in responders than 
non-responders.16,95 The original clinical studies of rituximab in NHL did not 
include dose-escalation to determine maximum efficacy or dose-limiting toxicities, 
rather the dose was rather arbitrarily chosen and this has become standard.  
Significant inter-individual variation in rituximab concentrations following the same 
dose has been noted;16 identifying the factors involved might enable more effective 
dosing.  Rituximab pharmacokinetics are believed to be similar to that of normal 
immunoglobulin.  In a study of 102 rheumatoid arthritis patients, the best model to 
describe the data was a two-compartment model with linear elimination 
pharmacokinetics.96 Soon after the infusion the drug concentration reflected a 
distribution volume equal to that of plasma volume.  There followed a biphasic 
decline in plasma antibody levels.  Initially a rapid fall occurred, reflecting drug 
removal and distribution from the intravascular to the extravascular compartment, 
with a half-life of 2.4 days.  During the later elimination phase the half-life was 19.7 
days.  In patients with FL, the observed half-life of rituximab increased from 3.2 
days following the first of four weekly infusions, to 8.6 days following the last.  
Median maximum serum levels increased from 239 µg/ml following the first 
infusion to 460 µg/ml following the last.16   This can be explained using the same 
two-compartment model with different distribution and elimination half-lives.  
Trapping of rituximab by circulating CD20 positive B-cells following the first 
infusion may contribute.   Rituximab is metabolised by non-specific catabolism in 
the liver and other organs, and excretion is predominantly renal. 
In the study in patients with rheumatoid arthritis, gender and body surface area 
accounted for some of the inter-individual variability in rituximab concentration.  
Drug clearance was increased in men resulting in a 30% reduction in drug 
exposure compared to women.96 There is a suggestion from the watch and wait 
study that men derive less benefit from rituximab maintenance than women (Dr 
Kirit Ardeshna personal communication).  There may be interethnic 
pharmacokinetic differences as a Japanese study found lower serum rituximab 
levels in its patients than previously reported. They also found higher rituximab 
levels in patients without extranodal disease compared to those with extranodal 
disease.97 The seminal study of rituximab in FL showed an inverse correlation 
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between rituximab serum concentrations and clinical response.16 The authors 
subsequently reported that baseline tumour burden and lymphocyte count 
correlated inversely with rituximab serum level.95 The hypothesis that increasing 
tumour bulk results in a lower rituximab serum level and reduced clinical 
effectiveness due to increased antigenic mass could have significant implications 
for optimum dosing schedules.  Work by Dayde et al in a murine model of 
disseminated lymphoma supports this hypothesis.  When a fixed dose of rituximab 
was given, mice with a higher tumour burden achieved lower rituximab serum 
concentrations and had shorter survival.  Increasing doses of rituximab were 
associated with improved response rates and survival, and through a 
pharmacokinetic / pharmacodynamic model the authors demonstrated that 
rituximab efficacy correlates with antigenic mass.98 Lower serum concentrations of 
rituximab were also measured in the patients with SLL compared to other indolent 
lymphomas, and they had inferior responses, as previously noted.  It is postulated 
that some of the reason for poorer response in SLL may be circulating tumour 
cells and antigen, which mops up available rituximab, lowering serum 
concentrations and decreasing response.  Similarly, several studies reported low 
response rates in CLL when using the standard NHL dose of 375mg/m2, but a 
dose-response effect can be demonstrated which probably relates to achieving 
higher drug concentrations.89 
Reduced or abnormal CD20 expression 
A plausible explanation for antibody resistance would be mutations affecting the 
binding site.  Several groups have investigated CD20 gene mutations and found 
no evidence of a significant contribution to rituximab resistance in DLBCL.99,100 
CD20 expression may be down regulated following rituximab therapy, although 
there is no evidence that this is an important cause of rituximab-refractory disease.  
Chronic exposure of lymphoma cell lines to rituximab can lead to pre-
transcriptional and post-transcriptional down-regulation of CD20.   
“Shaving” of rituximab:CD20 complexes from the surface of circulating malignant 
B-cells has been implicated in sub-optimal response to rituximab therapy, 
particularly in CLL.  It is suggested that, initially, circulating cells coated with 
rituximab are effectively killed by Fc:FcR dependent mechanisms, whether ADCC 
or clearance by liver and splenic macrophages.  However, if these mechanisms 
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become saturated, further rituximab-coated tumour cells have the antibody:antigen 
complex removed, and CLL cells with low CD20 expression can be detected.101 
Strategies for overcoming rituximab resistance 
Rituximab responses could theoretically be improved in three ways: optimising 
dosing, adding other factors to enhance effector mechanisms, or altering the 
antibody structure.   
Optimising dosing 
As previously discussed, the standard dose of rituximab employed was arrived at 
in a fairly arbitrary fashion.  If rituximab is an effective treatment, then will more be 
better?  Prolonging treatment with maintenance rituximab is of proven benefit after 
induction response in FL.35,44,102  Higher serum rituximab concentrations are 
correlated with improved clinical response.  Simply increasing the dose to all 
patients will increase the average serum level; there is evidence of a dose-
response effect in CLL.89 Alternatively, concentrating doses more closely together 
will lead to faster drug accumulation and an earlier concentration plateau.  In 
DLBCL, standard R-CHOP given every 14 or 21 days does not achieve a plateau 
in rituximab concentration until cycle 5 of therapy.  The regimens DENSE-R-CHOP 
and SMARTE-R-CHOP combine increased dose-density early in the treatment 
course with either more rituximab doses altogether or a longer duration of therapy, 
respectively.  Improved CR and EFS rates have been reported in around 100 
elderly patients for each regimen compared with historical controls; interestingly it 
seems that the benefit may be restricted to those with poor prognostic 
features.103,104 The authors conclude that standard rituximab dosing may be 
sufficient for low-bulk disease whilst increased dose-density may be needed to 
optimise responses in bulkier disease.   As serum concentrations may depend on 
disease bulk, histology and anatomical site, as well as patient gender and possibly 
race, optimising rituximab levels and therefore response may need to take all 
these factors into consideration.  Alternatively, measurement of serum levels in 
clinical practice could identify patients who would be expected to benefit from 
increased dose or frequency of rituximab administration.   
Increasing serum rituximab levels may be able to overcome any innate differences 
in patients’ effector responses.  An in vitro study of NK-medicated ADCC in Daudi 
Introduction 
 36 
cell line found that 50% cell lysis was achieved by NK cells from FCGR3A-158V 
homozygous donors (encoding the higher affinity receptor) at a 4.2 times lower 
rituximab concentration than NK cells from FCGR3A-158F homozygotes.  At 
saturating levels of rituximab, no difference was found in the degree of cell lysis, 
suggesting that any negative impact of the FCGR3A-158F allele in vivo might be 
overcome with increased serum levels.  A mathematical model incorporating 
tumour mass, polymorphism status, dosing schedule and rituximab 
pharmacokinetics has been used to simulate plasma concentrations and linked 
with efficacy data to predict patient outcome.  The model predicts improved PFS 
with higher doses of rituximab although this has not been tested prospectively.105 
Finally with respect to dosing regimens, it has been suggested that fractionated 
dosing may give better results in patients with circulating tumour cells.  Small, 
frequent doses of antibody would avoid saturating effector mechanisms, implicated 
in the “shaving” reaction whereby tumour cells lose CD20 expression and thus 
become resistant to further doses of rituximab.101 
Effector enhancement 
Effector functions which contribute to rituximab mechanism of action could be 
augmented by co-treating with other factors.  If CDC is an important mechanism 
and complement factors can be consumed, then replacement of complement with 
FFP may be a logical step.  Complement activation can be enhanced by antibody 
to C3bi or oral β-glucans (which bind to CR3 and promote interaction with C3bi).  If 
ADCC is of critical importance, expanding the effector cell number and increasing 
activation with cytokines such as IL-2, IL-12 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) might be beneficial.  Either mechanism may be 
enhanced by up-regulating CD20 expression, which has been achieved in vitro 
with cytokines and a DNA methylation inhibitor.91 Information on efficacy and 
tolerability in humans of any of these possible approaches is limited or non-
existent.  
Antibody modification 
The first generation of anti-CD20 monoclonal antibodies includes tositumomab as 
well as rituximab.  So called second generation antibodies have a humanised or 
fully human complement-determining region, reducing the theoretical risk of 
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neutralising antibody development.  Third generation antibodies have Fc 
modifications aimed at enhancing activation of effector cells or complement.  
 
Considerable efforts have been made to develop next-generation anti-CD20 
antibodies in the hope of improving response rates and providing options for 
patients who are rituximab-refractory.  Such antibodies may have differing actions 
to rituximab if they either bind to a different CD20 epitope or have their Fc region 
engineered to enhance immune effector functions.   
 
Antibodies may be divided into type I or type II, depending upon whether or not 
they relocate CD20 molecules into lipid rafts.  Lipid rafts are cholesterol-rich 
membrane microdomains, which serve to compartmentalise cellular processes.  
Clustering of CD20 molecules in rafts by type I antibodies leads to efficient binding 
of C1q and CDC.  Type II antibodies do not relocate CD20 to rafts and do not 
activate complement efficiently but are potent inducers of direct cell death.  A list 
of CD20 antibodies is shown in Table 2; ofatumumab and obinutuzumab have the 
most clinical data available and will be discussed in more detail below. 
 Type I Type II 
First generation Rituximab Tositumomab (B1) 
Second generation Ofatumumab 
Ocrelizumab 
Veltuzumab 
 
Third generation Ocaratuzumab (AME-
133) 
PRO 131921 
Obinutuzumab (GA101) 
Table 2: Therapeutic anti-CD20 monoclonal antibodies. 
 
 
 
Ofatumumab 
Ofatumumab’s binding site is very close to the cell membrane, on the small 
extracellular loop of CD20 (rituximab binds to the large loop).106 It is likely this 
proximity to the cell membrane that allows for more potent CDC than rituximab; it 
also has a much slower off-rate.  Ofatumumab also causes more potent ADCC 
than rituximab in vitro; whilst both seem to be influenced by FcRIIIa-V158F 
polymorphism in effector cells, both allotypes kill tumour cells more effectively with 
ofatumumab than rituximab.107 However, responses could be improved with 
increasing concentrations of rituximab.  Ofatumumab has not demonstrated 
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superior maximal efficacy (i.e. increased efficacy at the plateau of the dose-
response curve) to rituximab in vitro, nor has any other type I antibody. 
Ofatumumab was granted U.S. Food and Drug Administration (FDA) approval in 
2009 for treating patients with CLL refractory to fludarabine and alemtuzumab, 
having produced an ORR of 58% when used as monotherapy in this hard to treat 
group.108 It has efficacy in relapsed FL, including in a modest proportion of those 
resistant to rituximab.109 Studies are ongoing in a variety of B-cell neoplasms 
including using ofatumumab monotherapy and various combination regimens; 
currently no results are available from randomised trials against rituximab and the 
UK National Institute for Health and Clinical Excellence (NICE) have not approved 
its use.   
Obinutuzumab 
Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 antibody.  
Mossner et al (2010) describe the process by which it was created and selected 
for further study.110 Different humanized variants were produced from a parental 
murine antibody and tested for affinity to CD20 and ability to induce direct cell 
death in human B-cell lymphoma cells in vitro. Obinutuzumab demonstrated more 
potent binding to human CD20 compared to rituximab. Cellular assays 
demonstrated increased ADCC and direct cell death (and reduced CDC as 
expected in a type II antibody), and superior efficacy was demonstrated in animal 
models. However, higher concentrations or doses of rituximab were not evaluated 
to see if increased dosing could yield results comparable to obinutuzumab. 
Another study found obinutuzumab to be more efficient at inducing ADCC and 
direct cell death in vitro, compared to rituximab and ofatumumab, even at high 
antibody concentrations.111 Animal models in this study again showed better 
tumour control with obinutuzumab compared with rituximab or ofatumumab, when 
similar dosing schedules were used. 
 
Obinutuzumab has a sequence alteration in the elbow-hinge region.110 A valine 
residue is present at Kabat position 11, whilst the murine parent antibody had a 
leucine at this position.  A variant with this residue remutated back to the original 
leucine displayed loss of activity with cellular responses similar to that seen with 
rituximab, despite maintaining the higher binding affinity of obinutuzumab.110 
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Obinutuzumab has also been found to have higher affinity binding to FcgR3b and 
associated increased activation of neutrophil phagocytosis in vitro.112 
Obinutuzumab has shown clinical superiority over rituximab in a large, randomised 
trial in CLL.  The CLL11 trial randomised 781 relatively unfit, treatment-naive 
patients to chlorambucil alone, versus chlorambucil plus rituximab (R-
chlorambucil), versus chlorambucil plus obinutuzumab (G-chlorambucil).113 
Immunochemotherapy gave superior outcomes to chemotherapy alone.  G-
chlorambucil led to improved overall and complete remissions compared to R-
chlorambucil, with improved median PFS of 26.7 months compared to 15.2 
months (p<0.0001).  Of note, the doses of obinutuzumab used were higher than 
those of rituximab (3000mg vs. 375mg/m2 in the first cycle, with 1000mg vs. 
500mg/m2 in subsequent cycles).  The FDA approved its use in this setting in 
2013, and guidance from NICE is awaited. 
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Polymorphisms chosen for study 
FCGR3A-V158F 
FcRIIIa is a 29kD integral membrane glycoprotein encoded by the FCGR3A gene 
on chromosome 1. A SNP at nucleotide 559 (T-to-G) predicts a phenylalanine or 
valine at position 158, in the membrane-proximal IgG binding domain.  The 
residue at position 158 directly interacts with the lower hinge region of IgG1.114 
Allelic distribution shows little ethnic variation, with a minor allele (valine) 
frequency of 0.31 -0.37 and 9-16% homozygosity.64,115,116  In vitro, NK cells from 
FCGR3A-158V homozygous donors bind more IgG1 (and also IgG3 and IgG4) 
than do cells from FCGR3A-158F homozygotes (figure 6).62,63 This does not seem 
to be related to differences in levels of receptor expression between the 
genotypes.62,117 The number of circulating immune effector cells is also unrelated 
to polymorphism status.59 Rituximab binding to NK cells from V-allele bearers is 
also significantly higher in vitro than F homozygotes, although the effect can be 
overcome with saturating rituximab concentrations (figure 7).118,117 
 
Figure 6: IgG binding by natural killer cells in vitro.  NK cells from FCGR3A-158V 
homozygous donors bind significantly more IgG1, IgG3 and IgG4 than those from 
FCGR3A-158F homozygotes.  Cells from heterozygotes exhibited intermediate binding, 
indicating a dose effect.  Redrawn from Koene et al, 1997.63 
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Figure 7: Rituximab binding at differing rituximab concentrations by NK cells from 
VV, VF and FF donors.  NK cells were incubated with rituximab followed by FITC-labelled 
anti-CD16 antibody (graph from Hatjiharissi et al, 2007, top118) or with FITC-conjugated 
rituximab (graph from Congy-Jolivet et al, 2008, bottom117) and analysed by flow 
cytometry.  Both sets of authors found that rituximab binding increased with increasing V 
allele dose in the range 10-100µg/ml rituximab; saturating doses of rituximab largely 
overcame the difference. 
There is good evidence that the degree of NK cell activation by rituximab is 
influenced by FCGR3A-158F polymorphism.  Stimulation of NK cells in vitro with 
the anti-CD16 monoclonal antibody 3G8 produced a brisk rise in intracellular Ca2+  
whatever the genotype, whilst stimulation with aggregated IgG (still capable of 
cross-linking FcRIIIa molecules but presumably to a lesser degree) led to a 3-fold 
greater increase in intracellular Ca2+ in NK cells from V homozygous donors than F 
homozygous donors.62 In the presence of target cells (Raji Burkitt lymphoma cell 
line), higher rituximab concentrations were needed to produce increased CD54 
___ VV 
...... VF 
----- FF 
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expression on NK cells from F homozygotes than those from V homozygotes; the 
difference in activation was not statistically significant at saturating concentrations 
of rituximab.119 Similar findings have been reported in vivo.  Blood was taken 
immediately pre-, and four hours post-, the first dose of rituximab in 21 patients 
with lymphoma.  FCGR3A-158V allele bearers had a reduced percentage of NK 
cells in their circulating white cells, and increased CD54 and decreased CD16 
expression on the NK cells, whilst FCGR3A-158F homozygotes did not.61 
In vitro ADCC assays using purified NK cells against Daudi cell lines in the 
presence of rituximab have also shown increased cytotoxicity when using NK cells 
from FCGR3A-158V homozygous donors, either by chromium release assay with 
51Cr- labelled Daudi cells59 or colorimetric assay (figure 8).118 Again, there is 
evidence that the effect is overcome with saturating levels of rituximab, but the 
rituximab concentration resulting in 50% lysis (EC50) of target cells was 4.2 times 
lower with V homozygous donors than F homozygotes.59 
 
Figure 8: Increased natural killer cell-mediated antibody-dependent cell-mediated 
cytotoxicity (ADCC) in vitro using FCGR3A-158V homozygous donors compared to 
FCGR3A-158F homozygotes; Cells from Daudi cell-line were incubated with 10µg/ml 
rituximab and NK cells from genotyped donors before cytotoxicity calculated using a 
colorimetric-based lactate dehydrogenase assay. Graph from Hatjiharissi et al, 2007.  118 
Whilst many in vitro and in vivo studies have reported functional differences 
between FCGR3A-158V homozygotes and 158F homozygotes, heterozygotes 
have been variously reported to be similar to either group of homozygotes, or in 
between.  Differing levels of 158V protein expression have been documented 
amongst heterozygotes, with levels ranging from similar to V homozygotes to 
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similar to F homozygotes.120 This heterogeneity may explain the range of results 
reported for heterozygotes. 
These convincing in vitro demonstrations of correlation between FCGR3A-V158F 
polymorphism status and strength of IgG binding and effector cell activation 
prompted clinical investigation.  In a landmark publication in 2002, Cartron et al 
reported 49 patients with low tumour burden, previously untreated FL, treated with 
rituximab induction alone.64 Responses were indeed found to be associated with 
polymorphism status -100% and 90% response at 2 and 12 months respectively in 
VV patients, compared with 67% and 51% respectively in patients with at least one 
F allele.  Subsequently this finding was replicated in other small studies; however, 
other publications have reported negative findings.  Review of the literature is 
made more challenging by the use of different therapies to treat different types of 
B-cell malignancies in many of these reports. Table 3 summarises 29 publications 
in this area, published before or after our own work began.  These studies 
generated conflicting results with some supporting the association with 
polymorphism status and others not finding this effect.  Reports have involved 
different types of B-cell malignancies and different therapies, most involved small 
numbers and few are studies embedded were rigorous randomised controlled 
trials.  We felt that the clinical correlation between response to rituximab and 
FCGR3A-V158F polymorphisms was not proven.  The watch and wait trial offered 
an ideal opportunity to test the hypothesis in a larger patient cohort, rigorously 
followed up in a large, multicentre randomised controlled trial.  In addition, the 
patients in this trial were rather similar to those in Cartron et al’s original 
publication,64 being low tumour burden FL patients treated with rituximab alone.  
These patients would be expected to show the clearest influence of polymorphism 
status on rituximab response; patients with more aggressive disease or those 
treated with combination immunochemotherapy would likely owe less of their 
clinical response to rituximab, with subtle differences in response to rituximab less 
likely to be identified. 
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Study Year Diagnosis Therapy N Part of RT? Result 
Cartron et al
64
 2002 FL R-induction only 49 N + 
Weng & Levy
65
 2003 FL R-induction only 87 N + 
Boettcher et al 
121
 2004 FL R-CHOP+INF/ ASCT 75 Y – CLSG - 
Maloney et al 
122
 2004 FL CHOP then R 87 N - 
Farag et al
123
 2004 CLL R-induction only 30 N - 
Treon et al 
124
 2005 WM R-monotherapy 58 N + 
Ghielmini et al
90
 2005 
FL R+/- maint 
177 
Y – 
SAKK35/98 
+ 
Pierz et al
125
 2010 151 + 
Martinelli et al
126
 2010 202 - * 
Kim et al
127
 2006 DLBCL R-CHOP 113 N + 
Carlotti et al
128
 2007 FL CHOP then R 94 N - 
Mitrovic et al
129
 2007  DLBCL R-CHOP 58 N - 
Galimberti et al
130
 2007 MCL R-hyper CVAD 24 N - 
Dorman et al
131
 2010 CLL FC +/- R 419 Y - REACH - 
Zhang et al
132
 2010 DLBCL R-CHOP 34 Y +/- 
Weng et al
133
 2010 Various;  HDT + ASCT 35 Y - 
Cornec et al
134
 2011 FL+MZL R-induction only 50 N + 
Fernandez et al 
135
 2011 FL R maint post R-chemo 39 N - 
Ghesquires et al
136
  2011 DLBCL R-CHOP 554 Y-GELA - 
Ahlgrimm et al
137
 2011 DLBCL R-CHOP-14 263 Y-RiCOVER - 
Keane et al
138
 2011 DLBCL R-CHOP 115 N +/- 
Fabisiewicz et al
139
 2011 DLBCL R-CHOP 87 N - 
Prochazka et al
140
 2011 FL Risk adapted 60 N - 
Treon et al
141
 2011 WM R-chemo 159 N + 
Persky et al
142
 2012 FL mAB + chemo 76 Y - SWOG + 
Ghesquires et al
143
 2012 FL R-chemo +/- maint 460 Y- PRIMA - 
Varoczy et al
144
 2012 DLBCL R-CHOP 51 N - 
Chong et al
145
 2013 FL R-lenalidomide 18 N - 
Tuscano et al
146
 2014 FL R-lenalidomide 22 N - 
Zimmerman et al
147
 2014 PTLD R-monotherapy 25 N - 
Table 3: Published reports of rituximab response by FCGR3A-V158F polymorphism 
status in patients with B-cell malignancies.  FL=follicular lymphoma; DLBCL=Diffuse 
large B cell lymphoma; MCL=Mantle cell lymphoma; MZL=marginal zone lymphoma; 
PTLD=Post transplant lymphoproliferative disorder; R=rituximab; maint=maintenance.  
Positive results (+) reported more favourable clinical outcome in patients with V allele, 
negative results (-) found no association; +/- = non-statistically significant trend for benefit 
for V alleles. 
*Three reports from a similar patient cohort in the SAKK35/98 trial. FCGR3A-V158F 
polymorphism status predicted outcome in earlier reports; however, with longer follow-up 
the predictive power was lost in multivariate analysis.  
The FCGR3A-V158F polymorphism has been associated with risk and / or severity 
of various autoimmune diseases, which adds further circumstantial evidence for a 
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real clinical effect of enhanced Fc-FcR mediated immunity.  The V allele has been 
linked with increased risk of childhood immune thrombocytopenia (ITP),148 
inflammatory myopathies,149 atopy,150 rheumatoid arthritis151 and clinically 
significant heparin-induced thrombocytopaenia (HIT)152 and is associated with 
increased severity of Behҫet’s153 and IgA nephropathy.154   
Improved response to rituximab in rheumatoid arthritis was reported to be 
associated with V allele carriage or homozygosity (in 111 and 212 patient 
studies)155,156, but not in a different cohort of 177 (heterozygotes responded 
significantly better than either group of homozygotes in this series).157  Recently it 
has been reported that amongst 48 patients with ITP, responders were 
significantly more likely to be homozygous for the FCGR3A-158V allele.158  An 
increased incidence of late-onset neutropenia following rituximab use in the 
treatment of B-NHL has been described following autologous transplantation133 
and first-line rituximab containing regimens.138,159 
FCGR2A-H131R 
FcRIIa is a 40kD glycoprotein encoded by the FCGR2A gene on chromosome 1.  
A SNP at nucleotide 519 (G-to-A) results in an arginine (R) to histidine (H) 
substitution at position 131 in the FcRIIa molecule.  A range of minor allele (R) 
frequencies have been reported, from 0.19 in Japan,115 to 0.38 in Ghana160 and 
0.48 in Spain and the Netherlands.116,161 The substitution is in the extracellular 
region, in the membrane-proximal Ig-like domain involved in binding of IgG.  Whilst 
this region binds both IgG1 and IgG2, the specific loop bearing the polymorphism 
seems to play a greater role in IgG2 binding.162 The H131 variant has been shown 
to bind human IgG2-coated particles and lead to their phagocytosis in vitro.163 The 
R131 variant, on the other hand, is much less capable of binding IgG2.  Both 
variants bind IgG1 and IgG3; some authors have found the R allele to bind these 
subclasses more strongly.164   
Many associations between FCGR2A-H131R gene status and infectious, 
autoimmune and inflammatory conditions have been documented.  The reasons 
for such associations seem to be more complex than is the case with FCGR3A-
V158F, with susceptibility alleles for some infections and autoimmune conditions 
conferring protection against others.  This may be linked to differential effect on 
avidity of binding of different IgG subclasses.  Alternatively the explanation may lie 
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with differing modes of tissue damage in different inflammatory conditions.49  
Polymorphic variants leading to increased efficiency of IgG-Fc interactions may 
increase effector responses amplifying inflammatory cell-mediated tissue damage.  
Alternatively, they may reduce the chance of autoimmune pathologies related to 
circulating IgG complexes by enhancing clearance of such complexes.  Finally, 
binding of other molecules may be affected by the polymorphism - FcRIIa-131R 
has been found to bind C reactive protein (CRP) more avidly than FcRIIa-131H in 
vitro, and to be associated with lower serum CRP levels in vivo.165  This is likely to 
have interactions with risk of some inflammatory conditions, such as generation of 
cardiovascular atherosclerotic plaques.  The R allele has been linked to increased 
risk of severe malaria,160,166 Pseudomonas aeruginosa infection in cystic fibrosis 
patients167 and recurrent respiratory infections in Turkish children,168 but 
decreased risk of pneumonia following H1N1 influenza infection169 and decreased 
risk of bacteraemia170 and death171 with pneumococcal pneumonia. FCGR2A-
131R has been reported to be associated with increased risk of acute renal 
allograft rejection,172 myasthenia gravis,161 giant cell arteritis,116 heparin-induced 
thrmobocytopenia173 and atherosclerotic events.165  On the other hand, FCGR2A-
131H seems to be associated with risk of Guillain-Barré syndrome,174 
inflammatory bowel disease175 and Kawasaki disease.176 There are conflicting 
reports for several of these associations, possibly explained by genetic linkage 
with other important immune polymorphisms. 
The FCGR2A -H131R polymorphism has been reported by some to predict 
rituximab response in patients with lymphoma,65, 177 whilst others have suggested 
that any association is due to wide linkage between FCGR2A and FCGR3A.178,179  
Homozygosity for the H allele, which binds IgG2 more strongly, was reported to be 
associated with better responses and improved PFS in 87 FL patients, mostly 
relapsed, treated with rituximab monotherapy.65  Another group found better 
responses but not improved survival in 64 patients with NHL of various subtypes 
treated with R-chemotherapy.177 No association between polymorphism and 
outcomes were found in 58 patients treated first-line with R-CHOP chemotherapy 
for aggressive B-cell NHL,129 50 patients with indolent lymphoma treated with 
rituximab monotherapy,180 94 patients with newly-diagnosed FL treated with R-
CHOP128, 24 patients with mantle cell lymphoma treated with R-hyperCVAD130 or 
30 patients with CLL treated with rituximab monotherapy.123  More recently, the 
PRIMA investigators reported no impact of this polymorphism on response to R-
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chemo induction or maintenance rituximab in 460 FL patients, as part of a larger, 
randomised trial.143  Improved PFS in FCGR2A-131H carriers was reported in 39 
patients with previously treated, metastatic colorectal cancer treated with 
cetuximab,181 and 67 such patients treated with cetuximab in combination with 
irinotecan chemotherapy.182 
In view of the conflicting results generated by previous studies, and their small 
sample sizes, impact of the FCGR2A -H131R polymorphism on clinical outcomes 
was examined in our larger cohort of FL patients receiving rituximab. 
FCGR2B-I232T 
The inhibitory receptor FcγRIIb is a 34kD glycoprotein encoded by the FCGR2B 
gene on chromosome 1.  It is the only FcR found on B cells and cross-linking with 
the BCR leads to an increased threshold for cell activation and decreased 
antibody production.   FcRIIB is also found on other immune cells, when it inhibits 
the function of activating FcRs.  A T-to-C substitution in exon 5 of the gene leads 
to substitution of a polar threonine for a non-polar isoleucine at position 232 in the 
receptor transmembrane domain (figure 9).   The functional consequences for the 
FcRIIb-232T receptor are less efficient distribution of the receptor in lipid rafts, 
leading to reduced phosphorylation and reduced downstream inhibitory signal.183  
There is evidence linking the FCGR2B-232T allele to several autoimmune 
diseases, particularly SLE but also rheumatoid arthritis184 and idiopathic 
thrombocytopaenic purpura (ITP)185.  The homozygous FCGR2B-232T allele is 
associated with an odds ratio of 1.73 for developing SLE.51  The frequency of the 
minor allele varies considerably from 0.1 (1% homozygosity) in Caucasian 
populations to 0.22-0.29 (5-11% homozygosity) in Africa and Southeast Asia,115,186 
areas corresponding to endemic malaria.  FCGR2B-232T homozygosity has been 
shown to confer substantial protection against severe malaria in a Kenyan 
population.51  This protective effect may account for the higher frequency of this 
SNP in Africans and Southeast Asians, which in turn may at least partially account 
for known ethnic differences in risk of SLE. A case-control genetic association 
study of Cryptococcus infection in HIV negative Chinese patients found over-
representation of FCGR2B-232I homozygosity and under-representation of 
FCGR2B-232T homozygosity in the cases compared to controls.187 
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One could propose that such attenuated inhibitory signalling could improve 
rituximab response in FCGR2B-232T allele bearers.  A single previous study of 
101 patients with FL did not find any influence on response to rituximab 
monotherapy.188 Most of the patients in this study had had prior chemotherapy and 
only 2 were homozygous for the FCGR2B-232T allele with 15 heterozygotes. The 
potential association is re-examined in our larger cohort of FL patients.  Recently, 
the level of expression of FcγRIIb was found to correlate with ORR and FFS in FL 
patients treated with rituximab monotherapy on the SAKK35/98 trial.189 Stored, 
pre-treatment tumour blocks were stained with an anti- FcγRIIb antibody; 116 
patients had absent or low-level expression and 13 had medium or high level 
expression.  Those with medium/high expression had inferior ORR compared with 
those with negative/low levels (23.1% vs. 58.6%: p=0.02), and poorer FFS (2.8 
months vs. 8.3 months: p=0.002). 
 
Figure 9: The location of the T-to-C single nucleotide polymorphism in exon 5 of the 
FCGR2B gene.  Adapted from Smith and Clatworthy (2010)190 
C1QA-Gly70GGG/GGA 
The complement component C1q initiates the classical pathway of complement 
activation by binding to immune complexes, or non-immune complex activators 
such as lipopolysaccharide and outer membrane proteins of Gram-negative 
bacteria.  C1q has also been shown to play an important role in the clearance of 
apoptotic bodies.191  The C1q molecule comprises 18 polypeptide chains, 6 A, 6 B, 
and 6 C chains, coded by three genes clustered on chromosome 1; C1QA, C1QB 
and C1QC.192 Patients with hereditary C1q deficiency are highly susceptible to 
recurrent infections and to systemic lupus erythematosus (SLE), and nonsense or 
missense point mutations have been identified in most of these familial pedigrees.   
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A transcriptionally silent polymorphism in exon 2 of CIQA, the gene encoding the α 
chain of C1q, has been identified, where the third guanine in the codon for amino-
acid residue Gly70 is replaced by adenine (figure 10).85 Polymorphism frequency 
in normal control populations are 13-18% GG, 21-29% AA and 53-66% 
heterozygotes, with A allelic frequency of 0.56.85,83  Even translationally silent 
mutations may influence gene expression;193 alternative splicing of mRNA is a 
possible mechanism.  The C1QA-Gly70GGA allele is associated with lower levels of 
serum C1q and is strongly associated with a non-familial form of photosensitive 
skin disease, subacute cutaneous lupus erythematosus (SCLE).85  When 
epidermal keratinocytes undergo ultraviolet light induced apoptosis, auto-antigens 
such as Ro are present in membrane blebs. The pathogenesis of cutaneous lupus 
is thought to include abnormal clearance of such auto-antigens. C1q binds to 
these membrane blebs and this binding is thought to lead to clearance of apoptotic 
keratinocytes.191  Patients with familial C1q deficiency have a 93% prevalence of 
photo-sensitive lupus.194 
Intriguingly, the C1QA-Gly70GGG/GGA polymorphism has been reported to affect 
duration of rituximab response in FL.83  In 133 FL patients treated with rituximab 
monotherapy, there was a trend for C1QA-Gly70GGA allele carriers to have better 
responses than C1QA-Gly70GGG homozygotes.  Amongst those who responded, 
C1QA-Gly70GGA carriers had a significantly greater duration of response, leading 
the authors to hypothesize that lower levels of C1q are associated with slower 
clearance of tumour apoptotic bodies, providing greater opportunity to develop a 
long-lasting immune response.83  The same investigator group found the C1QA-
Gly70GGA allele to be associated with lower chance of metastasis in breast cancer 
patients, particularly haematogenous metastatic spread.195 Impairment of 
apoptotic tumour cell removal and therefore prolonged exposure of various 
components of the immune system to tumour antigens may lead to a superior 
antitumor cellular response. 
We decided to test for this polymorphism in our FL patient cohort in an attempt to 
confirm the findings of the single previous study. 
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Fig. 10: The position of the C1QA-Gly70GGG/GGA polymorphism. The intron is shown as 
a line, while the untranslated regions are represented by hatched areas. Adapted from 
Racila et al, 2006195 
C3-R102G 
CR3 is a 187kD β2-integrin which can bind multiple ligands including intracellular 
adhesion molecules, polysaccarhides and iC3b, a cleavage product of C3.196  It is 
encoded by the C3 gene on chromosome 19.  Two allotypic forms of C3 have 
been described with a single-nucleotide polymorphism (C-to-G) in exon 3 at 
nucleotide 364 leading to either a positively charged arginine (R) or a neutral 
glycine (G) at amino-acid position 102.197 This C3-R102G polymorphism is also 
called C3-S/F to refer to the slow or fast electrophoretic motility, and has also been 
referred to as C3-R80G or -Arg80Gly. The G allelic frequency is around 0.2 in 
Caucasians, less in black populations and extremely rare in Oriental 
populations.198 Numerous disease associations reported with C3-R102G 
polymorphism argue for functional differences of the two alleles. It has reported 
associations with the autoimmune conditions IgA nephropathy199 and systemic 
vasculitis200, presence of nephritic factor, an IgG autoantibody linked to 
mesangiocapillary glomerulonephritis and partial lipodystrophy,201 and late-renal 
transplantation outcome.202 Homozygosity for the C3-102G allele has been shown 
to confer an odds ratio of 2.6 for age-related macular degeneration (OR 1.7 in 
heterozygotes).203 There is also circumstantial evidence that the C3-102G allele 
may be advantageous in response to infection.  Its prevalence is significantly 
higher in descendants of Dutch emigrants to Surinam than in the parent Dutch 
population, with a degree of difference unlikely to be accounted for solely by 
population drift.204 The emigrant population was subject to a 60% mortality from 
typhoid and yellow fever shortly after establishing the colony in the 19 th century, 
strong selective pressure for polymorphisms enhancing recovery from infection. 
The polymorphism was reported to affect the ability of C3 fragments to bind 
complement receptors205, although this has been called into question by 
subsequent work.206 The polymorphism is not thought to be located near to known 
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CR binding sites but in the MG1 domain near the binding site for factor H (fH) and 
its co-factor factor I (fI).207 Amplification of the alternative pathway of complement 
activation is controlled by fH and fI, which inactivate C3b. The C3-102G allele has 
been shown to reduce affinity for fH, leading to reduced C3b inactivation and 
increased complement activity.208 Reduced positive charge associated with the 
switch from Arginine to Glycine at position 102 is presumably responsible for the 
change in binding affinity.  
In view of the associations with autoimmunity and infection, we decided to explore 
whether or not this polymorphism may have influence on the response to 
monoclonal antibody therapy. There have not been any previous such studies. 
Patients, Materials and Methods 
 52 
Patients, materials and methods 
Study population 
The study population comprised those patients who had received rituximab therapy 
on the intergroup randomised trial of rituximab versus a watch and wait strategy in 
FL.  Consenting adult patients with newly diagnosed, asymptomatic, advanced stage 
FL (grades 1–2 & 3a) and adequate bone marrow reserve were included in the 
randomised trial (schema appendix 1).  Trial inclusion and exclusion criteria, together 
with requirements for baseline assessment and randomisation procedures are listed 
in appendix 2. Between September 2004 and May 2009, 463 patients were 
randomised from 107 sites in 5 countries.  They were randomly assigned to watchful 
waiting (arm A; n=187), rituximab 375mg/m2 weekly for 4 weeks (arm B; n=84) or 
rituximab 375mg/m2 weekly for 4 weeks followed by rituximab maintenance every 2 
months for 2 years (arm C; n=192).  Patients were randomised in a 1:1:1 ratio; arm B 
was closed part way through the trial to speed full accrual, as more information on 
the benefits of maintenance rituximab was emerging.  
 Patients were required to have low tumour burden, with a subtly different definition 
than that used by the GELF: the largest mass had to be less than 7cm with no more 
than 3 nodal sites greater than 3cm in diameter, the spleen no greater than 16cm on 
CT scan and no significant serous effusions.  Additionally, haemoglobin had to be 
more than 10g/dl, neutrophils more than 1.5x109/l, platelets more than 100x109/l, and 
circulating tumour cells fewer than 5x109/l.  Lactate dehydrogenase (LDH) was 
normal except in 5% of patients in whom it was slightly elevated.   The primary 
clinical end point was time to initiation of next treatment (TTNT); secondary end-
points included response at 25 months, cause specific survival and overall survival, 
as well as frequency of spontaneous remissions in arm A.  The trial also included 
several quality of life end-points assessed by questionnaire.  The trial protocol 
required provision of peripheral blood and bone marrow aspirate at registration and 
other time points (see below). 
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Ethical considerations 
The randomised trial had appropriate regulatory and ethical approval and was 
conducted in accordance with the declaration of Helsinki.  It was emphasized that 
participation was voluntary and that patients could refuse further participation at any 
time without prejudicing their subsequent care. Documented informed consent was 
obtained for all patients included in the study before they are registered at the data 
centre.  Specific consent was sought for the storage and use of genetic material 
extracted from blood and bone marrow to correlate small differences in patients’ 
immune systems with rituximab response, and to detect low levels of lymphoma.  
Patients also consented to the storage of genetic material to be used in future 
research into lymphoma pathogenesis and therapy response.  Patients were able to 
participate in the clinical research study without agreeing to the use of their genetic 
material in this way.   
In order to preserve confidentiality, patients’ names were not recorded at the data 
centre; a sequential identification number was attributed to each patient registered in 
the trial. Patients’ initials, dates of birth and local hospital numbers were also 
recorded to avoid identification errors. 
Assessment of clinical response 
Clinical response assessments were carried out by local investigators according to 
the criteria set out by Cheson et al (appendix 3)209 one month after randomisation 
and every 2 months thereafter for 2 years, then 3 monthly until progression.  Once 
progression had occurred, follow-up continued 6 monthly.  Immediate notification of 
disease progression, histological transformation, new treatment or death was 
required. CT scanning was mandated at 7 and 25 months, at 13 months if in clinical 
complete response (CR) and at any time to confirm progression or before new 
treatment.  Bone marrow examinations were conducted at the same time points to 
confirm clinical and radiological CR if the marrow was involved prior to treatment.  
Data quality was checked by data managers employing computerised and manual 
consistency checks on newly received case report forms; queries were issued in 
case of inconsistencies and/or missing data and followed up until resolution.  Once 
Patients, Materials and Methods 
 54 
accrual was complete further database cleansing was undertaken.  A random 
sample of patient files was physician-reviewed to ensure that accurate registration 
data had been recorded on the database. All reports pertaining to response 
assessments, disease progression including transformation, new treatment and 
patient death were physician-reviewed centrally, blinded to genotype results.  Further 
queries were generated for clarification and in cases where the central reviewer 
disagreed with assessments performed at sites.  In such cases the site principal 
investigator was invited to reconsider their assessment to reach consensus; if no 
consensus was reached the principal investigator’s assessment was used.   
Statistical analyses 
The primary endpoint of the randomised trial was TTNT, defined as the time from 
randomisation until the first day of chemotherapy or radiotherapy administration.  
Progression free survival (PFS) was defined as time from randomisation to 
progression, transformation or death from any cause. Patients who are still alive are 
censored at the time they were last known to be alive. Overall survival (OS) was 
defined as time from randomisation to death from any cause. Patients still alive are 
censored at the time they were last known to be alive. 
Overall response rates (ORR) and complete response rates (CRR) were analyzed by 
polymorphism and contingency tables created.  CR and CR unconfirmed (CRu) were 
combined in all analyses.  Fisher’s exact test was used to derive p values from 2x2 
contingency tables.  The chi-square test was used to test for significant difference in 
contingency tables larger than 2x2.  Where three patient groups are compared 
(homozygotes in either direction plus heterozygotes), p values derived from the chi-
square test for independence (treating each group separately) and the chi-square 
test for trend are quoted.  Kaplan-Meir survival curves for TTNT, PFS and OS were 
constructed; comparisons between groups were performed using the log-rank test.  
The product of the dimensions of the largest baseline node was calculated and 
patients were split at the median value and outcomes compared for those with lower 
bulk (LB) versus higher bulk (HB).   
The sample size for the randomised trial was calculated to detect an improvement in 
the median TTNT in the rituximab arm of 18 months (a hazard ratio of 0.625) with a 
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5% significance level and 90% power, assuming a median TTNT of 30 months in the 
watch and wait arm. To observe the required 192 events, 180 patients were to be 
recruited into each of arms A and C with 2 years further follow-up after entry of the 
last patient. 
 Specimen collection and initial processing 
Peripheral blood and aspirated marrow were collected at the time of registration, 
with repeat samples required at 7, 13 and 25 months if the patient was clinically 
and radiologically in CR.  Blood and marrow were also required if a patient was due 
to start chemotherapy or radiotherapy.  The protocol requested 20-30ml peripheral 
blood and the first 2-3ml aspirated marrow, each collected into 
ethylenediaminetetraacetic acid (EDTA), and stated that “samples should ideally be 
taken in the early part of the week (Monday to Wednesday preferably) and sent by 
first class post/guaranteed next day delivery if possible”.  
On arrival at the central laboratory, samples were registered by trial number, patient 
initials and date received, spun to isolate mononuclear cells and a white cell count 
performed.  For those with adequate cell numbers, the sample was split to enable 
future ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) extraction.  Samples 
for RNA extraction were stored at -80ºC in 1ml trizol; those for DNA extraction were 
stored at -20ºC in dodecyltrimethylammonium bromide (DTAB).  Where cell numbers 
were very low, samples were only stored for RNA extraction.  This initial processing 
had been carried out by various staff prior to the commencement of this project.  
Australasian samples were received in frozen pellet form.  Prior to DNA extraction 
they were defrosted at room temperature and re-suspended in 1.5ml DPBS.  The 
suspension was transferred to a 15ml centrifuge tube, 3ml DTAB added and mixed 
by inversion.  Samples were then frozen at -20ºC and DNA extracted in batches (see 
below). 
A list was compiled of patients from whom no adequate sample of blood or marrow 
had ever been received, who were randomised to receive rituximab.  A letter was 
sent to principal investigators at sites requesting a fresh sample or stored material 
from blocks or slides (appendix 4). Due to concern that patients who had died on trial 
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were more likely to fall into this category, particular efforts were made to obtain 
stored material from them to reduce possible bias.  
DNA isolation from blood or marrow 
Genomic DNA was extracted in batches, using phase separation by centrifugation.  
Samples stored in DTAB were thawed to room temperature, mixed well with an 
equal volume of chloroform and centrifuged at 3500rpm for 15 minutes.  The upper 
aqueous layer was pipetted into a clean tube and an equal volume of 100% ethanol 
added to precipitate the DNA.  Further centrifugation at 3500rpm for 5 minutes 
formed the DNA into a pellet, which was removed to a 1.5ml eppendorf. The pellet 
was washed with 1ml 70-75% ethanol, centrifuged at 13000rpm for 1 minute, the 
supernatant removed and sample air-dried.  The pellet was re-suspended in 
nuclease-free water, the volume of which was ascertained by the cell count of the 
original sample (<10 cells, 50µl water; 10-15 cells, 100µl; 15-20 cells 200µl, 20-40 
cells, 300µl; >40 cells, 600µl).  A cell count was not possible for Australasian 
samples; these pellets were re-suspended in 200µl nuclease-free water.  Extracted 
DNA was stored at 4ºC.  DNA was quantified by spectrophotometer and samples 
diluted to approximately 250ng/µl for use in PCRs. 
RNA extraction from blood or marrow 
Samples frozen in trizol were defrosted at room temperature, 200µl chloroform 
added and shaken vigorously.  Centrifugation at 12000rpm for 15min at 4ºC resulted 
in separation into an organic phase and an aqueous phase containing the RNA.  The 
upper aqueous layer was transferred to a fresh tube and 0.5 ml isopropyl alcohol 
added to precipitate RNA.  Samples were incubated at room temperature for 10 
minutes then centrifuged for 10 minutes at 12000rpm and 4ºC.  The supernatant was 
discarded, 1ml cold 75% ethanol added and sample centrifuged for 5 minutes at 
7500rpm and 4ºC.  The supernatant was carefully removed leaving the RNA pellet 
undisturbed.  The pellet was air-dried at room temperature and re-suspended in 
nuclease-free water; the sample was stored at -80ºC. 
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Alternative DNA sources 
Where no genomic DNA was available, complementary DNA (cDNA) was prepared 
from RNA using Invitrogen Superscript III kit.  RNA was defrosted and quantified by 
spectrophotometer.  Working on ice, 1µg RNA was made up to 10µl with water in 
PCR tubes before adding 2µl random decamers (Ambion) and 4µl 2mM 
deoxynucleoside triphosphates (dNTPs).  Samples were heated to 70ºC for 3 minute 
and returned to ice for 1 minute.  Reverse transcriptase, 10xRT buffer and RNAs 
inhibitor (1µl of each) were added prior to incubation at 42ºC for one hour then 95ºC 
for 5 minutes.  Samples were refrigerated for use within the next few days or frozen 
at -20ºC for future use. 
Where no peripheral blood or bone marrow aspirate was available, DNA was 
recovered from stained, glass slides.  They were soaked overnight in xylene to 
facilitate coverslip removal.  Each slide had 20µl proteinase K and 200µl phosphate 
buffered saline (PBS) added and the material scraped into a 1.5ml eppendorf tube.  
Following the addition of 200µl AL buffer the samples were incubated at 56ºC for 5 
hours to achieve cell lysis.  200µl absolute ethanol was added before transfer to a 
DNeasy mini spin column and centrifugation at 8000rpm for 1 minute; flow-through 
was discarded.  500µl buffer AW1 was added and the column centrifuged at 
8000rpm for 1 minute with flow-through discarded; 500µl buffer AW2 was added and 
spun at 14000rpm for 3 minutes.  The column was placed in a new 1.5ml eppendorf 
tube with 100µl buffer AE, kept at room temperature for 5 minutes before 
centrifugation at 8000rpm for 1 minute.  A second aliquot of buffer AE was added 
and further spun into the receiving eppendorf. 
Analyses for polymorphisms by polymerase chain reaction (PCR) 
and allele-specific restriction enzyme digestion 
General PCR methods 
Primers were synthesized and lyophilized by Integrated DNA Technologies.  On 
receipt in the laboratory they were reconstituted with nuclease-free water to 100µM 
stock solutions and frozen at -20ºC.  Prior to use they were thawed at room 
temperature, diluted to 25µM in nuclease-free water, and re-frozen in aliquots for 
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each PCR batch to minimise the potential for contamination.  Each PCR reaction 
was carried out in a 50µl volume containing 1µl of each primer at this working 
dilution (25pmol), 25µl Taq 2x mastermix (New Eng biolabs: 25µl contains 1.25units 
Taq DNA polymerase, 0.4mM dNTPs, standard Taq reaction buffer and stabilisers), 
21µl nuclease-free water and 2µl of each DNA sample (approximately 500ng).  
Larger sample volumes were used in cases of very low DNA concentration, and less 
water added. 
A blank control was carried out in parallel for each batch, replacing the DNA sample 
with water. Great care was taken with labelling of the tubes and pipetting patient 
samples to ensure correct identification.  PCR reactions were performed on a DNA 
Engine Tetrad 2 thermal cycler (Bio-rad). 
FCGR3A-V158F polymorphism detection 
The FCGR3A-V158F polymorphism was ascertained by nested PCR and restriction 
enzyme digestion based on a published method.63 The FCGR3A gene sequence, 
location of the SNP and sites of primer annealing were identified (appendix 5).  The 
first PCR reaction used outer primers (forward MP6965: 5’-ATA TTT ACA GAA TGG 
CAC AGG -3’ and reverse MP6966 5’-GAC TTG GTA CCC AGG TTGA A-3’; 
characters in bold denote mismatches introduced to increase specificity) to amplify a 
1.7kb fragment containing the polymorphic site. Patient samples were processed in 
batches of 18 in 50µl reaction volumes (see above).  Initial denaturation for 10 
minutes at 95ºC was followed by 35 cycles of denaturing at 95ºC for 1 minute, primer 
annealing at 56ºC for 90seconds and extension at 72ºC for 90seconds, followed by a 
final extension of 8minutes at 72ºC.   
The second PCR used inner primers (forward MP6967: 5’-atc aga ttc gAT CCT ACT 
TCT GCA GGG GGC AT-3’ and reverse MP6968: 5’-acg tgc tga gCT TGA GTG 
ATG GTG ATG TTC AC-3’; capital letters denote annealing nucleotides) to amplify a 
94bp fragment.  The forward primer contained a mismatch (A instead of T two 
nucleotides from the 3’ end), which created an NlaIII restriction site (5’...CATGꜜ...3’) 
in FcR3A-158V encoding DNA but not FcR3A-158F.  2µl of the first PCR product 
was used as the template for this second PCR.  Reaction conditions were 5 minutes 
denaturing at 95ºC, 1 minute annealing at 64ºC and 1 minute extension at 72ºC for 
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the first cycle, followed by 35 cycles in which the denaturing time was 1 minute, 
followed by a final 9½ minute extension at 72ºC.  The DNA product was transferred 
to a QIA quick spin column for purification.  Binding buffer PB was added at five 
times volume (250µl) and spun for 1 minute with through-flow discarded.  750µl 
wash buffer PE was added and centrifuged for 1 minute; flow-through was discarded 
and the samples spun for a further minute.  The DNA was then eluted into 30µl 
nuclease-free water. 
Digestion was carried out in 50µl reaction volumes using 10µl DNA and 2µl NlaIII 
enzyme (New England Biolabs) with the recommended buffer, incubated at 37ºC for 
2 hours.  In FcR3A-158V encoding DNA, the 94bp fragment was cut into two 
fragments of 61bp and 33bp, whereas FcR3A-158F encoding DNA remained 
undigested.  Previously identified FF, VV and VF samples were included in each 
batch as a control for adequate digestion.  Following digestion and the addition of 
10µl DNA load, samples were run on 3.5% agarose gels containing gelstar, viewed 
under UV light and the genotype recorded.  Sample gels are shown in figure 11. 
The product of the second PCR was too short to generate a good quality sequencing 
result.  The product of the first PCR from homozygous F, homozygous V and 
heterozygous patient samples was sequenced using the forward primer to 
corroborate the results (figures 12 and 13). 
Assay optimisation: 
1) Work was required to optimize the staining of the gels to pick up small 
fragments.  Gels were pre- or post-stained with gelstar or ethidium bromide.  
Pre-staining with either stain produced an extra non-specific band, slightly 
larger than the 61bp fragment, not seen on post-stained gels (figure 1C).  
However, pre-staining with gelstar gave the sharpest band appearance and 
hence this method was used for patient samples (3.15g agarose melted in 
90ml TBE with 9µl gelstar added). 
2) Initially there were problems with contamination (product in the blank control) 
despite carrying out the assay in a room reserved for PCR using techniques 
standard in the laboratory.  This was largely solved by reserving a set of new 
pipettes and separate tips for this work. 
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Figure 11: FCGR3A-V158F polymorphism analysis: high-resolution agarose gel 
photographed under UV light post electrophoresis.  A) 94bp undigested product 
(arrowed) in screening samples 1-4 (also present in blank control) B) Post digestion bands of 
94bp, 61bp and 33bp are seen, depending on genotype.  This gel was post-stained with 
gelstar.  Homozygous F samples (uncut) are easily identifiable but the difference between 
homozygous V and heterozygous is less clear-cut.  C) Digested screening samples run on 
gels containing gelstar.  A non-specific band is seen relating to the F allele (arrowed) but the 
VV and VF samples can now be well differentiated.  D), E) Patient samples following nested 
PCR, restriction digest and electrophoresis on 3.5% high resolution agarose gels containing 
gelstar, viewed under UV light.  Patients 1, 3, 5, 6, 9, 10, 11, 13 and 14 are homozygous F; 
patients 4, 12, 15, 16 and 17 are heterozygous; patients 2 and 18 are homozygous V.  No 
product was identified for patients 7 and 8 and these were repeated.  F) Hyperladder V used 
in the first lane in gels A-E.  NT = No template (blank control)  
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Figure 12: Direct sequencing of the FCGR3A-V158F polymorphic region analysed on 
Sci Ed Central.  A) The main region of homology between the known gene sequence (top) 
and sequenced amplicon (bottom).  B), C), D) Homozygous F, homozygous V and 
heterozygous, respectively comparisons in sequence view showing the FCGR3A gene with 
the sequenced amplicon. Matched bases are represented by a dot; non-matches are 
highlighted in colour.  The location of the SNP is marked with a star and the allele-specific 
potential restriction site is highlighted in aqua. 
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Figure 13: FCGR3A-V158F polymorphism detection: direct sequencing.  A), B), C) DNA 
sequence trace chromatograms of homozygous F, homozygous V and heterozygous 
amplicons, respectively. 
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FCGR2A-H131R polymorphism detection 
The FCGR2A-H131R polymorphism was also genotyped using a published 
method.210 The FCGR2A gene sequence, SNP location and primer annealing sites 
were ascertained (appendix 6).  The oligonucleotides had been chosen by Jiang et al 
to specifically amplify the FCGR2A gene and not the highly homologous FCGR2B 
and FCGR2C genes (forward MP7931: 5’-GGA AAA TCC CAG AAA TTC TCG C-3’ 
and reverse MP7932: 5’-CAA CAG CCT GAC TAC CTA TTA CGC GGG-3’).  The 
forward primer contains a single-nucleotide substitution (CG, shown in bold), 
producing a BstUI restriction site (5’CGꜜCG-3’) in FcR2A-131R encoding DNA but 
not FcR2A-131H.  The reverse primer contains a double-nucleotide substitution 
(CTGC) introducing a BstUI restriction site into all products, regardless of 
polymorphism, to act as an internal control of enzyme function.  The conditions for 
this single-step PCR assay were 94ºC for 3 minutes followed by 35 cycles of 94ºC 
for 15 seconds, 55ºC for 30 seconds and 72ºC for 40 seconds, with a final extension 
of 7 minutes.   
Digestion was carried out in 40µl volumes using 14µl PCR product, 2µl BstUI, 4µl 
buffer R and water, incubated at 37ºC for 1½hours.  The 366bp undigested PCR 
product contained either one or two restriction sites depending on genotype.  Post-
digestion the identifiable fragment sizes were 343bp for FcR2A-131H encoding 
DNA and 322bp for FcR2A-131R.  Following the addition of 10µl DNA load, 
samples were electrophoresed on high-resolution agarose gels, viewed under UV 
light and genotype recorded.  Different gel concentrations and staining methods 
were tested; cleanest band separation was achieved using 3% agarose gels 
containing ethidium bromide (80ml TBE, 2.4g agarose and 5µl ethidium bromide). 
Normal donor samples were screened to identify homozygous H, homozygous R and 
heterozygous controls, confirmed by direct sequencing of the amplicon using the 
reverse primer.  Patient samples were analysed in batches of 24 and a negative 
control containing water instead of DNA was included with each batch.  Sample gel 
photographs and sequencing results are shown in figures 14-16. 
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Figure 14: FCGR2A-H131R polymorphism determination: high-resolution agarose gel 
electrophoresis following PCR and BstUI restriction digest.  A) Hyperladder V used in 
first lane of each gel.  B-E) Screening samples post digestion run on 1% (B, D) and 3% (C, 
E) gels stained with gelstar (B, C) and ethidium bromide (D, E).  F-G) Patient samples 
following single-step PCR, restriction digest and electrophoresis on 3% high resolution 
agarose gels containing ethidium bromide.  Patients 4, 5 and 10 are homozygous H; patients 
2, 6, 7, 11 and 15 are homozygous R; patients 1, 3, 8, 9, 12, 13, 14 and 16 are 
heterozygous.  NT = no template (blank control), UC = uncut. 
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Figure 15: Direct sequencing of the FCGR2A-H131R polymorphic region analysed on 
Sci Ed Central.  A) The main region of homology between the known gene sequence (top, 
blue) and sequenced amplicon (bottom, green).  B), C), D) Heterozygous, homozygous R 
and homozygous H, respectively comparisons in sequence view showing the FCGR2A gene 
with the sequenced amplicon beneath (sequence reversed as reverse primer used). 
Matched bases are represented by a dot; non-matches are highlighted in colour.  The 
location of the SNP is marked with a star and the allele-specific potential restriction site is 
highlighted in aqua.   
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Figure 16: FCGR2A-H131R polymorphism detection: direct sequencing.  A), B), C) 
DNA sequence trace chromatograms of heterozygous, homozygous R and homozygous H 
amplicons, respectively.  
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FCGR2B-I232T polymorphism detection 
The previously published method for detecting the FCGR2B-I232T SNP involved a 
nested PCR with melting point analysis.115 The FCGR2B sequence and SNP 
location were ascertained (appendix 7).  A type II restriction endonuclease was 
identified which was allele-specific; BsmFI cuts 10bp down-stream from 5’-GGGAC-
3’ with a 4bp overhang.  New inner primers were designed (by Martin Pule) to 
amplify a 455bp section of DNA surrounding this site (forward MP8231: 5’-GCT GTG 
GTC ACT GGG ATT GCT GTA GCG-3’ and reverse MP8232: 5’-TAC AAA CCT 
GAA ATC CGC TTT TTC CTG-3’).  This fragment contains one restriction site in the 
wild-type FCGR2B-232I DNA but two sites in FCGR2B-232T.  A two-step PCR was 
necessary because the core sequence was repeated at greater than 99% homology.  
One forward (MP8235: 5’-CGG GTC CTC TGC GGT TTT TTG-3’ and two reverse 
(MP8236: 5’-ACT ACA CTG CTC TCC CCA AGA C-3’ and MP8237: 5’-TCC CAC 
CTG GGC CAG GGC TTG-3’) outer primers were designed to anneal at sites of 
difference from the pseudogene (see appendix 7 for all sites of primer annealing).  
Outer primers used by Kyogoku et al115 were also synthesized (forward MP8233: 5’-
AAG GAC AAG CCT CTG GTC AA-3’; reverse MP8234: 5’-CCC AAC TTT GTC 
AGC CTC AT-3’).  Three different pairs of outer primers were tested (figure table + 
gel picture); bands of the correct size were seen using the previously published 
primers (A) and the new combination MP8235 with MP8236 (B).   
Amplicon Forward primer Reverse Primer Expected size 
A115 MP8233 MP8234 4317bp 
B MP8235 MP8236 1535bp 
C MP8235 MP8237 3145bp 
The latter reaction generated a much smaller fragment with no additional bands seen 
and therefore this amplicon was selected to take forward to the second PCR and 
digest. The first PCR used the following conditions: initial denaturation for 90 
seconds at 96ºC followed by 35 cycles of denaturing at 96ºC for 30 seconds, primer 
annealing at 56ºC for 30 seconds and extension at 72ºC for 2 minutes, followed by a 
final extension of 5 minutes at 72ºC.  Conditions for the second PCR were identical 
except that extension was carried out for 45 seconds per cycle with a final extension 
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of 4 minutes; the product of the second PCR was 455bp long.  The amplicon was 
purified using QIA quick spin columns and digested with BsmFI. Digestion was 
carried out in 50µl volumes using 2µl enzyme, 5µl buffer 4, 0.5µl BSA, 15µl purified 
DNA and water, incubated at 65ºC for 90 minutes.  The FcR2B-232I allele product 
contains a single restriction site leading to fragments of 305bp and 150bp. The 
FcR2B-232T allele product contains a further restriction site producing fragments of 
305bp, 88bp and 62bp.  The products were electrophoresed in 3% high-resolution 
agarose gels stained with ethidium bromide, visualised under UV light and the 
genotype recorded.  Gel photographs and sequencing results are shown in figures 
17-19. 
TOPO TA cloning 
During initial screening for normal controls, no SNP homozygotes (TT) were 
identified.  More samples were screened and direct sequencing used to confirm the 
amplicon was of the expected sequence.  Wild-type homozygotes (II) and 
heterozygotes (IT) were identified, but no SNP homozygotes (previous studies report 
the frequency to be 2-3% in Caucasian healthy controls).  A SNP homozygote was 
therefore generated by TOPO-TA cloning of a heterozygote, as described below.  
The first PCR product from a heterozygote was inserted into a plasmid vector; by 
chance some vectors then contained FcR2b-232I encoding DNA and some 
contained FcR2b-232T. Bacterial colonies transfected with the vector were cloned 
and picked individually.  This sequence was then extracted from such colonies, 
providing template for the second PCR which was homozygous in one direction or 
the other.  
The product from the first PCR in a confirmed heterozygote was electrophoresed on 
1% agarose gel.  The 1.5kb product was identified and cut out of the gel under blue 
light; gel extraction was then performed using QIA quick spin columns.  The product 
was weighed and 3x QC buffer added before incubation at 50ºC for 10 minutes with 
occasional vortex.  An equal volume of isopropanol was added, transferred to the 
column and centrifuged for 1 minute with the flow-through discarded.  Following the 
addition of 750µl PE buffer, the column was spun for 1 minute and flow-through 
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discarded.  The column was spun for a further minute before transfer to a clean 
1.5ml eppendorf tube and elution with 30µl nuclease-free water.   
A TOPO-TA cloning kit (Invitrogen) with pCR®II-TOPO® plasmid vector (figure 20) 
was used. Topoisomerase I binds duplex DNA and cleaves the phosphodiester 
backbone after 5’-CCCTT in one strand of the vector.  Single 3’-thymidine overhangs 
allow efficient ligation with the single deoxyadenosine added to the ends of PCR 
products by Taq polymerase (nontemplate-dependent terminal transferase activity).  
The vector contains antibiotic resistance genes and the cloning site is flanked by 
EcoRI restriction sites (GꜜAATTC) to allow extraction of the cloned sequence.  A 
50µl aliquot of high-efficiency competent E. coli bacteria (New Eng Biolabs C2987H) 
was defrosted on ice. A combination of 1µl TOPO-kit salt mix, 1µl vector and 2µl 
water were gently mixed with 1µl cleaned PCR product and incubated at room 
temperature for 15 minutes.  In a 0.5ml eppendorf tube, 2µl of this ligation reaction 
was added to 25µl cells and kept on ice for 45 minutes.  The bacteria were 
transfected by 35 second heat shock at 42ºC in a water bath, then returned to ice for 
2 minutes.  The bacteria were added to 250µl SOC medium in a 12ml round bottom 
falcon tube and incubated on a bacteria shaker at 200rpm at 37ºC for one hour.  An 
agar plate containing carbenicillin was dried and evenly spread with 50µl X-Gal.  The 
plate was inoculated with 250µl SOC/bacteria using the Pasteur method with a 
disposable loop spreader, and incubated at 37ºC overnight.  The colonies were 
picked the next day (only untransformed bacteria express β-galactosidase and 
cleave X-Gal; blue/white screening used), added to 4ml LB medium with carbenicillin 
and kept on a bacterial shaker at 200rpm at 37ºC overnight. 
The next day, 1.5ml of each sample was transferred to an eppendorf tube, spun for 
10 minutes at 14000rpm and the supernatant discarded.  The plasmid was then 
extracted using commercial mini-prep kits (Qiagen).  The pellet was resuspended in 
250µl P1 buffer containing EDTA.  Cell lysis was achieved by adding 250 µl alkaline 
P2 buffer and shaking well to mix.  After 5 minutes 350µl neutralisation buffer N3 
was added and the sample mixed gently but thoroughly.  The sample was 
centrifuged for 10 minutes and the supernatant applied to a Qiaprep spin column.  
The column was spun for 1 minute at 13ooorpm, the flow-through was discarded and 
750µl PE wash buffer was added.  This was spun for 1 minute, flow-through 
Patients, Materials and Methods 
 70 
discarded and spun for a further minute.  The column was then placed in a clean 
1.5ml eppendorf tube and the DNA eluted into 50µl water. 
The FCGR2B DNA sequence was then extracted from the plasmid by EcoRI digest.  
The digestion reaction containing 1.5µl enzyme, 3µl buffer 3, 3µl DNA sample and 
22.5µl water was incubated at 37ºC for 2 hours.  The digested product was run on 
1% agarose gels containing ethidium, with 10µl sample and 2µl DNA load per well.  
Those with identifiable bands of the correct size were sent for sequencing and as 
expected some had a T and some a C at the polymorphic site of interest.  These 
were then used as template for the second PCR reaction and subsequent BsmFI 
digestion and gel electrophoreses.  Bands of the predicted sizes were found and 
these cloned PCR products were subsequently used as homozygous normal 
controls during patient sample processing. 
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Figure 17: FCGR2B-I232T polymorphism determination: high resolution agarose gel 
electrophoresis following nested PCR and BsmFI restriction digest, photographed 
under UV light.  A) Three different outer primer pairs were tested using four screening 
samples, with expected amplicon sizes a) 4317bp, b) 1535bp and c) 3145bp.  Primer pair b) 
gave a band of the expected size with no other bands so this amplicon was then used in the 
second (nested) PCR.  B) Undigested nested PCR product from screening samples 
corresponding to the expected band size of 455bp.  C) Digested nested PCR product from 
screening samples corresponding with expected I homozygous band sizes of 305bp and 
D E F 
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150bp. D) Hyperladder V used in figures B)-H).  E) Controls used with each patient batch.  
The negative control contained no template (NT); uncut (UC) product acted as an internal 
control of enzymatic activity.  The T homozygote has three bands of 305bp, 88bp and 62bp; 
control product was generated by TOPO-TA cloning as no screening sample was identified. 
Heterozygotes have four bands of 305bp, 150bp, 88bp and 62bp.  F), G), H) Patient 
samples.  Patients 8, 10, 12 and 20 are heterozygous; patient 27 is homozygous T; patient 6 
has an unclear result repeated in the next batch; the remaining patients are homozygous I. 
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Figure 18: Direct sequencing of the FCGR2B-I232T polymorphic region analysed on 
Sci Ed Central.  A), C) The main region of homology between the sequenced homozygous I 
amplicon (bottom in each picture) and known gene sequence and pseudogene, respectively.  
B), D) Comparisons in sequence view showing the FCGR2B gene (B) or pseudogene (D) 
with the sequenced homozygous I amplicon beneath (sequence reversed as reverse primer 
used). Matched bases are represented by a dot; non-matches are highlighted in colour.  The 
location of the SNP is marked with a star.  Comparisons showing the gene sequence 
compared with heterozygous and homozygous T amplicons are shown in E) and F), 
respectively. 
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Figure 19: FCGR2B-I232T polymorphism detection: direct sequencing.  DNA sequence 
trace chromatograms of homozygous I (A), heterozygous (B) and homozygous T (C) 
amplicons.  The location of the polymorphism is highlighted in green. 
Patients, Materials and Methods 
 76 
 
Figure 20: Schematic representation of the pCR®II-TOPO® plasmid vector showing the 
cloning site flanked by EcoR I digestion sites.  LacZα encodes β-galactosidase which will 
produce a blue dye from the substrate X-gal.  Successful insertion of the amplicon disrupts 
this gene and prevents β-galactosidase expression; colonies of transformed bacteria will be 
white.  The plasmid also contains antibiotic resistance genes. 
 
C1QA-Gly70GGG/GGA  polymorphism detection 
The C1QA gene sequence and location of the SNP of interest were ascertained 
(appendix 8).  Initially, published primers were used in a single-step PCR but the 
correct amplicon was not generated.  Collaboration with investigators in Montpelier 
was initiated and it was decided to follow the same methods as much as possible, 
with a joint publication in mind.  The primers were therefore ordered to match those 
used by the Montpelier group (forward MP11356: 5’-GCC TTA AAG GAG ACC AGG 
GGG AAC-3’ and reverse MP11357: 5’-CCC TTG AGG AGG AGA CGA TGG AC-
3’).  PCR conditions used by the Montpelier group were tried but no bands were 
visible when the product was electrophoresed.  Following optimisation of the 
conditions for our laboratory the PCR produced detectable product and thus the 
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following conditions were used for this single-step PCR assay: initial denaturation at 
95ºC for 5 minutes followed by 35 cycles of 95ºC for 30 seconds, 65ºC for 30 
seconds and 72ºC for 45 seconds, with a final extension of 5 minutes.   
Digestion was carried out in 50µl volumes using 12µl PCR product, 2µl ApaI, 5µl 
buffer 4, 0.5µl BSA and water, incubated at 37ºC for 2 hours.  The 348bp undigested 
PCR product contained either two or three restriction sites (GGGCCꜜC) depending 
on genotype.  Post-digestion the identifiable fragment sizes were 281bp for C1qa-
Gly70GGA encoding DNA and 262bp for C1qa-Gly70GGG.  Following the addition of 
10µl DNA load, samples were electrophoresed on high resolution agarose gels, 
viewed under UV light and genotype recorded.  Different gel concentrations and 
staining methods were tested; cleanest band separation was achieved using 3.5% 
agarose gels containing ethidium bromide (80ml TBE, 2.4g agarose and 5µl ethidium 
bromide).  Normal donor samples were screened to identify homozygous G, 
homozygous A and heterozygous controls, confirmed by direct sequencing of the 
amplicon using the reverse primer.  Patient samples were analysed in batches and a 
negative control containing water instead of DNA was included with each batch.  Gel 
photographs and sequencing results are shown in figures 21-23. 
  
Patients, Materials and Methods 
 78 
 
 
 
Figure 21: C1QA-Gly70 polymorphism detection.  The PCR product was digested with 
ApaI restriction enzyme, had DNA loading dye added and was electrophoresed on 3.5% 
agarose gels containing ethidium bromide, then viewed under UV light.  The first lane in 
each gel contains hyperladder V.  Each gel has three positive controls: in A homozygotes a 
single 281bp band is seen, G homozygotes have a single 262bp band and heterozygotes 
have both bands.  The uncut (UC) amplicon is included as a control of enzymatic activity 
(348bp); the blank control used no template (NT).  Patients 7, 12, 15, 16, 20, 23 and 25 are 
A homozygotes; patients 1, 4, 11 and 22 are G homozygotes; patients 5, 6, 8, 9, 10, 13, 14, 
17, 18, 19, 21, 24, 26 and 27 are heterozygotes; no product was obtained from patients 2 
and 3 and these were repeated in a subsequent batch. 
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Figure 22:  C1QA-Gly70 polymorphism detection: direct sequencing.  Using Sci Ed 
Central the known C1QA gene sequence is compared with screening samples 2 (fig A; 
heterozygote), 3 (fig B; homogygous A) and 7(fig C; homozygous G). The C1QA sequence 
is shown on top in each picture, with the sequenced amplicon beneath (sequence reversed 
as reverse primer used for sequencing).  Matched bases are represented by a dot; non-
matches are highlighted in colour.  Potential ApaI restriction sites (GGGCCꜜC) are 
highlighted in aqua; the SNP location is marked with a star. Fig D shows the main region of 
homology between the known C1QA gene sequence (above; highlighted blue) and 
sequenced amplicon (below; highlighted green).    
Patients, Materials and Methods 
 80 
 
 
 
Figure 23: C1QA-Gly70 polymorphism detection: direct sequencing.  DNA sequence 
trace chromatograms of homozygous A (A), heterozygous (B) and homozygous G (C) 
amplicons.  The location of the polymorphism is highlighted in green.
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C3-R102G polymorphism detection 
The C3 gene sequence and location of the SNP were ascertained (appendix 9).  
Primers described by the Montpelier group were made (forward MP11350: 5’-CCA 
AAA CGG CCA CCT CGG AA-3' and reverse MP11351: 5'-CCG TCC GGC CCA 
CGG GTA GC-3’) and used to amplify a 431bp segment of DNA, containing the 
polymorphic site.  The conditions for the single-step PCR were initial denaturation at 
94ºC for 5 minutes followed by 30 cycles of 94ºC for 1 minute, 65ºC for 30 seconds 
and 72ºC for 30 seconds, with a 5 minute final extension at 72ºC.  Again, these 
conditions were slightly different than those employed by the Montpelier group. 
The PCR product was purified using QIA quick spin columns as before.  Digestion 
was carried out in 20µl volumes using 6µl amplicon, 0.5µl HhaI, 2µl buffer 4, 0.2µl 
BSA and water, incubated at 37ºC for 2 hours.  A single GCGꜜC restriction site was 
present in C3-102-R encoding DNA, yielding fragments of 264bp and 167bp.  C3-
102-G encoding DNA remained uncut.  Following the addition of 5µl DNA loading 
dye, samples were electrophoresed on agarose gels, viewed under UV light and the 
genotype recorded.  Different gel concentrations and staining methods were tested; 
adequate band separation was achieved using 2% gels (using 90ml TBE, 1.8g fine 
resolution agarose and 5µl ethidium bromide), Normal donor samples were screened 
to identify homozygous G, homozygous R and heterozygous controls, confirmed by 
direct sequencing of the amplicon using the reverse primer.  Patient samples were 
analysed in batches of 27 and a blank control run in parallel with each batch.  Gel 
photographs and sequencing results are shown in figures 24-26. 
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Figure 24: C3-R102G polymorphism analysis: PCR and HhaI restriction digest 
followed by agarose gel electrophoresis, photographed under UV light.  The expected 
band sizes are 264bp and 167bp for the C3-102-R allele containing the restriction site and 
431bp for the C3-102-G allele which lacks the restriction site.  Three bands are seen for 
heterozygotes.  A) Screening samples run on 1% agarose gel containing ethidium bromide, 
with hyperladder V in lane 1.  Sample 5 appears to be heterozygous with the others all 
homozygous R.  B), C), D) Patient samples run on 2% fine grade agarose gels containing 
ethidium bromide, with hyperladder IV in lane 1.  Each gel has a negative control (NT = no 
template) and three positive controls.  Patients 3, 5-10, 12, 15-19, 21 and 23-27 are 
homozygous R; patients 4, 13, 14 and 20 are homozygous G; patients 1, 2, 11 and 22 are 
heterozygous.
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Figure 25: C3-R102G polymorphism analysis: direct sequencing. Using Sci Ed Central 
the known C3 gene sequence is compared with screening samples found by restriction 
digest and gel electrophoresis to be A) heterozygous, B) homozygous G, and C) 
homozygous R.  The C3 sequence is shown on top in each picture with the sequenced 
amplicon beneath (reversed as reverse primer used).  Matched bases are represented by a 
dot; non-matches are high-lighted in orange.  The potential HhaI restriction site (GCGꜜC) is 
high-lighted in aqua and a star marks the location of the SNP.  Fig D shows the region of 
homology between the known C3 gene and the sequenced amplicon. 
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Figure 26: C3-R102G polymorphism analysis: direct sequencing.  DNA sequence trace 
chromatograms of heterozygous (A), homozygous R (B) and homozygous G (C) amplicons.  
The location of the polymorphism is highlighted in green. 
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Collaborations and future directions 
Constitutional DNA is now stored from the majority of patients entered on this trial, 
and the clinical dataset has been thoroughly reviewed and cleaned up such that the 
outcome assessments are robust and reliable.  The trial has completed accrual but 
will continue to collect data for years to come, in order to investigate long-term 
survival differences between randomisation arms.  In the future it will be possible to 
look for any OS differences by polymorphism status.  Meanwhile, the clinical data 
linked with patient DNA is a valuable resource for investigation of other putative 
patient factors in FL natural history and response to rituximab therapy.  Ideally, 
tumour DNA would also be available and linked to this to allow evaluation of 
biomarkers. 
Patient DNA at approximate 250 ng/µl dilution were sent in mini-racked tubes 
(Micronic) containing 10µl sample each, to collaborating groups in Montpelier, 
France (Cartron et al) and St Barts, London (Fitzgibbon et al). Two polymorphisms in 
the ITGAM gene encoding complement c3 receptor (CR3/CD11b) were investigated 
in the laboratory of the Montpelier group. The polymorphism of interest theorised to 
modify the C3/CD11b interaction ITGAM-M425T, and a control polymorphism 
ITGAM-P1130S localised outside the C3/CD11b interaction site, were previously 
thought to influence PFS after rituximab therapy in FL.91 The St Barts group 
analysed patient samples for the rs2072407 mutation in the EZH2 gene which 
encodes a histone methlytransferase.  Mutations within this gene have been 
reported in several malignancies, including lymphoma.211 Ultimately, a comparison 
between constitutional and tumour DNA with link to clinical outcome should address 
whether this mutation has significant influence on response to rituximab therapy. 
In order to establish a tumour DNA archive, diagnostic tumour blocks will be recalled 
from participating sites.  In preparation for this, whole genome amplification from 
formalin-fixed, paraffin-embedded (FFPE) tissue has been performed using the 
REPLI-g kit (Qiagen).  The process prepares and randomly ligates fragmented DNA 
(damaged in the fixing process) before amplification.212 This kit has been tested on 
spare tonsil specimens, and subsequent PCR for the FCGR3A-V158F polymorphism 
yielded a result in two of the three cases. 
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Results 
Availability of genetic material 
Of 276 patients randomised to receive rituximab on trial, availability of genetic 
material allowed FCGR3A-V158F polymorphism status to be ascertained in 259.  In 
234, genomic DNA extracted from peripheral blood or bone marrow aspirate was 
used, 2 patients had genomic DNA recovered from stored glass slides (one bone 
marrow aspirate and one lymph node biopsy), and 23 patients with no available 
genomic DNA had cDNA generated from RNA.  No sample was received from 14 
patients (8 of those from outside the UK) and 3 samples were of poor quality and 
yielded no results. 
Some of the smaller and poorer quality samples became exhausted and as such 
fewer results were obtained for the other polymorphisms: 256 for FCGR2A-H131R 
and FCGR2B-I232T, 250 for C1QA-Gly70GGG/GGA and 242 for C3-R102G. 
Missing samples for the 187 patients randomised to watch and wait (arm A) were not 
pursued so aggressively; availability of genetic material allowed FCGR3A-V158F 
polymorphism status to be ascertained in 87.  These results are not included in the 
following analyses, which relate purely to patients randomised to receive rituximab.  
The results from these samples are shown in Appendix X. 
FCGR3A-V158F 
Observed polymorphism frequencies were as follows: 111 FF(43%); 117 VF(45%); 
31 VV(12%).  The groups were broadly comparable in terms of age, gender, stage, 
marrow involvement and FLIPI score (table 14.  The VV group were slightly younger 
(median age VV, 55 years; VF, 60 years; FF, 59 years), and a greater proportion had 
low-risk FLIPI scores (0/1 VV 48%; VF 28%; FF 40%) and excellent performance 
status (PS0 VV 94%; VF 92%; FF 88%).  The only statistically significant difference 
in the populations was in the proportion of patients in the rituximab maintenance 
randomisation arm.  72% of VF/FF patients were randomised to R4+M; however for 
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FCGR3A-158V homozygotes only 52% were in this arm, with 48% randomised to R4 
only (p=0.04).   
With a median follow-up of 46 months, there was no significant difference in overall 
response rate (ORR) or complete response rate (CRR) by polymorphism at 7, 13 or 
25 months (table 5).  This was true comparing heterozygotes separately or combined 
with either group of homozygotes (table 6).  The ORR (CRR)  were FF:87%(63%); 
VF:85%(55%); VV:76%(41%) at month 7 and FF:73%(65%); VF:71%(61%); 
VV:72%(61%) at month 25.  Contrary to previous reports, there was a trend for 
FCGR3A-158V patients to have worse outcomes, particularly CRR at 7 months (41% 
VV vs 59% FF/VF; p=0.07).  There was also no correlation between polymorphism 
status and TTNT, PFS or OS (figure 27). 
Response by treatment arm was considered to assess the impact of rituximab 
maintenance (table 7).  Those randomised to R4+M had higher ORR and CRR than 
those randomised to R4, which was highly significant by month 25 (ORR (CRR) R4: 
73% (44%); R4+M: 81% (56%); p=0.03 (0.01)). There was no significant interaction 
for the FCGR3A polymorphism.  When looking at response by polymorphism results, 
each genotype had at least a trend towards better response rates when treated with 
R4+M than with R4, at every time point.  As proportionately fewer VV patients were 
randomised to R4+M than VF/FF patients (52% vs. 72%), weighting calculations 
were performed to give theoretical response rates if 72% VV patients had been 
allocated maintenance (table 8).  ORR (CRR) would be 78% (46%) and 82% (63%) 
at 7 and 13 months, respectively, still no better than FF/VF patients.  At 25 months, 
VV patients would be expected to have slightly better response rates than FF/VF 
patients; however, these are still not significantly different (ORR (CRR) VV: 81% 
(72%); FF/VF: 72% (63%); p=0.53 (0.36)).   
As there are relatively small numbers of VV patients, results may be 
disproportionately swayed by a few random events.  Transformation occurred in 2/31 
(6%) VV patients who received rituximab and 5/228 (2%) VF/FF patients.  On the 
other hand, 4/228 (2%) of VF/FF patients but no VV patients died of second 
malignancies.  A predictive effect of V homozygosity on response was not seen even 
when patients with histological transformation were excluded. 
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Baseline tumour bulk 
The range of the products of the bidimensional measurements of the largest baseline 
involved lymph node was 84-4485mm2, with a median value of 448mm2.  FCGR3A-
158V homozygotes were significantly more likely to have LB at baseline compared 
with VF/FF patients (VV: 20LB, 11HB; VF/FF: 107LB, 121HB; p=0.08) (table 3).  
CRR was significantly better for LB patients than HB patients (67% vs. 45% at 
7months: p=0.0004; 71% vs. 51% at 25 months: P=0.001) whilst the difference in 
ORR was less marked and did not reach statistical significance (83% vs. 80% at 7 
months: p=0.63; 77% vs. 63% at 25 months: p=0.01)(tables 9A and 9B; figure 28).  
The PFS event rate was 26% for LB and 34% for HB patients (p=0.22) whilst the 
proportion starting new treatment was 16% and 23%, respectively (p=0.06)(table 10; 
figure 29).  There was no interaction between polymorphism status and the effect of 
disease bulk on response or event rates. 
 
FCGR2A-H131R and FCGR2B-I232T 
The observed polymorphism frequencies for FCGR2A-H131R were 53(21%) HH, 
142(55%) HR and 61(24%) RR and for FCGR2B-I232T, 212(83%) were II, 42(16%) 
IT and 2(1%) TT.  There were no significant differences in the baseline 
characteristics by polymorphism in terms of age, gender, stage, performance status 
marrow involvement and FLIPI score (table 4).  For the FCGR2A-H131R 
polymorphism, the difference in proportion of patients randomised to each arm 
approached significance when comparing HH with HR/RR (79% vs 67% randomised 
to R4+M, respectively, p=0.09). 
There was no significant difference in ORR or CRR by either polymorphism at 7, 13 
or 25 months (table 5).  This was true comparing heterozygotes separately or 
combined with either group of homozygotes (tables 11 and 12).   There was also no 
correlation between polymorphism status and TTNT, PFS, or OS (figure 30). 
As previously stated, rituximab maintenance significantly improved overall CRR and 
ORR rates.  When looking at response by polymorphism results and randomisation 
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arm, each genotype had better response rates when treated with R4+M than R4, at 
every time point (table 7).  The single exception was FCGR2A-131R homozygotes at 
month 7, in which CRR was slightly lower with maintenance.  It did appear that 
patients with the FCGR2A-HH genotype derived greater benefit from maintenance R 
due to a low response rate in the 12 HH patients who only received R4. Maintenance 
rituximab seemed to confer less response benefit in FCGR2B-T allele bearers with 
25 months CRR 50% vs. 67% (p=0.31) and ORR 67% vs. 73% (p=0.81) in R4 and 
R4+M patients, respectively. 
 
  
 FCGR3A-V158F   FCGR2A-H131R   FCGR2B-I232T  
FF 
(n=111) 
VF 
(n=117) 
VV 
(n=31) 
p 
 HH 
(n=53) 
HR 
(n=142) 
RR 
(n=61) 
p 
 II  
(n=212) 
IT  
(n=42) 
TT  
(n=2) 
p 
Median age (years) 59 60 55   59 60 57   59 60 57  
Male gender N(%) 54 (49) 55 (47) 14 (45) 0.93  25 (47) 69 (49) 28 (46) 0.94  103 (49) 18 (43) 1 (50) 0.79 
Stage N(%) 
II 30 (27) 19 (16) 8 (26) 
0.22 
 11 (21) 33 (23) 13 (21) 
0.97 
 44 (21) 12 (29) 0 (0) 
0.61 III 37 (33) 54 (46) 11 (35)  22 (42) 53 (37) 26 (43)  88 (42) 13 (31) 1 (50) 
IV 44 (40) 45 (38) 12 (39)  19 (36) 56 (39) 24 (39)  80 (38) 18 (43) 1 (50) 
PS N(%) 
0 98 (88) 109 (92) 29 (94) 
0.48 
 46 (87) 130 (92) 57 (93) 
0.44 
 191 (90) 39 (93) 2 (100) 
0.77 
1 13 (12) 9 (8) 2 (6)  7 (13) 12 (8) 4 (7)  21 (10) 3 (7) 0 (0) 
FLIPI N(%) 
0/1 44 (40) 32 (28) 15 (48) 
0.23 
 
17 (32) 49 (35) 24 (39) 
0.20 
 
70 (33) 19 (45) 1 (50) 
0.33 2 47 (42) 51 (44) 11 (35)  22 (42) 62 (44) 13 3(8)  95 (45) 12 (29) 1 (50) 
3/4 20 (18) 33 (28) 5 (16)  14 (26) 30 (21) 14 (23)  46 (22) 11 (26) 0 0) 
Marrow involved N(%) 44 (40) 45 (38) 12 (39) 0.98  19 (36) 56 (39) 24 (39) 0.89  80 (38) 18 (43) 1 (50) 0.78 
Raised LDH N(%) 7 (6) 3 (3) 2 (6) 0.36  4 (8) 6 (4) 2 (3) 0.52  11 (5) 1 (2) 0 (0) 0.70 
PD Largest node  
Median (range) 
450 (88-
4485) 
462 (84-
3600) 
312 (85-
3038) 
 
 480(84-
2500)  
425 (84-
3600) 
452 (100-
3000) 
 
 450 (84-
4485) 
408 (84-
2200) 
1869 (700-
3038) 
 
Lower bulk N(%) 53 (49) 54 (47) 20 (65) 0.18  22 (42) 73 (52) 30 (50) 0.47  104 (50) 22 (54) 0 (0) 0.35 
Randomised R4  31 (28) 33 (28) 15 (48) 
0.07 
 11 (21) 46 (32) 22 (36) 
0.18 
 66 (31) 12 (29) 0 (0) 
0.61 Randomised R4+M 80 (72) 84 (72) 16 (52)  42 (79) 96 (68) 39 (64)  146 (69) 30 (71) 2 (100) 
 
Table 4: Baseline characteristics by FCGR3A-V158F, FCGR2A-H131R and FCGR2B-I232T polymorphisms.  PS=Performance Status; 
FLIPI= Follicular Lymphoma International Prognostic Index; LDH=Lactate Dehydrogenase, PD=Product Dimensions (mm2).  R4 = rituximab 
induction (4 doses at weekly intervals); R4+M = rituximab induction plus maintenance (4 doses at weekly intervals followed by maintenance 
dose every 2 months for 2 years).  P values are derived from the chi-square test for independence.  In addition, Fisher’s exact test was used to 
compare the following: lower bulk FF/VF vs VV p=0.08; HH vs HR/RR p=0.28; randomisation arm FF/VF vs VV p=0.04; HH vs HR/RR p=0.09. 
  
 
FCGR3A-V158F  FCGR2A-H131R  FCGR2B-I232T 
FF VF VV  HH HR RR  II IT TT 
N (%) N (%) N (%)  N (%) N (%) N (%)  N (%) N (%) N (%) 
7 months 
response 
N(%) 
CR / CRu 67 (63) 62 (55) 12 (41)  26 (53) 77 (57) 37 (62)  119 (58) 21 (55) 0 (0) 
PR 26 (24) 33 (30) 10 (35)  14 (29) 39 (28) 16 (27)  51 (25) 15 (40) 1 (50) 
SD/PD/death 14 (13) 17 (15) 7 (24)  9 (18) 20 (15) 7 (11)  35 (17) 2 (5) 1 (50) 
Unknown 4  5  2   4  6  1   7  4  0  
                        2 I CRR p=0.11; ORR p=0.34 
                      2T CRR p=0.04; ORR p=0.19 
2 I CRR p=0.65; ORR p=0.62 
2T CRR p=0.04; ORR p=0.19 
 2 I CRR p=0.25; ORR p=0.07 
2T CRR p=0.33; ORR p=0.26 
13 months 
response 
N(%) 
CR / CRu 72 (67) 66 (59) 16 (55)  26 (54) 89 (65) 38 (62)  126 (62) 26 (67) 1 (50) 
PR 22 (21) 21 (19) 7 (24)  10 (21) 25 (18) 15 (25)  42 (20) 7 (18) 0 (0) 
SD/PD/death 13 (12) 25 (23) 6 (21)  12 (25) 22 (16) 8 (13)  37 (18) 6 (15) 1 (50) 
Unknown 4  5  2   5  6  0   7  3  0  
                        2 I CRR p=0.32; ORR p=0.13 
                       2T CRR p=0.14; ORR p=0.09 
2 I CRR p=0.38; ORR p=0.24 
2T CRR p=0.44; ORR p=0.11 
 2 I CRR p=0.78; ORR p=0.46 
2T CRR p=0.68; ORR p=0.90 
25 months 
response 
N(%) 
CR / CRu 66 (65) 68 (61) 17 (61)  27 (59) 85 (63) 39 (67)  125 (63) 25 (63) 1 (50) 
PR 8 (8) 11 (10) 3 (11)  6 (13) 13 (10) 3 (5)  18 (9) 4 (10) 0 (0) 
SD/PD/death 27 (27) 32 (29) 8 (28)  13 (28) 37 (27) 16 (28)  54 (28) 11 (27) 1 (50) 
Unknown 10  6  3   7  7  3   15  2  0  
                        2 I CRR p=0.80; ORR p=0.94 
                       2T CRR p=0.54; ORR p=0.77 
2 I CRR p=0.67; ORR p=0.99 
2T CRR p=0.37; ORR p=0.95 
 2 I CRR p=0.92; ORR p=0.78 
2T CRR p=0.79; ORR p=0.76 
 
Table 5: Response assessments at 7, 13 and 25 months by FCGR3A-V158F, FCGR2A-H131R and FCGR2B-I232T polymorphisms.  
Response assessments were physician reviewed centrally, blinded to genotype results.  P values are shown derived from the chi-square test 
for independence (2 I) and chi-square test for trend (2T).  CR = Complete Response; CRu = Complete Response uncertain; PR = Partial 
Response; SD = Stable Disease; PD = Progressive Disease.  
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Response at month 7 by FCGR3A-V158F polymorphism 
 FF/VF VV  FF VF/FF 
 N N  N N 
CR/CRu 129 12 CR/CRu 67 74 
PR 59 10 PR 26 43 
SD/PD/Died 31 7 SD/PD/Died 14 24 
 
CRR p=0.11 
ORR p=0.17 
 
CRR p=0.12 
ORR p=0.48 
Response at month 13 by FCGR3A-V158F polymorphism 
 FF/VF VV  FF VF/FF 
 N N  N N 
CR/CRu 138 16 CR/CRu 72 82 
PR 43 7 PR 22 28 
SD/PD/Died 38 6 SD/PD/Died 13 31 
 CRR p=0.42  
ORR p=0.61 
 CRR p=0.15 
ORR p=0.06 
Response at month 25 by FCGR3A-V158F polymorphism 
 FF/VF VV  FF VF/FF 
 N N  N N 
CR/CRu 134 17 CR/CRu 66 85 
PR 19 3 PR 8 14 
SD/PD/Died 59 8 SD/PD/Died 27 40 
 
CRR p=0.84  
ORR p=1.00 
 
CRR p=0.59 
ORR p=0.77 
 
Table 6: Comparison of response assessments at 7, 13 and 25 months by FCGR3A-
V158F polymorphism, combining heterozygotes with each group of homozygotes.  
Fisher’s exact test was used to test for significance and the p values are shown.  
CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; 
SD=Stable Disease; PD=Progressive Disease; CRR=Complete Response Rate; 
ORR=Overall Response Rate. 
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Time to Next Treatment 
 
Progression Free Survival 
 
Overall Survival 
 
Figure 27. Kaplan-Meier estimates of time to next treatment, progression free survival 
and overall survival by FCGR3A-V158F polymorphism status.  P values are derived 
from the log-rank test. 
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Month 7  Month 25 
CR OR  CR OR 
R4 R4+M p R4 R4+M p  R4 R4+M p R4 R4+M p 
FCGR3A-V158F    FCGR3A-V158F  
FF 18(60) 49(64) 0.73 23(77) 70(91) 0.05  13(48) 53(74) 0.03 15(56) 59(82) 0.02 
VF 15(47) 47(59) 0.25 25(78) 70(88) 0.21  14(45) 54(69) 0.02 18(58) 61(78) 0.03 
VV 4(29) 8(53) 0.18 10(71) 12(80) 0.59  5(36) 12(86) 0.01 7(50) 13(93) 0.01 
Total 37(49) 104(60) 0.08 58(76) 152(88) 0.02  32(44) 119(73) 0.0001 40(56) 133(81) 0.0001 
FCGR2A-H131R    FCGR2A-H131R  
HH 4(36) 22(58) 0.54 6(55) 34(89) 0.16  2(22) 25(69) 0.04 2(22) 31(86) 0.001 
HR 19(43) 58(63) 0.04 34(77) 82(89) 0.12  18(44) 67(74) 0.004 25(61) 73(80) 0.06 
RR 14(67) 23(59) 0.76 18(86) 35(90) 0.97  12(55) 27(75) 0.19 13(59) 29(81) 0.14 
Total 37(49) 103(61) 0.09 58(76) 151(89) 0.01  32(44) 119(72) 0.0001 40(55) 133(80) 0.0001 
FCGR2B-I232T    FCGR2B-I232T  
II 32(50) 87(62) 0.16 47(73) 123(87) 0.03  26(43) 99(73) 0.0001 32(54) 111(83) 0.0001 
II/IT 5(45) 16(55) 0.85 10(91) 27(93)                                                                                                                         0.81  6(50) 20(67) 0.51 8(67) 22(73) 0.96
Total 37(49) 103(61) 0.13 57(76) 150(88) 0.02  32(44) 119(71) 0.0001 40(56) 133(80) 0.0002 
 
Table 7. Response by treatment arm and FCGR3A-V158F, FCGR2A-H131R and 
FCGR2B-I232T polymorphism status.  The figures in parentheses represent percentages.  
P values based on Chi-square tests (using Yate’s correction) are given for each comparison 
between arms. CR = Complete Response; OR = Overall Response.  R4 = rituximab 
induction (4 doses at weekly intervals); R4+M = rituximab induction plus maintenance (4 
doses at weekly intervals followed by maintenance dose every 2 months for 2 years).   
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R4 + R4+M * n = 
“corrected” 
N (%) 
7 month 
CR [28%(4/14) + 72%(8/15)] * 29 = 13.5 (46) 
OR [28%(10/14) + 72%(12/15)] * 29 = 22.5 (78) 
13 month 
CR [28%(5/14) + 72%(11/15)] * 29 = 18.2 (63) 
OR [28%(10/14) + 72%(13/15)] * 29 = 23.9 (82) 
25 month 
CR [28%(5/14) + 72%(12/14)] * 28 = 20.0 (72) 
OR [28%(7/14) + 72%(13/14)] * 28 = 22.6 (81) 
 
Table 8: Weighting calculations to give theoretical response rates in VV patients.  
Patients randomised to Rituximab induction plus maintenance (R4+M) had better response 
rates than those randomised to Rituximab induction alone (R4).  VV patients were 
significantly less likely to be randomised to R4+M than VF/FF patients (52% vs. 72%, 
p=0.04).  The above calculations provide an estimate of the number of complete responses 
(CR) and overall responses (OR) expected had 72% of VV patients been randomised to 
R4+M.  
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CR/CRu PR SD PD dead unknown 
VV lower bulk (n=20) 10 4 3 2 0 1 
VV higher bulk (n=11) 2 6 2 0 0 1 
VF lower bulk (n=54) 34 9 7 4 0 0 
VF higher bulk (n=62) 29 24 4 3 0 2 
FF lower bulk (n=53) 41 8 3 1 0 0 
FF higher bulk (n=55) 26 16 8 2 0 3 
All lower bulk (n=127) 85 21 13 7 0 1 
All higher bulk (n=128) 57 46 14 5 0 6 
 
Table 9A: Response at month 7 by FCGR3A-V158F polymorphism and disease bulk.  
The product of the dimensions of the largest baseline node was calculated for each patient; 
those below the median value were designated “lower bulk” and those above the median 
value designated “higher bulk”.  CR=Complete Response; CRu=Complete Response 
unconfirmed; PR=Partial Response; SD=Stable Disease; PD=Progressive Disease. 
 
 
 
CR PR SD PD dead unknown 
VV lower bulk (n=20) 13 2 0 3 1 1 
VV higher bulk (n=11) 5 1 1 4 0 0 
VF lower bulk (n=54) 35 4 1 10 3 1 
VF higher bulk (n=62) 35 7 3 13 0 4 
FF lower bulk (n=53) 42 2 2 4 1 2 
FF higher bulk (n=55) 25 7 4 14 1 4 
All lower bulk (n=127) 90 8 3 17 5 4 
All higher bulk (n=128) 65 15 8 31 1 8 
 
Table 9B: Response at month 25 by FCGR3A-V158F polymorphism and disease bulk.  
The product of the dimensions of the largest baseline node was calculated for each patient; 
those below the median value were designated “lower bulk” and those above the median 
value designated “higher bulk”.  CR=Complete Response; CRu=Complete Response 
unconfirmed; PR=Partial Response; SD=Stable Disease; PD=Progressive Disease. 
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Figure 28: Response at months 7 and 25 by FCGR3A-V158F polymorphism and 
disease bulk at diagnosis.  The products of the dimensions of the largest baseline lymph 
node for each patient were calculated; those smaller than the median measurement were 
designated “lower bulk” and those larger than the median designated “higher bulk”. 
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Progressed/ 
dead 
Alive, no 
progression 
 
New 
treatment 
No new 
treatment 
VV lower bulk (n=20) 4 16  4 16 
VV higher bulk (n=11) 5 6  4 7 
VF lower bulk (n=54) 20 34  10 44 
VF higher bulk (n=62) 19 43  14 48 
FF lower bulk (n=53) 9 44  6 47 
FF higher bulk (n=55) 19 36  11 44 
All lower bulk (n=127) 33 94 
 
20 107 
All higher bulk (n=128) 43 85  29 99 
 
Table 10: Number of patients suffering progression/death and commencing new 
treatment by FCGR3A-V158F polymorphism and disease bulk.  The product of the 
dimensions of the largest baseline node was calculated for each patient; those below the 
median value were designated “lower bulk” and those above the median value designated 
“higher bulk”. 
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Figure 29: Proportion of patients suffering progression/death and commencing new 
treatment by FCGR3A-V158F polymorphism and disease bulk.  The product of the 
dimensions of the largest baseline node was calculated for each patient; those below the 
median value were designated “lower bulk” and those above the median value designated 
“higher bulk”. 
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Response at month 7 by FCGR2A-H131R polymorphism 
 HH/HR RR  HH HR/RR 
 N N  N N 
CR/CRu 103 37 CR/CRu 26 114 
PR 53 16 PR 14 55 
SD/PD/Died 29 7 SD/PD/Died 9 27 
 CRR p=0.46 
ORR p=0.53 
 CRR p=0.52 
ORR p=0.50 
Response at month 13 by FCGR2A-H131R polymorphism 
 HH/HR RR  HH HR/RR 
 N N  N N 
CR/CRu 115 38 CR/CRu 26 127 
PR 35 15 PR 10 40 
SD/PD/Died 34 8 SD/PD/Died 12 30 
 CRR p=1.00  
ORR p=0.43 
 CRR p=0.19 
ORR p=0.13 
Response at month 25 by FCGR2A-H131R polymorphism 
 HH/HR RR  HH HR/RR 
 N N  N N 
CR/CRu 112 39 CR/CRu 27 124 
PR 19 3 PR 6 16 
SD/PD/Died 50 16 SD/PD/Died 13 53 
 CRR p=0.53  
ORR p=1.00 
 CRR p=0.50 
ORR p=1.00 
 
Table 11: Comparison of response assessments at 7, 13 and 25 months by FCGR2A-
H131R polymorphism, combining heterozygotes with each group of homozygotes.  
Fisher’s exact test was used to test for significance and the p values are shown.  
CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; 
SD=Stable Disease; PD=Progressive Disease; CRR=Complete Response Rate; 
ORR=Overall Response Rate. 
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Response at month 7 by 
FCGR2B-I121T polymorphism 
 II IT/TT 
 N N 
CR/CRu 119 21 
PR 51 16 
SD/PD/Died 35 3 
 CRR p=0.60 
ORR p=0.16 
Response at month 13 by 
FCGR2B-I121T polymorphism 
 II IT/TT 
 N N 
CR/CRu 126 27 
PR 42 7 
SD/PD/Died 37 7 
 CRR p=0.72  
ORR p=1.00 
Response at month 25 by 
FCGR2B-I121T polymorphism 
 II IT/TT 
 N N 
CR/CRu 125 26 
PR 18 4 
SD/PD/Died 54 12 
 CRR p=0.86  
ORR p=0.85 
Table 12: Comparison of response assessments at 7, 13 and 25 months by FCGR2B-
I232T polymorphism, combining heterozygotes with TT homozygotes.  Fisher’s exact 
test was used to test for significance and the p values are shown.  Due to the very small 
number of T homozygotes, an analysis of II/IT vs. TT was not performed. CR=Complete 
Response; CRu=Complete Response unconfirmed; PR=Partial Response; SD=Stable 
Disease; PD=Progressive Disease; CRR=Complete Response Rate; ORR=Overall 
Response Rate. 
  
Results 
 102 
FCGR2A-H131R FCGR2B-I232T 
Time to Next Treatment 
  
Progression Free Survival 
  
Overall Survival 
  
Figure 30: Kaplan-Meier estimates of time to next treatment, progression free survival 
and overall survival by FCGR2A-H131R and FCGR2B-I232T polymorphism status.  P 
values are derived from the log-rank test. 
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C1QA-Gly70GGG/GG 
The observed polymorphism frequencies for C1QA-Gly70GGG/GGA were AA 77(31%), 
AG 125 (50%) and GG 48 (19%).  There were no significant differences in the 
baseline characteristics by polymorphism in terms of age, gender, stage, 
performance status marrow involvement and FLIPI score (table 13).   
There was no significant difference in ORR or CRR by polymorphism at 7, 13 or 25 
months (table 14).  This was true comparing heterozygotes separately or combined 
with GG homozygotes (table 15).   There is a trend at all time points for GG patients 
to respond more poorly than AA/AG, reaching statistical significance at month 13.  
There was no correlation between polymorphism status and TTNT or PFS (figure 
31).  As previously stated, rituximab maintenance significantly improved overall CRR 
and ORR rates.  When looking at response by polymorphism results and 
randomisation arm, each genotype had better response rates when treated with 
R4+M than R4, at every time point (table 16).   
It has previously been reported that patients with follicular lymphoma who respond to 
rituximab monotherapy may have a greater duration of response if they are C1QA-
Gly70GGA homozygotes.  Therefore further analyses were carried out, looking at 
responders at month 7.  TTNT and PFS were compared by polymorphism status in 
complete and overall responders to rituximab (figure 32).  Again, there is no 
significant difference by polymorphism; however there is a trend for poorer PFS in 
C1QA-Gly70GGG homozygotes. 
 
 
C3-102-RG 
The observed polymorphism frequencies for C3-102RG were GG 34(14%), RG 46 
(19%) and RR 162 (67%).  Baseline characteristics by polymorphism are shown in 
table 13.  The groups are broadly comparable in terms of age and gender.  However, 
RR patients have a trend to poorer performance status, more advanced stage and 
Comment [LL1]: ?logrank for GG vs 
AG/AA for PFS in responders significant 
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more marrow involvement, and they are significantly different from GG and RG 
groups in terms of likelihood of higher FLIPI scores.   
Comparing GG, RG and RR patients separately, difference in ORR or CRR by 
polymorphism did not reach significance, although there was a trend for better 
responses in RR patients at the earlier time points of 7 and 13 months, which was 
much less marked by month 25 (table 14).  When comparing RR patients with 
GG/RG combined, the difference in CRR was statistically significant at month 7.  
Differences in ORR at month 7 and CRR at month 13 were of borderline statistical 
significance.  Again, by month 25 this difference was no longer apparent (table 16).   
There was no significant correlation between polymorphism status and TTNT or PFS 
(figure 31).  Any trend is for worse PFS in GG patients.  As previously stated, 
rituximab maintenance significantly improved overall CRR and ORR rates.  When 
looking at response by polymorphism results and randomisation arm, each genotype 
had better response rates when treated with R4+M than R4, at every time point 
(table 17).  The single exception is in RG patients in which the R4+M group had 
slightly inferior CRR at month 7.  There is no evidence of influence of C3-102-RG 
polymorphism status on the benefit derived from rituximab maintenance.
Results 
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C1QA-Gly70GGG/GGA 
 
C3-102-RG 
 
AA  
(n=77) 
AG 
(n=125) 
GG 
(n=48) 
p 
 
GG 
(n=34) 
RG 
(n=46) 
RR 
(n=162) 
p  
Age median (range) 58 (41-82) 59(35-86) 61(29-80)  
 
62(29-78) 58(41-82) 60(36-86)  
Male gender N(%) 36 (47) 60 (48) 24 (50) 0.94 
 
15 (44) 23 (50) 79 (49) 0.86 
Stage N(%) 
II  20 (26) 29 (23) 7 (15) 
0.51 
 8 (24) 13 (28) 35 (22) 
0.58 III  26 (34) 51 (41) 19 (40)  16 (47) 16 (35) 59 (36) 
IV  31 (40) 45 (36) 22 (46)  10 (29) 17 (37) 68 (42) 
PS N(%) 
0  72 (94) 115 (92) 41 (85) 
0.27 
 32 (94) 45 (98) 145 (90) 
0.17 
1  5 (6) 10 (8) 7 (15)  2 (6) 1 (2) 17 (10) 
FLIPI N(%) 
0/1 
 
31 (40) 45 (36) 13 (27) 
0.18 
 
12 (35) 21 (46) 54 (33) 
0.03 2  31 (40) 46 (37) 26 (54)  18 (53) 20 (43) 60 (37) 
3/4  15 (20) 34 (27) 8 (19)  4 (12) 5 (11) 48 (30) 
Marrow involved N(%) 31 (40) 45 (36) 22 (46) 0.28 
 
10 (29) 17 (37) 68 (42) 0.37 
Raised LDH N(%) 4 (5) 6 (5) 2 (4) 0.95 
 
1 (3) 2 (4) 9 (6) 0.80 
PD Largest node  
Median (range) 
418 
 (84-4485) 
440  
(88-3080) 
504  
(84-3600) 
 
 400  
(89-2107)  
532  
(100-3072) 
458 
 (84-3600) 
 
Lower bulk N(%) 38 (50) 62 (49) 21 (44) 0.77 
 
20 (59) 20 (43) 80 (49) 0.40 
Randomised R4  18 (23) 40 (32) 18 (37) 
0.21 
 11 (32) 14 (30) 47 (29) 
0.92 Randomised R4+M 59 (77) 85 (68) 30 (63)  23 (68) 32 (70) 115 (71) 
 
Table 13: Baseline characteristics by C1QA-Gly70GGG/GGA and C3-102-RG 
polymorphisms.  P values are derived from the chi-square test for independence.  In 
addition, Fisher’s exact test was used to compare the following: Performance Status (PS) 
C1QA-Gly70GGG/GGA AA/AG vs GG p=0.15; C3-102-RG GG/RG vs RR p=0.09; FLIPI score 
C3-102-RG GG/RG vs RR p=0.03; randomisation arm C1QA-Gly70GGG/GGA AA vs AG/GG 
p=0.14. FLIPI= Follicular Lymphoma International Prognostic Index; LDH=Lactate 
Dehydrogenase, PD=Product Dimensions (mm2).  R4 = rituximab induction (4 doses at 
weekly intervals); R4+M = rituximab induction plus maintenance (4 doses at weekly intervals 
followed by maintenance dose every 2 months for 2 years). 
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C1QA-Gly70GGG/GGA  C3-102-RG 
AA AG GG  GG RG RR 
N (%) N (%) N (%)  N (%) N (%) N (%) 
7 months 
response 
N(%) 
CR / CRu 46 (63) 71 (59) 22 (48)  15 (47) 23 (52) 101 (65) 
PR 19 (25) 32 (26) 14 (29)  12 (38) 11 (25) 38 (25) 
SD/PD/death 8 (12) 17 (15) 10 (23)  5 (15) 10 (23) 16 (10) 
Unknown 4  5  2   2  2  7  
                     2 I CRR p=0.25; ORR p=0.26 
                    2T CRR p=0.12 ;ORR p=0.12 
2I CRR p=0.08; ORR p=0.10 
2T CRR p=0.03; ORR p=0.14 
 
13 months 
response 
N(%) 
CR / CRu 50 (68) 79 (65) 21 (47)  20 (63) 22 (50) 106 (68) 
PR 14 (19) 24 (20) 11 (24)  7 (22) 11 (25) 29 (19) 
SD/PD/death 9 (13) 18 (15) 13 (29)  5 (25) 11 (25) 20 (13) 
Unknown 4  4  3   2  2  7  
                      2 I CRR p=0.06; ORR p=0.05 
                     2T CRR p=0.04 ;ORR p=0.03 
2I CRR p=0.08; ORR p=0.15 
2T CRR p=0.17; ORR p=0.30 
25 months 
response 
N(%) 
CR / CRu 49 (68) 75 (65) 24 (55)  18 (40) 26 (61) 102 (67) 
PR 7 (10) 10 (9) 5 (11)  3 (10) 7 (16) 11 (7) 
SD/PD/death 16 (22) 31 (27) 15 (34)  9 (30) 10 (23) 39 (26) 
Unknown 5  9  4   4  3  10  
                      2 I CRR p=0.32; ORR p=0.37 
                     2T CRR p=0.16 ;ORR p=0.17 
2I CRR p=0.61; ORR p=0.81 
2T CRR p=0.35; ORR p=0.76 
 
Table 14: Response assessments at 7, 13 and 25 months by C1QA-Gly70GGG/GGA and 
C3-102-RG polymorphisms.  Response assessments were physician reviewed centrally, 
blinded to genotype results.  P values are shown derived from the chi-square test for 
independence (2 I) and chi-square test for trend (2T).  CR = Complete Response; CRu = 
Complete Response uncertain; PR = Partial Response; SD = Stable Disease; PD = 
Progressive Disease.  
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Response at month 7 by C1QA-Gly70GGG/GGA polymorphism 
 AA/AG GG  AA AG/GG 
 N N  N N 
CR/CRu 117 22 CR/CRu 46 93 
PR 51 14 PR 19 27 
SD/PD/Died 25 10 SD/PD/Died 8 17 
 CRR p=0.14 
ORR p=0.16 
 CRR p=0.54 
ORR p=0.83 
Response at month 13 by C1QA-Gly70GGG/GGA polymorphism 
 AA/AG GG  AA AG/GG 
 N N  N N 
CR/CRu 129 21 CR/CRu 50 100 
PR 38 11 PR 14 35 
SD/PD/Died 27 13 SD/PD/Died 9 31 
 CRR p=0.03  
ORR p=0.02 
 CRR p=0.25 
ORR p=0.26 
Response at month 25 by C1QA-Gly70GGG/GGA polymorphism 
 AA/AG GG  AA AG/GG 
 N N  N N 
CR/CRu 124 24 CR/CRu 49 99 
PR 17 5 PR 7 15 
SD/PD/Died 47 15 SD/PD/Died 16 46 
 CRR p=0.17  
ORR p=0.26 
 CRR p=0.38 
ORR p=0.34 
 
Table 15: Comparison of response assessments at 7, 13 and 25 months by C1QA-
Gly70GGG/GGA polymorphism, combining heterozygotes with each group of 
homozygotes.  Fisher’s exact test was used to test for significance and the p values are 
shown.  CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial 
Response; SD=Stable Disease; PD=Progressive Disease; CRR=Complete Response Rate; 
ORR=Overall Response Rate. 
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C1QA-Gly70GGG/GGA C3-102-RG 
Time to Next Treatment 
  
Progression Free Survival 
  
 
Figure 31: Kaplan-Meier estimates of time to next treatment and progression free 
survival by C1QA- Gly70GGG/GGA and C3-102-RG polymorphism status.  P values are 
derived from the log-rank test. 
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Month 7  Month 25 
CR OR  CR OR 
R4 R4+M p R4 R4+M p  R4 R4+M p R4 R4+M p 
C1QA-Gly70GGG/GGA    C1QA-Gly70GGG/GGA  
AA 10(59) 36(64) 0.90 14(82) 51(91) 0.57  6(38) 43(77) 0.008 9(60) 47(84) 0.04 
AG 21(55) 50(61) 0.69 29(76) 74(90) 0.08  19(53) 56(70) 0.11 21(58) 64(80) 0.03 
GG 6(33) 16(57) 0.20 13(72) 23(82) 0.67  7(39) 17(65) 0.15 10(56) 19(73) 0.38 
Total 37(51) 102(61) 0.16 56(77) 148(89) 0.02  32(46) 116(72) 0.0003 40(57) 130(80) 0.0005 
C3-102-RG    C3-102-RG  
GG 3(30) 12(55) 0.36 8(73) 19(86) 0.65  4(40) 14(70) 0.24 5(50) 16(80) 0.20 
RG 8(57) 15(50) 0.91 9(64) 25(83) 0.31  6(50) 20(65) 0.60 8(67) 25(81) 0.57 
RR 26(58) 75(68) 0.29 38(84) 101(92) 0.28  22(50) 80(74) 0.008 27(61) 86(80) 0.03 
Total 37(54) 102(63) 0.24 55(80) 145(90) 0.07  32(48) 114(72) 0.002 40(61) 127(80) 0.005 
 
Table 16: Response by treatment arm and polymorphism status.  The figures in 
parentheses represent percentages.  P values based on Chi-square tests (using Yate’s 
correction) are given for each comparison between arms. CR = Complete response; OR = 
Overall Response.  R4 = rituximab induction (4 doses at weekly intervals); R4+M = rituximab 
induction plus maintenance (4 doses at weekly intervals followed by maintenance dose 
every 2 months for 2 years).   
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Figure 32: Duration of response in responding patients by C1QA-Gly70GGG/GGA 
polymorphism.   Comparisons of Progression Free Survival and Time to Next 
Treatment were made by polymorphism status for patients achieving complete and 
overall responses at month 7.   
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Response at month 7 by C3-102-RG polymorphism 
 GG RG/GG  GG/RG RR 
 N N  N N 
CR/CRu 15 124 CR/CRu 38 101 
PR 12 49 PR 23 38 
SD/PD/Died 5 26 SD/PD/Died 15 16 
 CRR p=0.12 
ORR p=0.78 
 CRR p=0.03 
ORR p=0.06 
Response at month 13 by C3-102-RG polymorphism 
 GG RG/GG  GG/RG RR 
 N N  N N 
CR/CRu 20 128 CR/CRu 42 106 
PR 7 40 PR 18 29 
SD/PD/Died 5 31 SD/PD/Died 16 20 
 CRR p=0.84  
ORR p=1.00 
 CRR p=0.06 
ORR p=0.12 
Response at month 25 by C3-102-RG polymorphism 
 GG RG/GG  GG/RG RR 
 N N  N N 
CR/CRu 18 128 CR/CRu 44 102 
PR 3 18 PR 10 11 
SD/PD/Died 9 49 SD/PD/Died 19 39 
 CRR p=0.54  
ORR p=0.65 
 CRR p=0.37 
ORR p=1.00 
 
Table 17: Comparison of response assessments at 7, 13 and 25 months by C3-102-RG 
polymorphism, combining heterozygotes with each group of homozygotes.  Fisher’s 
exact test was used to test for significance and the p values are shown.  CR=Complete 
Response; CRu=Complete Response unconfirmed; PR=Partial Response; SD=Stable 
Disease; PD=Progressive Disease; CRR=Complete Response Rate; ORR=Overall 
Response Rate. 
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Discussion 
Understanding the mechanisms of action of rituximab and the reasons for variability 
in clinical response could pave the way for development of more effective treatment 
regimens and new, more potent therapeutic antibodies.  There is large body of 
literature derived from in vitro and animal studies looking at the presence, and 
relative contribution, of ADCC, CDC and other mechanisms in rituximab’s action.  
However, it is difficult to know what is applicable in the clinical setting, and many of 
the studies throw up conflicting evidence.  Differences in clinical outcomes that can 
be linked to random genetic variation in the immune system would provide the 
strongest evidence for a central role of that part of the immune system.  
Our study population, derived from a multi-centre, rigorously conducted, randomised 
phase III trial, is ideal to explore real clinical effects of constitutional polymorphisms 
which have been proposed to be significant.  In addition, differences in rituximab 
responsiveness, which could be overwhelmed by rapidly growing disease or the 
effects of chemotherapy, should be more easily identifiable in patients with indolent 
disease, treated with antibody monotherapy.  However, despite the fairly large 
sample size, small patient numbers in some groups quickly limits interpretation of 
subset analysis. 
 
FCGR3A-V158F polymorphism  
It has been accepted by many that the FCGR3A-V158F polymorphism is predictive 
of response to rituximab in FL and it has even been suggested that treatment 
decisions may be guided by genotype, with FF patients less likely to benefit from 
costly rituximab maintenance.  However, in this, the largest study to date looking at 
this issue, no association has been found.  Indeed, there is not even a trend in the 
direction of benefit for patients bearing the VV alleles. 
There has been much investigation and debate concerning the relative contribution 
of ADCC, CDC and other mechanisms to the action of rituximab.  Evidence for a 
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central role of ADCC comes from murine studies in which response to rituximab was 
abrogated in mice lacking the common Fc chain but preserved in mice with 
congenital deficiencies in complement receptors.  However, there is also a 
substantial body of evidence for the role of CDC and other mechanisms in rituximab 
response.  Different murine models found that mice rendered deficient in cellular 
effectors did not demonstrate any reduction in response to rituximab; however, 
complement depletion abolished it.80 FcR polymorphism studies have been taken 
by many to provide the most compelling evidence for a central role of ADCC in 
patients.  There is good evidence that FcRIIIa-158V has a higher affinity for IgG1 in 
vitro than FcRIIIa-158F63,62 and patients with at least one V allele have a greater 
degree of NK cell activation following rituximab infusion.61  FCGR3A-158V 
homozygous patients are more prone to a number of autoimmune diseases, 
including SLE.62   
When two small studies reported improved response to rituximab in V homozygotes 
with lymphoma64,65 as predicted by laboratory research, the results generated much 
enthusiasm, which has translated into significant academic and commercial interest 
in designing new therapeutic antibodies to enhance ADCC.  However, there is a risk 
that such enthusiasm can lead to a lack of appreciation for negative findings and 
acceptance of a theory without evidence from adequately powered studies.  Several 
recent publications have assumed an impact on rituximab response by 
polymorphism status; when no difference is identified authors have gone so far as to 
interpret this as evidence that a regimen under study has the power to improve 
response in F-allele bearers to the level of VV. 145 
Since the first report of improved outcomes in FCGR3A-158V homozygous patients, 
the findings have been replicated in seven other patient groups,65,124,90,127,134,141,213 
but not in at least a further eighteen (see page 43).121,123,128-131,133,135-137-139,140,143-
147  Two additional studies reported a non-statistically significant trend in the direction 
of better outcomes for FCGR3A-158V allele bearers.132,214  However, the original 
study involved previously untreated patients with low-bulk follicular lymphoma 
treated with rituximab monotherapy.  Most studies previously reporting a negative 
result have either included patients with more aggressive lymphoma subtypes, or 
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who have been treated with chemotherapy in combination with rituximab.  In such 
patients the response directly attributable to rituximab would be expected to be less 
and therefore very large patient numbers would be needed to see a beneficial effect 
of enhanced ADCC in VV patients.  Three of the eight patient groups in which the V 
allele has been reported to predict favourable outcome were also treated with 
combination immunochemotherapy for FL,213 Waldenström’s macroglobulinaemia 
(WM),141 and DLBCL.127 Five remaining positive reports concern rituximab 
monotherapy in indolent lymphoma, and these will be considered in further detail 
below.  Of note, three studies of FCGR3A-V158F polymorphism in lymphoma 
patients treated with chemotherapy but without rituximab have found no association 
with outcome.213,215,216 
Cartron et al64 studied 49 patients with FL, previously untreated, with low bulk 
disease by GELF criteria. FCGR3A-158V homozygous patients (n=10) had 
significantly improved overall and complete response rates at 2 months and 12 
months following rituximab induction, and a trend to improved PFS, which was not 
significant, when compared with FCGR3A-158F carriers.  The patients are stated to 
be not different by sex, disease stage, marrow involvement or number of extranodal 
sites involved and FCGR3A-158V genotype was the only predictive factor for 
response by logistic regression (relative risk response at 12 months 1.7; 95% CI 1.2-
2.5; p=0.03). 
Weng and Levy65 studied 87 patients with FL, the majority of which had had previous 
chemotherapy and half of which are described as having bulky disease.  Baseline 
characteristics were similar by polymorphism; VV patients had only slightly less 
chance of bulky disease (46% vs. 54% in F carriers).  Response rates between 1 
and 12 months and PFS were significantly better in FCGR3A-158V homozygotes 
(n=13) and this genotype emerged as the strongest predictor of response by logistic 
regression analysis (OR 12.25; 95%CI 1.35-111.16).  Interestingly, the next 
strongest predictor was FCGR2A-131H homozygosity.  Although this finding has 
been replicated177 there has been less acceptance of it as a true effect; again there 
have been many negative studies and it has been suggested that the effect may be 
due to genetic linkage with FCGR3A-V158F.134,128,129,178,179  The fact that the 
scientific rationale for the effect of the polymorphism is less convincing (H 
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homozygotes having an increased affinity for IgG2 rather than IgG1) may contribute 
to the lack of acceptance of the results, compared with the FCGR3A evidence.   
Cornec et al134 studied a small group of 37 FL (12 previously treated) and 13 
marginal zone lymphoma (MZL) patients and found CR rates of 100% in the six VV 
patients (95% CI 51.7-100%) and 52.3% in F carriers (95% CI 36.9-67.3%); p=0.02.  
The baseline characteristics are stated to be comparable.  In 58 patients with WM 
and an overall response rate of 26% to rituximab monotherapy, Treon et al found a 
response benefit for V carriers (36% vs. 9% in F homozygotes; p=0.03).124 More 
recently they reported a similar effect in patients treated with rituximab in 
combination, with an ORR of 73%.141 Attainment of CR or very good partial response 
was seen in 45% of patients with at least one V allele and 9% of F homozygotes.  
There have been no other studies of FCGR polymorphisms in WM. 
Prior to our current data, the largest study of FCGR polymorphisms in FL treated 
with rituximab monotherapy was the SAK 35/98 study, with 151 patients.  
Independent predictive factors were sought by a stepwise multivariate analysis 
procedure. In 2005 it was reported that FCGR3A genotype impacted upon EFS but 
not response rate (this paper included a smaller number of patients with mantle call 
lymphoma).90 Independent predictive factors identified by multivariate analysis 
included tumour bulk and lymphocyte count at randomisation when genotype was 
not included in the analysis; when genotype was included and selected by stepwise 
procedure, bulk and lymphocyte count were no longer selected.  This may suggest 
some correlation between “favourable” genotype and lower bulk disease and/or 
lower presenting lymphocyte counts.  With longer term follow-up of the same cohort 
genotype was no longer independently predictive of EFS.126 Patients with at least 
one copy of the V allele were reported to have improved response at 2 and 12 
months compared with F homozygotes; this data has been published in abstract 
form only.125  
If the FCGR3A-V158F polymorphism is predictive of response to rituximab, it is likely 
that response to other IgG1 monoclonal antibodies may be similarly impacted. 
Trastuzumab (Herceptin), a humanized anti-HER2 IgG1 monoclonal antibody, has 
efficacy against HER2 positive breast tumours.  In vitro, increased ADCC has been 
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noticed in FCGR3A-158V homozygotes and FCGR2A-131-H homozygotes.217 Two 
small, underpowered studies (in 54 and 50 patients respectively) reported that the 
predicted clinical correlation of improved outcomes did in fact occur.217,218 However, 
a much larger study in 1218 patients did not find a clinical correlation.219 
Cetuximab is a chimeric IgG1 monoclonal antibody directed against the extracellular 
domain of Epidermal Growth Factor Receptor (EGFR), used in metastatic colorectal 
cancer and head and neck cancers. Data regarding the use of FCGR2A and 
FCGR3A polymorphisms to predict the response to cetuximab are inconsistent. 
Three retrospective studies (in 69, 52 and 106 patients respectively) report that the 
V/V genotype is the most beneficial FCGR3A genotype 182,220,221 whereas three 
other retrospective studies (in 39, 65 and 58 patients each) report that the F/F 
genotype is the most beneficial.181,222,223  These inconsistent findings suggest that 
FcgR polymorphisms are not currently useful predictive biomarkers of response to 
cetuximab. 
The absence of conclusive evidence of a significant clinical effect of the FCGR3A-
V158F polymorphism on response to rituximab was the foundation for the current 
study.  The results are negative for response at any time point, PFS, TTNT and OS.  
Indeed, any trend towards a difference by polymorphism is in the opposite direction 
than previously reported, with VV patients doing worse.  This study as part of a 
rigorously conducted, multi-centre, randomised trial, including more patients than 
any positive report, suggests that polymorphisms are not implicated in actual clinical 
responses to rituximab monotherapy in low bulk follicular lymphoma, despite the 
convincing scientific rationale and in vitro data.  We have examined potential sources 
of bias, which could have given an erroneous negative result. 
Patients with the VV genotype did not have less favourable baseline characteristics 
in terms of age, gender, stage, marrow involvement, FLIPI score or performance 
status; indeed they had slightly more favourable characteristics (see page 89).  
However, randomisation to maintenance therapy or induction alone was not equal 
across the polymorphism groups.  A smaller proportion of VV patients were allocated 
to R4+M (16/31 (52%)) compared to those with at least one F allele (164/228 (72%)); 
p=0.04.  As maintenance therapy improved response rates, particularly at month 25, 
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as well as PFS and TTNT in the entire cohort, this is a potential source of bias.  
However, sub-analyses by treatment arm do not suggest this to be the case (page 
93) and calculated theoretical response rates if the same proportion of VV patients 
as FF/VF had been allocated to R4+M were still not superior to FF/VF (page 94). 
Serum rituximab concentrations during therapy correlate with response, and 
correlate inversely with baseline disease bulk.95 In in vitro ADCC assays, increasing 
the rituximab concentration eventually overcomes the difference in cytotoxicity 
observed when using NK cells from FCGR3A-158F homozygotes or FCGR3A-158V 
homozygotes.59 It is therefore possible that patients with very low bulk disease may 
achieve very high rituximab concentrations in their serum and that this would negate 
any potential difference in tumour kill related to FCGR3A-V158F polymorphism 
status.  Although the seminal paper by Cartron et al included only patients with low 
bulk disease by GELF criteria,64 it is possible that the patients in our cohort had 
lower average tumour burden.   The patients in the current study would all have been 
managed expectantly if no trial were available.  If this were the explanation for the 
negative findings in the current study, one would expect to see the higher bulk FF 
patients doing particularly badly, with less influence of bulk in VV patients; this is not 
the case.  Although patients with higher bulk disease had lower CR rates and higher 
change of progression or requiring new treatment, there was no interaction with 
polymorphism status (see pages 95-98). 
As there are relatively small numbers of VV patients, results may be 
disproportionately swayed by a few random events.  Transformation occurred in 2/31 
(6%) VV patients who received rituximab and 5/228 (2%) patients with at least one F 
allele.  On the other hand, 4/228 (2%) of VF/FF patients but no VV patients died of 
second malignancies.  A predictive effect of V homozygosity on response was not 
seen even when patients with histological transformation were excluded. 
Although this is one of the biggest reported series investigating the influence of 
FCGR3A-V158F polymorphisms on rituximab response in lymphoma, a bigger study 
would have greater power to detect a difference, which may have been missed here.  
This study was not primarily powered to look at polymorphism result; rather it was 
powered to detect differences in clinical outcomes between rituximab monotherapy 
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and watchful waiting.  However, this study has >90% power to detect a 15% increase 
in ORR at 7 months of V allele bearers over F homozygotes, at 5% significance.  
The statistical power falls to around 70% when comparing V homozygotes to F allele 
bearers, so a real difference may not have been detected.  However, any trend 
towards better response is actually in the opposite direction; hence it is unlikely that 
a lack of statistical power underlies the negative results. 
Since this work began, a further large series has been published, reporting no 
association between outcomes and polymorphism status.  The PRIMA investigators 
reported on 460 patients from within a larger, randomised controlled trial, treated 
with up-front immunochemotherapy plus or minus rituximab maintenance.143 After 
induction therapy, CR was observed in 65%, 67%, 66% (p= 0.86) of patients with 
FCGR3A-VV, VF, FF genotypes, respectively. After 2 years of maintenance therapy, 
response rates or PFS were found not to be influenced by FCGR genotype. 
(However, FCGR3A polymorphisms were found to be associated with the risk of 
developing grade 3 – 4 neutropenia during treatment.  This is consistent with other 
reports;214,133 Fc-FcR mediated immune mechanisms mediated may well play a role 
in rituximab-induced neutropenia.) 
It is a distinct possibility that previous reports on this subject have been influenced by 
small study bias.  As well as a lack of power to adequately address the issue, it has 
been argued that small studies are more prone to reporting bias, with positive 
studies reported and negative studies remaining unpublished.224 Where studies are 
embedded in randomised controlled trials with pre-specified protocols and trial 
outcomes, the risk of publication and selective reporting bias is reduced.  Of those 
studies described above reporting a positive association, only the SAK 35/98 trial 
was part of a randomised study. 
It has also been assumed that the genetic variation in question has no bearing upon 
the natural history of the disease, independent of treatment.  This is only supported 
by the fact that no difference was seen in patients treated with chemotherapy without 
rituximab (this being counter to the argument that the reason studies with rituximab 
in combination with chemotherapy failed to show an association was because the 
power to detect a subtle difference related to the rituximab was reduced).  No studies 
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have looked at the polymorphism in untreated individuals.  The current data hint at a 
possible explanation for better outcomes in VV patients in other studies; VV patients 
with FL may be more likely to present with less bulky disease.  Clinical follow-up of 
patients from the same trial, randomized to a watchful waiting approach, may provide 
further insight. 
In conclusion, no evidence has been found that FcR polymorphism status can be 
used to predict clinical response to rituximab therapy in FL. Considerable doubt has 
been cast on the assumption that increasing the strength of Fc: FcR interactions in 
future generations of therapeutic monoclonal antibodies will improve clinical 
response.  It is perhaps unwise to interpret a lack of difference in response by 
polymorphism as evidence of better therapies for F allele bearers. 
 
FCGR2A-H131R polymorphism 
In this cohort, FCGR2A-H131R polymorphisms had no effect on clinical outcome and 
this negative result cannot be accounted for by differences in baseline 
characteristics, tumour bulk, or randomisation arm.  Indeed, the FCGR2A -131H 
homozygotes previously reported to have better response were somewhat more 
likely to be allocated to the more effective therapy, R4+M, but still did not fare better 
than FCGR2A-131R allele bearers.  Statistically, the HH patients seemed to derive 
more benefit from rituximab maintenance than R allele bearers, but this was due to 
poor response in the 12 HH patients treated with R4, rather than improved response 
in the R4+M group.  It is difficult to propose a plausible explanation for such an effect 
and it seems highly likely to be related to the small subset sample size. 
Whilst two small studies suggested an influence of the FCGR2A-H131R 
polymorphism on response to rituximab in indolent lymphoma, there are more 
published negative reports than positive (see page 45).  This is perhaps unsurprising 
as the polymorphism primarily affects strength of IgG2 binding, whereas rituximab is 
an IgG1 antibody.  The polymorphism also affects strength of CRP binding in vitro 
and may have other effects not clearly elucidated which could conceivably influence 
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response to biological therapies in cancer.  However, the current study adds a 
sufficient weight of evidence to conclude that there is no clinically meaningful effect 
on rituximab response. 
 
FCGR2B-I232T polymorphism 
The FCGR2B-232T allele exerts a reduced down-stream inhibitory signal and has 
been linked to increased incidence of several autoimmune diseases, as well as 
better outcome from severe malaria.51 Indeed, it has been suggested that a reduced 
risk of death from malaria conferred by the T allele has led to the increased 
frequency in certain racial groups, in part explaining ethnic differences in 
susceptibility to SLE.51 It has been proposed that such reduced inhibitory signal 
would increase rituximab-mediated tumour killing in lymphoma; however a previous 
study did not find any effect.188 That study included 101 patients, of whom 15 were 
heterozygotes and only 2 T homozygotes.  Our study in 256 patients identified 42 
heterozygotes but again only 2 homozygotes.  There is no suggestion of an effect on 
rituximab response from the current data.  However, the number of T homozygotes 
included is clearly too small to draw a definite conclusion that there is no effect.  It 
would be interesting to perform a similar study in a more racially diverse group, 
which would likely have a higher frequency of the minor allele. 
 
C1QA-Gly70GGG/GGA polymorphism  
Results from the C1QA-Gly70GGG/GGA polymorphism, whilst not highly statistically 
significant, are in line with a previous publication83, and deserve further 
consideration.  There is a trend for poorer response in G homozygotes at all time 
points, reaching statistical significance at month 13, and a slight trend for poorer PFS 
in GG patients.  The trend for poorer PFS in G homozygotes is stronger when only 
complete or overall responders to therapy are considered.  G homozygotes have, on 
average, higher serum c1q levels than A homozygotes.  It was proposed by Racila et 
al that, following rituximab-mediated tumour-cell killing, apoptotic bodies are 
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opsonised by c1qa, with higher levels of the complement component leading to more 
effective removal.83   In patients with lower levels of c1q, tumour debris would be 
expected to persist for longer, allowing more time for the development of cellular and 
humoral immunity.  Our results looking at the interaction of this polymorphism with 
tumour burden are intriguing – the poor prognostic significance of higher baseline 
tumour burden is more marked in GG patients than AA or AG.  Whilst the numbers in 
each group are small and must be interpreted with caution, it is possible that the 
favourable genotype is able to abrogate the negative impact of higher tumour 
burden.  However, if the proposed mechanism is correct, it seems unlikely that this 
would solely relate to rituximab therapy; lymphoma cells, and indeed other 
malignancies, killed by other means would also provide more fragments for dendritic 
cell processing and presentation when less effectively removed from the circulation.  
Racila et al have also reported an increased rate of metastasis in breast cancer 
patients bearing the G allele compared with A homozygotes.195 
 
C3-R80G polymorphism  
Whilst the C3-R80G polymorphism does not seem to impact on TTNT, PFS or late 
responses to rituximab, there is a significant difference in early responses.  R 
homozygotes had better responses, and this was despite their slightly unfavourable 
baseline characteristics.  It is known that complement activation occurs shortly after 
rituximab infusion in vivo.  A functional difference in the two C3 alleles is strongly 
suggested by its association with various disease states, although the mechanism of 
such a difference is not clear.199,200,202  It may be that the complement pathway 
exerts disease control early in rituximab therapy and inter-individual differences in 
CDC affect this early response.  Other mechanisms such as ADCC and vaccinal 
effects may be more important later in the treatment course and in maintaining 
remission.   
 
Conclusions 
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It is clear that none of the five polymorphisms studied could be used to select a 
group of patients who would not respond to rituximab or derive benefit from 
maintenance therapy.  It seems likely that the response to rituximab in a given 
individual is influenced by a wide variety of factors, including tumour bulk and 
histology, serum rituximab level achieved and genetic factors including 
polymorphisms in various complement components and FcRs.  Rituximab seems to 
exert effects by various mechanisms, and the effect of genetic differences in one 
effector mechanism are likely compensated for in other areas, precluding the 
detection of large clinical outcome differences. 
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Appendix 1 – Schema for the randomised trial 
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Appendix 2 – Randomisation requirements 
Inclusion criteria: 
 Minimum age 18 years, no upper age limit  
 Follicular lymphoma grade 1, 2 and 3a  
 Stage II, III and IV disease  
 Asymptomatic without “B” symptoms or severe pruritus  
 Blood count: Hb > 10g/dl, Neuts > 1.5 x 10
9
/l, Plts > 100 x 10
9
/l and < 5x10
9
/L 
circulating tumour cells  
 Renal function: Creatinine < 2 x ULN for reasons other than lymphoma  
 Normal liver function (bilirubin (must not exceed 30 μmol/l), alanine 
transaminase/aspartate transaminase, alkaline phosphatase)  
 Low tumour burden, defined as:  
o LDH within normal range  
o Largest nodal or extra nodal mass less than 7cm  
o No more than 3 nodal sites with a diameter more than 3cm  
o No significant serous effusions detectable clinically or on CT (small, clinically 
non-evident effusions on CT scan are not deemed significant)  
o Spleen enlargement less than or equal to 16cm by CT  
 No other (non-lymphoma) immediately life-threatening disease  
 Must have disease measurable in at least 2 dimensions either clinically or 
radiologically  
 Entry within 3 months of biopsy with no prior therapy  
 ECOG Performance status 0-1  
 No evidence of histological transformation  
 No second malignancy unless treated with curative intent and patient has been 
disease free for >2 years  
 If second malignancy was basal cell carcinoma or squamous cell carcinoma of the 
skin or carcinoma of the cervix, the patient need only be currently disease free  
 Patient must be able to give informed consent  
 No critical organ failure or organ compression (e.g. ureteric obstruction)  
 
Exclusion criteria: 
 Patients known to be HIV positive  
 Patients with Hepatitis B infection.  
 Pregnant or breast feeding patients  
 Women of childbearing potential not willing to take adequate contraceptive 
precautions if randomised to rituximab containing arm  
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Baseline assessment: 
1. Full history and physical examination with site and dimensions of palpable lesions 
recorded (a maximum of 6 target lesions should be identified: see response criteria, 
appendix 3).  
2. Measurement and documentation of spleen and liver size and ENT examination if 
indicated.  
3. CT scan chest, abdomen and pelvis with measurement of nodal and extra nodal 
masses. Neck CT if cervical lymph nodes palpable. Ideally scans should be within 8 
weeks of registration. If there was any clinical progression of the disease in the 
intervening period then an up to date scan should have been performed. MRI, PET, 
bone scan, ultrasound scan if indicated (not mandatory).  
4. Bone marrow and tumour biopsy for histological classification according to WHO 
classification (bone marrow biopsy could be performed after consent and registration 
but before randomisation to prevent need for repeat biopsy). 
5. Full blood count with differential. Blood and bone marrow for DNA and RNA 
extraction for bcl-2 or t(14;18) PCR analysis and Fc receptor polymorphism.  
Biochemistry including blood urea, serum creatinine, total protein, albumin, alkaline 
phosphatase, ALT or AST, LDH, total bilirubin. Serum immunoglobulin quantification 
and protein electrophoresis, Beta-2 microglobulin.  
6. Hepatitis B serology  
7. Baseline pre-randomisation questionnaire and post-randomisation (but prior to 
treatment) questionnaire.  
Patient registration and randomisation  
Following confirmation of eligibility, written informed consent and verification that baseline 
pre- randomisation Quality of Life questionnaire had been completed, patient details were 
sent to the Lymphoma Trials Office by fax. Registration was allowed prior to bone marrow 
examination, provided all other criteria were fulfilled. This allowed samples for PCR to be 
sent at the time of the initial staging marrow and thus prevented the need for a repeat bone 
marrow examination. Randomisation was performed once the result of the staging bone 
marrow was known. Patients were centrally randomised using a minimisation technique for 
random treatment allocation stratifying by institution and according to grade, stage and 
age. 
 
  
Appendices 
 151 
Appendix 3 - Response criteria  
The criteria for response evaluation according to Cheson et al
13 
were used.  
During the initial measurement, a maximum of 6 target lesions were selected according to 
the following features:  
• clearly measurable in at least two perpendicular dimensions  
• from as disparate regions of the body as possible  
• include mediastinal and retroperitoneal areas of disease whenever these sites are involved  
 
Complete remission (CR)  
1. Complete disappearance of all detectable clinical and radiographic evidence of disease 
and disappearance of all disease-related symptoms if present before therapy, and 
normalisation of those biochemical abnormalities definitely attributable to NHL for a 
minimum period of 2 months.  
2. All lymph nodes and nodal masses must have regressed to normal size (≤1.5 cm in their 
greatest transverse diameter for nodes > 1.5 cm before therapy). Previously involved 
nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must 
have decreased to 1 cm in their greatest transverse diameter after treatment, or by more 
than 75% in the sum of the products of the greatest diameters (SPD).  
3. The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must 
have regressed in size and must not be palpable on physical examination. However, no 
normal size can be specified because of the difficulties in accurately evaluating splenic 
and hepatic size. Any macroscopic nodules in any organ detectable on imaging 
techniques should no longer be present. Similarly, other organs considered to be 
enlarged before therapy due to involvement by lymphoma, such as liver and kidneys, 
must have decreased in size.  
4. If the bone marrow was involved by lymphoma before treatment, the infiltrate must be 
cleared on repeat bone marrow biopsy of the same site. The sample on which this 
determination is made must be adequate (should ideally be 20 mm biopsy core).  
 
Complete Remission uncertain (CRu [i.e. PR 75%])  
Criteria 1 & 3 same as listed above for CR but with one or more of the following features:  
i. A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has 
regressed by more than 75% in the SPD. Individual nodes that were previously confluent 
must have regressed by more than 75% in their SPD compared with the size of the 
original mass.  
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ii. Indeterminate bone marrow (increased number or size of aggregates without cytological 
or architectural atypia).  
 
Partial remission  
1. At least 50% decrease in SPD of the six largest dominant lesions.  
2. No increase in the size of the other nodes, liver, or spleen.  
3. Splenic and hepatic nodules must regress by at least 50% in the SPD.  
4. With the exception of splenic and hepatic nodules, involvement of other organs is 
considered assessable and not measurable disease.  
5. Bone marrow is irrelevant for determination of a PR because it is assessable and not 
measurable disease. However, if positive, the cell type should be specified in the report, 
e.g. large cell lymphoma or low grade lymphoma.  
6. No new sites of disease.  
 
No change or stable disease  
No change or stable disease is defined as less than a PR (see above) but is not 
progressive disease (see below).  
 
Progressive disease  
Progressive disease (PD) (in patients who achieved PR or non responders) requires the 
following:  
1. 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or 
non-responders.  
2. Appearance of any new lesion during or at the end of therapy.  
 
Relapsed disease  
Relapsed disease (in patients who achieved CR, CRu (PR 75%)) requires the following:  
1. Appearance of any new lesion or increase by 50% in the size of previously involved sites.  
2. 50% increase in greatest diameter of any previously identified node greater than 1 cm in 
its short axis or in the SPD of more than one node.  
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Appendix 4:  Letter to sites requesting missing samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<Date>          
«GPsname» 
«Address» 
«Address_1» 
«Address_2» 
«Post_code» 
Dear Dr «GPsname» 
NCRI “Watch and Wait” trial in asymptomatic, advanced follicular lymphoma 
Re: Patient: «Patients_name» Date of Birth:  «D_O_B» Trial No: WW Trial No. 
This patient was entered into the Watch and Wait trial in follicular lymphoma.  A protocol requirement 
was the provision of blood and marrow samples at diagnosis / trial registration for bcl-2 or t(14;18) 
PCR and analysis of Fc gamma receptor polymorphisms, which have been linked to rituximab 
response.  Unfortunately no samples have ever been received for your patient.  However, Fc gamma 
receptor polymorphism status can be ascertained on any DNA-containing sample, from any time-point 
before or after treatment.  Therefore, we asking that you provide a further sample from this patient to 
fully comply with the protocol.  Ideally, this would be a new blood or bone marrow sample.  However, 
if that is not possible, stored, unstained slides or tissue blocks would be acceptable as DNA can be 
extracted from these. 
Blood (20-30ml) or bone marrow (first 2-3ml) should be added to EDTA and sent by first class post or 
guaranteed delivery, preferably not on a Friday or weekend.  Samples should be addressed: 
For the attention of Yashma Patel 
UCL Cancer Institute, Department of Haematology 
72 Huntley Street 
LONDON   
WC1E 6DD 
Tissue blocks or unstained slides should also be sent to Yashma Patel at the same address. 
Many thanks for your help in this matter. 
Yours sincerely, 
 
 
Dr Kirit Ardeshna     Professor David Linch 
Chief Investigator     Clinical Trial Coordinator 
  
Haematology Trials Group  
Cancer Research UK & UCL Cancer Trials Centre                          
90 Tottenham Court Road 
London W1T 4TJ 
Tel:  +44 (0)20 7679 9283 
Fax: +44 (0)20 7679 9861 
Email:  ll@ctc.ucl.ac.uk 
 
 
LTO Director: Professor DC Linch 
Centre Director: Dr J A Ledermann 
 
CANCER RESEARCH UK & UCL CANCER TRIALS CENTRE 
UCL Cancer Institute 
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Appendix 5: FCGR3A gene sequence - Selected section showing primer annealing 
and polymorphic sites. 
 
 85621 TACCAGTCCCGCCCTTCCCCTCCCTGGTGTTTACATTGAGTTCTCCTTCACAATTTCTGC   85680 
 85681 AGCCACTCCGTGGCCACCGTCACCTTATTCCTGACTGCCACAAGAGTCTTTCAATATTCC   85740 
 85741 TTTGATTGCCTATTCCTTCTGAAATCTACCTTTTCCTCTAATAGGGCAATTCATCATTTT   85800 
 85801 CAAATGCAATTTTTACTCTGATCTAGAACTTACTGTGAATCCTTGTCACCTGCCACAGCA   85860 
 85861 AATCTAAGTCTAGCACTTAAGGATCCTGCAGATATGCTCATCGTTGCTTCTCACTTACCT   85920 
 85921 CATTGCTTAGTCCCTCTGCTCTAACCCTGTGTGTTGATCACATGTGTGTGTGTCCCTCTT   85980 
 85981 CCCCATTAGACAAAGGTCTTGGTATGACTTCAGTTCTCTTGCAGGGCCCCATCAGCTCTT   86040 
 86041 CCCCAAAGGGAGCTATGCAGGGTTGACTCCCAATCTGGCTTTCCCTTATGTCTCAGGATC   86100 
 86101 TGGGTGGTACGTGGCCCCTTCACAAAGCTCTGCACTGAGAGCTGAGGCCTCCCGGGCCTG   86160 
 86161 GGGTGTCTGTGTCTTTCAGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG   86220 
 86221 GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA   86280 
 86281 TATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA   86340 
                    atcagattcga 
 86341 AAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT   86400 
                                            gagtcgtgca 
 86401 GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTGAGACATGTGCCACCCTGGAA   86460 
 86461 TGCCCAGGGACGCCTGTGTGTGGAACCTGCAATCACACTGGGAAGTTGAGTTGGGAGGAG   86520 
 86521 ATTCCTGATTCTTACACGCACTTCTTCATATGTGGTTCCCTCCTGGTGATCACCAGGAGG   86580 
 86581 TCCCCAAAAGTCCCTGATTGCAGGGTAGGTTTGCAGCTCTGTTTCAGTCCATTCTTTTGG   86640 
 86641 GGTAGCTAGGAGGTGTCATTCACTCTGCAGCATGATGGCAGGAGCAGAAGCCACATCTCC   86700 
 86701 TCCCCAATAAATACCTCTGTCTTTCCTTACGCTAATCACACCCACGGTGTCATATGTTCC   86760 
 86761 TATCGTGCTGGCCTCCTTCTTATCCAAGCCTTTTAGCCACGATCCAAACTGGCAGGAGCC   86820 
 86821 CCTCATCCCCTCACAGAAAGAGCCCAGAACCTGGGTTCTGGCCCTGCAGCTAATTAACCA   86880 
 86881 TCTGACCAGAGGTGAGCCACTTAGTCTCTCTGAACCCCAATTTCTTCTTCCGTAACAAAA   86940 
 86941 ATAAGCTGACATTTATTGGGCACCTTTCAGTGTGCTAGACTCTGTGCTAAACAATTCTTT   87000 
 87001 ACATGCACCTGGTTTGACTATCACAGTAGACCTTCACAACATGAGATAGGTAATATTCCA   87060 
 87061 TTTTACAGATGAAGTAACCGAGGTGCAAAAATAAATAAATAAGTTTCCCTAAGGTCACAT   87120 
 87121 CAAAGACTTCAAAGCCTGTATATTTAACCAGTAAGTAAAAGATTTGAACAAGCACTAATA   87180 
 87181 TCCTATGATCCCATTAAGTCATCCACAAAACATCTCTAGGTTCTGTAGCACCAGCCTCCA   87240 
 87241 GAATCAGAGCTCTAGAGTGGTGTGCCTGGACTTTCCAGTTTCACAGAACTTCTATCTGTA   87300 
 87301 ACTAGCCCAAGACATAAATTGTAAACAATTTGCATGTAGAAAGGCAGCAAAACACCTTTT   87360 
 87361 GAGATTTTGACACTACAATGCCATAATTTGTACAAAAATAATTTCATGACACTTTAAACT   87420 
 87421 GAAAGTAAATACTCCCAAGTGGTTAGGGAAAGAGAGCAAATAAAGCAAATGGGGTAACAT   87480 
 87481 GTAAACAATGAGTGGATCTGGGTAAAGGATATACGAGATTAAACTATTCTGGTCATTTTT   87540 
 87541 TTTTTAAGTTTGGAAATATATCAAAATCAAGAGTTTAAAAAATTGAAATGCAAAATCAAC   87600 
 87601 AAATTTGTCCCAGTTTCTAGACCATAGCATTGTCTGACAATTTCTTAACTGTCACACAAA   87660 
 87661 ACCCAGCTTACAACCTAACTTGTTAACGCTCCCTGTCACATCTCTGTCAAACAAGCAGGA   87720 
 87721 GCCTTTGCTCAGTGTTTGGTGAGCTGTCCTCTGCTCAGATAGCACTAAGATCAGGAACCA   87780 
 87781 ATGGGAGGAAGCAATACTTTCCCCCAGACTTCCCCACCATTCCTACCACTTGCCTGTTGG   87840 
 87841 CTGTTGTCAAAGACTTTCTACTGGTGACCTCACTGTTTGTTCCAAATATCTGCCTTAGTG   87900 
 87901 ACTGTCATTTTTTTTCATCTCTCCACTTCTCCTAATAGGTTTGGCAGTGTCAACCATCTC   87960 
 87961 ATCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGC   88020 
 88021 AGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTG   88080 
 88081 GAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGACCCCCATCCCATGG   88140 
 88141 GGGTAATAAGAGCAGTAGCAGCAGCATCTCTGAACATTTCTCTGGATTTGCAACCCCATC   88200 
 88201 ATCCTCAGGCCTCTCTACAAGCAGCAGGAAACATAGAACTCAGAGCCAGATCCCTTATCC   88260 
 88261 AACTCTCGACTTTTCCTTGGTCTCCAGTGGAAGGGAAAAGCCCATGATCTTCAAGCAGGG   88320 
  
..   SNP TG (predicting PheVal)               
..... Outer primers         
.....  Inner primers – lower case letters show non-annealing nucleotides 
..          Deliberate primer mismatch 
CATGꜜ   Potential NlaIII restriction site 
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Appendix 6: FCGR2A gene sequence - Selected section showing primer annealing 
and polymorphic sites. 
      
  4801 CTGCTTTTAGAAGTCCCAYAGATATAATACCATATATTGCCTATAAGAGAATGCTCACAT   4860 
  4861 CTGTCATGAAGCATCTTCATTTCTGTCTGCCAGACATCATGTCAAGTTCTGTGAGTAACR   4920 
  4921 TACCTCTGAGACTGAAAAACCCTTGGAATCTATCCTTACAACTTTTTCTTATCATATTTR   4980 
  4981 TGTCTTTCAGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACC   5040 
  5041 ATCRTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAG   5100 
  5101 AATGGAAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAAC   5160 
  5161 CACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCC   5220 
  5221 AAGCCTGTGACCATCACTGTCCAAGGTATGGGGAGTCTGCCAAGATGTAGGGAGGGGAGA   5280 
  5281 AGAGGGGATGGACAAGGGCTGAGGTCACATGGGCCTACATGGAGGTCTGAGAAAGCCCAT   5340 
  5341 AGCAGCAAAATTGGGCACTGGAGCAAAGAGGAGTGGGGTGGAAGCCTGGCTAAGTATTGA   5400 
  5401 CCAACAAGTAGGGGCCAGAGCTTGGAGCCCTCACGTCCCAGGTAATAGGTAGTCAGGCTG   5460 
  5461 TTGTTTCACTTTGAAATGTAGGCCCCAGACTAAAGATGGCAGTGAAGCAGAGCTCCCTCA   5520 
  5521 TTGATGCAGAGGTTCCCTAAGCTCCTGGGCATTCCTAAGAGCTGAGGTTTGCCTCGTTTC   5580 
  5581 TTCTCATGGCTCATGTTATARCCATTCACTCCAGAAAGCCTGGCACGTCATGGACTGTTC   5640 
  5641 AAGGCTGTGCTCCATAGAGTAATGATGCCTCCAGCTATGCGAGGCTTTGGGCCCACCCTC   5700 
  5701 CGTACTGTCCCCAGGGGMTAAGGGGAATCCTTCCCTCTGCTCSTGCATGCTCACCAGTGT   5760 
  5761 GCTTTCATTCATTTGGTGGAGAAACCTGGGTAGGGAGGAGGCACAAGTCCAGCCACAGAA   5820 
  5821 ACCCTGTGCCAGTGAGGCTGGGGATGTGGTGAATCTTGCATTGGTGAGTGACTCAGACAC   5880 
  5881 AGAAGAGCTTCAGGTGACAAGCACTGGGACATAGCATTGGAGGTGGGAGGTGGGACAGGG   5940 
  5941 AGAATACAAACGTTGTCATTAAAATAGTAACCCCCCATCCTGCCCTAATGTCTGTCTTCC   6000 
  6001 CTAGTGCCCAGCATGGGCAGCTCTTCACCRATGGGGRTCATTGTGGCTGTGGTCATTGCG   6060 
  6061 ACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGG   6120 
  6121 ATTTCAGGTTTGTAGCTCCTCCCAGTCCCTTTTGTTATCAGTTTCCATTTGGCCCAGGGC   6180 
  6181 CTAACCCCAGACATTGCCAGAATCCCGCTCTTAGGGCTAGATATGCATTCCGATCTAGGC   6240 
  6241 CCACCTTTTATTTATTAGTTCATTTATTAGTTCATCCTCAACAAGAGCACTAATAGGAGT   6300 
   
..  SNP GA (predicting ArgHis) 
.....  Primers forward MP7931 and reverse MP7932 
..  Substitutions in primers to create restriction sites 
CGꜜCG Potential BstUI restriction sites 
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Appendix 7: FCGR2B gene sequence - Selected section showing primer annealing 
and polymorphic sites. 
 
 91621 CAAATTTTCCTCAAAAGTACACAGCAAACGAATGACCCACTGGTGACACTGCTGCCTTTA  91680 
 91681 GACCCTGCTGGAAAGAAGCTCCACATTTATTAACATTCCCGAAGTAAATTTATCAGGTAG  91740 
 91741 CATTCATCAGGTAACATTTGTTGCACATTCATGACTTTTCTACTGTCCACAAAGGCATAT  91800 
 91801 GTCCTTATCATATGCGGACTCCTCGGTCACACTGGATTCTTCCTTCCCTCCTCGACATGG  91860 
 91861 AAGAGATGGCATCTTAGGGTCTCTTGTGTTCTTCCTGCAGAGGCCTGTCGGGCAGGAAAA  91920 
 91921 GGCTGCAGCTGCCTTCCTGGGAGAAGGAGGAGATGAGTGTATCCTGAACACCTATTATGT  91980 
 91981 GCTAGGGGCTATTGTAGATACATGACACTATCATGCTCATTTTCACGAATGAGGAAACTG  92040 
 92041 AGGCTCAGAAGACTTAAATTATTTGCCCAAGAGTTCATAAATGACAGAGCCAGCATTAGA  92100 
 92101 GTCCAGGACTGTCTGATTTCAGACCTAAGCTGTTCCCTCTGCACATCGTGTCCCACCAGT  92160 
 92161 AAGGAAGATCTGGGTCTCAGAGCTGAGCCAAGACCTCCCGGGTCCTCTGCGGTTTTTTGT  92220 
 92221 GTCTTTCAGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCA  92280 
 92281 TCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGA  92340 
 92341 ATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTCTCCATCCCACAAGCAAACC  92400 
 92401 ACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTACTCATCCA  92460 
 92461 AGCCTGTGACCATCACTGTCCAAGGTATGCGGAGTCTGCCAAGATGTAAGGAGGGGAGAA  92520 
 92521 GAGGGGATGGACAAGGGCTGAGGTCACATGGGCCTACATGGAGGTCTGAGAAAGGCCACA  92580 
 92581 GCGCAAAATTGGGCACTGGAGCAAAGAGGAGTGGTGTGGAGGCCTGGCTAAGTATTGACC  92640 
 92641 AATGAGCAGGAGTAGGGGCCAGAGCTTGGAGCCCTCAGGTGATAGGTGACCAGGCTGTTG  92700 
 92701 TTCCACTTTGAAATGCAGGCCCCAGACTAAGGACGGCAGCGAAGCAGAGCTCCCTCGTTG  92760 
 92761 GTGCAGAGGTTCCCTAAGCTCCTGGGCATTCCTAAGAACTGAGGTTTGCCTTTATTCTTC  92820 
 92821 TCATGGCTCATGTTACAGCCATTCACTCCAGAAAGCCTGGCACGTCATGGACCGTTCAAG  92880 
 92881 GCTGTGCTCCATAGAGTAATGATGCCTCCAGCTATGCGAGGCTTTGGGCCCACCCTTCCC  92940 
 92941 ACTGCCCCTGAGGGCTAAGGGGAGCCCTTCCCTCTGTTCCTGCCTGCTCACAAATGTACC  93000 
 93001 TTTATTAGTTTGGTGGAGAAACCTCGGTAAGCAGGAGGCATAAGTCCAGCCACAGAAACC  93060 
 93061 CTGTGCAGATGAGGCTGGGGATGTAGTGAGTGCTGCAGAAGTGAGTGACTCAGACACAGA  93120 
 93121 AGAGCTTCGGGTGACAAGCACTAGGACATAGCATTGGATGGGGGGGAGGTGGGACAAGGA  93180 
 93181 GAGTACTGCCTGTCCTGATGTCTGTCTTCCCTAGCTCCCAGCTCTTCACCGATGGGGATC  93240 
 93241 ATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTAGTGGCCTTG  93300 
 93301 ATCTACTGCAGGAAAAAGCGGATTTCAGGTTTGTAGCTCCTCCCGGTCCCTTTGGTTATC  93360 
 93361 AGTTTCCACTTGGCCCAGGCCCTAACCCCAGACATTGCCAGAATCCCTCTCTTTGGGCTA  93420 
 93421 GATACACATTCAGATCTAGGCCCGTATTGTATTATAGTCATTCATTCGTTTATTAGATCA  93480 
 93481 TTCATTTGACAAGACTTGAACAAACTAGCTTATGTGTCAGCCAATGCGTGAGACATGGTG  93540 
 93541 GGTGATGCCAAGAGAAGTCCAGTCCCTGCCCTTGGGGAGTTCTCAGCATTGTGAGGAAGA  93600 
 93601 CAGGGTCATTATAATAAGATGGGATAAGAGCAATGATAGGGACATGAAAAGCCTAGGATA  93660 
 93661 GAAGTACAGAGGAGGCTCCATAGCCCAACAAGGGCTGAGGCAGTTGGAGAAGGTCTTGGG  93720 
 93721 GAGAGCAGTGTAGTGTAGTGATGGAGTGCACATAGTGGGGCCAGACTGCCTGAGTTCAAA  93780 
 93781 TCTAGTTCTACAGCATACCAACTATATGACCCAAGTGAGTCACTCCACCTCTCTGTGCCT  93840 
 93841 CAGCTGTCTCAAGTGGAAAATGGGGACACTAATAGGACTTACCTCAGAGGGTTGCCATGG  93900 
 93901 GGATGAAAGAGGCTGATGCTCTTACACAGTGCCTGGTAGGCAGTAACAGCACACAAACAG  93960 
 93961 GGCTGTTGCCATTCTGGAGGAGGTGGTGTGTGAGGGCAGCGCTTAGCTAGGGAAGGAGGA  94020 
 94021 CCCTCCAGGCACTGGGCCAAGGCAGGGATTGAAGCCGGGTGGGGCTCATATGGGTGTCGA  94080 
 94081 AGGGGGAGTAGAGAGGGTACTGCAAGCCACCAAGAAAGAAAGAATCCTGCTAACACCTCA  94140 
 94141 CAAAGCACTTTTCAATTGGTTCATAGCCAACACCTCAGTTACTGATGATAAGTAAATACA  94200 
 94201 GAGAAACAGAGAGAGAGAGACTGAGACACAGGGGTGTTTTTAAAAGGCAGAGCAAGCCTC  94260 
 94261 AGACAGATGCCATGGCGTGGACTTTCTGACACTCCTGGGCATCCCCATGGGTGAGCTGAA  94320 
 94321 TTCTGCCTCTGGACCAGCCCTTTTCCAGGCGGGAGCAGCCTCTGAGCAGGGGAGCTGGGG  94380 
 94381 GTGGGAGGACAGGAAACATCTGCCAGAGTGAAGGCCTGAGCTGGTCCCATCCAACCCTGG  94440 
 94441 CCCTGGTCCTTGGTCCTGAGGACTCAGGCCCCACCGCCTAATCCTACTAACCTCCTGTGT  94500 
 94501 GCCCCTCCCAGCTCTCCCAGGATACCCTGAGTGCAGGGAAATGGGAGAGACCCTCCCTGA  94560 
 94561 GAAACCAGGTGAGTACAGGTTGTCTCAGGGATTCAGTGATGGCTCACCAGGGCTGCCGGC  94620 
 94621 TGGACTGGAGCCAGGGAGAAGGGGCTTGTGCAAGTTCAGCTGGGAGCCAGGGAGGGAGCA  94680 
 94681 GCAGTGGGAGGATGGCTGGGGCTCAAATCGCTTGGTCAGCTCTTAGTCTAACTCCTGGGC  94740 
 94741 CTAAAGACGACCTCTCTGGAGATGAGAAGAGAAACACCAGTCCCAGATACAGAAGAGAGG  94800 
 94801 GCTGTGTCCGAATTTCTGGTACCAGGAATCTGGTGATATTTCCAGAGCAAGAAATCAGAG  94860 
 94861 ATACTTTGGTCTTCCTGTGGAGCTTTGGCAGAGCTGGCAAAGGATGGGGTTAGGGGCTGT  94920 
 94921 AAGACTGAGGCCAATAGGACGTGGGAGGCAGGAGTCTAAGGGGAAAGGAGGAGGAGGCCT  94980 
 94981 GGAAACCCCTTGATTTGCTGAGGAATCTGCCTCTGTGGAGGGATGGGGTGGAGTGGCCAG  95040 
 95041 GCTCAGCTGTCTGTGGAACACTAGGAGGAGGTTTGGGCTTGAGAAAATTCTGGGGGACTA  95100 
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 95101 GGGGCACTAGTGGGCTCTACTCTGTGGGCAAAACTCAGTTCTGATGCCCATGCACTCAAG  95160 
 95161 GTTGACTGAATTTTGGCCTGGTTCTGCCCTCATCACACAGTGGAGCCCTGAGCAAGTCAG  95220 
 95221 TCTCCCTGATGGGGTTCAGTCTCCTCACTGAGGAAATGAGTGGGTGGCCAGGGTGACCTC  95280 
 95281 TCAGGTCTTCTAGATTTGACATTCTGAGAACCAGGGGCCACCCAAGCCCTGGCCCAGGTG  95340 
 95341 GGAGTGTGTAAAGGAACTTCCAGGAGGATGCCAGGCAACTTCCAGACTGTAGTTAAAGTC  95400 
 95401 AGAGCACAAAGGAAACCAGTGCTTTCTCTGGGGGCTTCCATGACAGTAAGAACAGGCAGA  95460 
 95461 AAAAAGAGGCTGTCAAAGACCCCACCTCAGATGGCTGGAGTATGATTCAGAGCAGAGCCA  95520 
 95521 ACAGATTTAAGAGCTTGAGCAAAATATCACTTGTTCAGCTGTGCTTGCAGCAAGGTCGCA  95580 
 95581 TGTCTGCTGGCCAGGCCCAGTGGTGATAGGGGCCTGTGTTCACACCAGGGCCAAAACAGA  95640 
 95641 TCTGGAAAAAACAAAGTCCAAGCAACTGGATTATCCATCTTGTTGTGTGGTTCTGTCTGC  95700 
 95701 ACTGGCATAAGCACATTTCACAAGGCACTTTTGCAGCCAGGCATTGGGGCTGCATAAATG  95760 
 95761 GTTTTTTAAAAATCCTTTCCCAAAAGGCAAAGCTGGGTTGCTGGGATTCTTGGGAAATGT  95820 
 95821 AATAGAATGGGAATTCAGAATGCGGTTTACTGCAGAATTTACAGCATGGCAATAAAGGCT  95880 
 95881 CTCTATGTTCAGGGGGTGAGAGAAGAGACTAGATGCATTGTCTCAGATGTCTCCTGACTT  95940 
 95941 CCTGAGAAATGCCACTTTGCAGATATGGGGCTGCTTTTCACACTGGCTAAGTCAGTTCAT  96000 
 96001 GGCAAAATATGAGGGAATTCAGTGTGTTTCAGACACTAACCAAAGTCCATCCTTCCTTTC  96060 
 96061 TCCTTCCGTCCCTCCCTTCCTCCCTTTCTCACTCACTCTCTCTTTCTTTTTAATGCCATG  96120 
 96121 GAGTACCATATTTTTCAAAGTTCCAACAAAGATGCACTACATTTAGACAATGTGGAAATG  96180 
 96181 GCCCTCAGCCTTCTCTCCCTGAAGTCTGTGGCCAGCAAAAATCTGGACTTTACTTCACTC  96240 
 96241 TGATGCTGAACACCCCCCTCCCCCACCTCTTCCCCAATATCTCAGATCCCAAGCCTCCCT  96300 
 96301 GGTTTGCTTCTAGGAAAGCTCAGCAATTCCCTGAAAAGAATGCAGCTCAAGTGACTGCTC  96360 
 96361 CACTTTTTCACCTTGGCCTTTGCGGAAGGCTGTGGCTGGGCTACCCTATGCATCGATCAA  96420 
 96421 TGAGGTCATATTTACCCAGTGCTTGGCCTAGAGGCCCAAGACAGGGTCAGCAGTGCTTGC  96480 
 96481 TTTGGCTCTAGTTTGGGCGTTGGTTTTGCAGCCTCAGCATCAGCACAGGCAGGCCCTCTT  96540 
 96541 CTCCAGCAGTGCTCTGGCTGATATTTCTTCTTTTTCCCACAGCCAATCCCACTAATCCTG  96600 
 96601 ATGAGGCTGACAAAGTTGGGGTGAGTGATCCCAGCCATCTCCCCCTCCCTTCTCCCCTGT  96660 
 96661 TGCCTTTTCTGTTGCCTTCTTTCCTAGGCCCTCTCTGTGGATCCTTACTGCTGGTTTCTG  96720 
  
.. SNP TC (predicting IleThr) 
..... Previously published outer primers forward MP8233 and reverse MP8234 
..... Forward primer MP8235 used for patient samples 
..... Reverse primer MP8236 used for patient samples 
..... Reverse primer MP8237 
..... Inner primers forward MP8231 and reverse MP8232 used for patient samples 
GGGAC Potential BsmFI restriction site cuts 10 bp downstream with 4bp overhang 
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Appendix 8: C1QA gene sequence showing primer annealing and polymorphic sites. 
     1 AAATTTTTAGTAGAGATGGAGTTTCACCATGTTGGCCAGGCTGGTCTCGAACTCCTGACC     60 
    61 TCAAGTGATCCGCCTGCCTTGACCTCCCAAAATGCTGGGATTACAGGCGTGAGCCAAAGC    120 
   121 ACCTAGACTTGCTGTTTTTTTAAATGTTGGCAAAAGCTAGTGACTAAGTGTTCACCATGT    180 
   181 GCCAAGTGTTTTGTATGTGCAAGTCATTAAAATGTTATAATAATCAGATGATATAGGACC    240 
   241 CCGTTCCCAGTGTACAGATAAAACTGAGGGCTCAGGAGGTCAAGTAATTTCCCAAAGACA    300 
   301 TGCAACTAGGAAGCAGCAAGTCTAGAAACAGATTGCTGTGCTTCCTTCTCACCAATGCAC    360 
   361 TGTTCTTTCTTCTTTGTATTTTCCAAGCTTTTGGCAATGAATTGCATGTCACTTTCATAA    420 
   421 TCATGAAAAGTCCTACAAGGGACAGATTTTTTTAAAGATTCCTTCCGCTCTGGTGTTCTG    480 
   481 TGCTTCGCTGGTTCTCAGAACCTCACCCTGCACGGCCTCCACCCCACATCCTCACAGGCA    540 
   541 CTGGCCTCACTGCCCCCACTCCCACACCAGCTGTTGCTGGGGCAGGACGCCCAATGTCCC    600 
   601 AGTCTTGCTGAAGTCTGCTTGAAATGTCCCTGGTGAGCTTCTGGCCACTGGGGAAGTTCA    660 
   661 GGGGGCAGGTCTGAAGAAGGGGAAGTAGGAAGGGATGTGAAACTTGGCCACAGCCTGGAG    720 
   721 CCACTCCTGCTGGGCAGCCCACAGGGTCCCTGGGCGGAGGGCAGGAGCATCCAGTTGGAG    780 
   781 TTGACAACAGGAGGCAGGTGAGGCCAGAGTCCCAGAGGGAGGGGGCTGCAGAGTTCTGGG    840 
   841 ACCCAGGGGAGCTGGCCCAGGAGGCTGGGCAGCTGAGGCAGGGAGGGAGGGAAATAACTG    900 
   901 TGCCTGATTCTAGGACAGGGATGGGGGTGCAGCACTGATCCAGGACCCAGAATGGGTGAG    960 
   961 TGGAGGGACCTTAACTCCTTGAGCCAGGGCTTGGGGGAGGGTGAGAGGCGATGAGTTAGA   1020 
  1021 CCTAACAACTGAAGGGTAAGACCAGGGTTCCTGGGTCCTGGCCCCATAACACATAAGAAA   1080 
  1081 CCAGGAAAAGCCTGGGGTGCTAGAGCTGGCAGTGGGACCCAGCAGAGGGGACTGTAGGGG   1140 
  1141 CAGCCAGTCACCCATGCTCAGGTGGATGCTGAAAGGCGCTGAGCATGCAGAAGAGTGAGC   1200 
  1201 AGGTGTCGCTTTGGGCGTTTGTGAATTCCTGTGTGTATGCAGAGCTCCACCATCTGGGTG   1260 
  1261 AGCCAGTGTTAATTAAATAAGGAGCAGGCGCTCAATACATATTTGTTCAATGAAATCGAT   1320 
  1321 TACCTGTGGGAGTGTATGAATGTGTGTGTCCGTGCAAGTGAGGGACAGGGTCTATTTGGG   1380 
  1381 TATCAGTTGTGTGTCTAGGGGGGTATAGTGGATTTCTGAGTTTGCCTACTGTGTTTTGTA   1440 
  1441 GGTGCGTGGATGAGAGCTGTGTTTGTGTGAGTGTGTGAAGATGTGGGTGTGCTCTGTTGC   1500 
  1501 ATGTGTGGATGTGTGTGAGTTTGTGGTTCTGTGTATATGCGTGGGGTCCTGGGGCTGGAT   1560 
  1561 TGAGAGTGGACATTGAGAGCCCCAGAGGGTGCATGTGCACTTGGGGAGGACTGTGCATAT   1620 
  1621 ATCATTGTGTGCATGGGACTCAAGGGTGGGAGCTGGGTGTGAGTGTGATGTCCAACCTGC   1680 
  1681 CCAGGCCCTCCCGTGTCTCCACAGAGGCATCATGGAGGGTCCCCGGGGATGGCTGGTGCT   1740 
  1741 CTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGA   1800 
  1801 CGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGA   1860 
  1861 GCAAGGGGAGCCGGGTAAGCACCCTTCCTCGGGACCCAGCCCCTTGGACCTTGGCCTGAC   1920 
  1921 TTGGCCTCCAGGGTGAAGGCTTGGGGTGGCACTGAGAATCAGGAGTCCGTCTGCCCCCAG   1980 
  1981 TGCCCCATGAATCCTCTCCAGTTTGTACTTGGCCACAGGGGCTAAGGGAGGCCTAGCCTT   2040 
  2041 CTCGGGCCATGTCCTCAGGCCTCTCCACTCCCTGTGTACTGCCTGGGCCCTCTTTCTTCG   2100 
  2101 GCTTCACCTTCCCCCTCTGGAGAATGACTTGCTTTGACCAGTGAAAGTGAAAGTTCTGGC   2160 
  2161 AGCAATGCTGAGTCCTTGTTCATGTTTCTCTTGCCAGAAAAACGAGGACTCAGAGTTTAG   2220 
  2221 ACTCAGGAGCCACTGCCTTGCTGTGTGACCTCAAGCAAGTTATTGGCCCTCTCTGAGCCT   2280 
  2281 AAGTGGGCTCATCTGTAAAATGGAAAAATAACACTGCCTGGCACATAGAGAGGGATCAAA   2340 
  2341 TAACTGAATCTGTCCCTTCACTTCCTTCCAGCACCCCCAACACTGTCCCTGCTTCCCCCT   2400 
  2401 CCCCAGCCCCTTCAGGCTTCAGAGACTCACATTCTAGAAGAAAGGCCAGGGGTAATGGAA   2460 
  2461 AAGGGAAGAGGTCCTGACCAAAGTAGAAAGGGAGTCTCATGGAATCACCCTGGGCCTCCT   2520 
  2521 AGTCCAAAGCAGACCAGAAGGATCACATAGACATTTGCAGTAATTTGCATCCGGGCATCC   2580 
  2581 TACATGTGGTACCTGAACCTGAAGCCAAGTCAAGGTCAGTGCCCCAGAGGGGTATGAAGT   2640 
  2641 CCTCAGCCTTGGGCAGGAACACAGCAGAGCAGCCAGAGTTCCATGCATTTCCCAGAACCT   2700 
  2701 GACACTTTCCCAAGTGCCTGTTCACACTTCTCTCCACTTTACAGATGAAGTGGAGGCTCA   2760 
  2761 GAGAGGTTGAGACACTTGCCCAAAGTCACACAGCCAATCAGAATCGATGTCCTGAAGGCC   2820 
  2821 CAGGTGCTTCATTGCCCTTTATCCCATAGACTCAGGGGGTCCAGCTCTCTCCCTGAGGAC   2880 
  2881 CAGTAGGCATTGGACTCTCACTTCCAATCTGGCATTTCTCCCCACAGGGGCCCCTGGCAT   2940 
  2941 CCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCC   3000 
  3001 CGGCAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAAT   3060 
  3061 TAAAGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGC   3120 
  3121 CATTCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAA   3180 
  3181 CCAGGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTA   3240 
  3241 CTACTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTC   3300 
  3301 AAGGGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCA   3360 
  3361 GGTGGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAA   3420 
  3421 AGACCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTT   3480 
  3481 CCTCATCTTCCCATCTGCCTGAGCCAGGGAAGGACCCCCTCCCCCACCCACCTCTCTGGC   3540 
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  3541 TTCCATGCTCCGCCTGTAAAATGGGGGCGCTATTGCTTCAGCTGCTGAAGGGAGGGGGCT   3600 
  3601 GGCTCTGAGAGCCCCAGGACTGGCTGCCCCGTGACACATGCTCTAAGAAGCTCGTTTCTT   3660 
  3661 AGACCTCTTCCTGGAATAAACATCTGTGTCTGTGTCTGCTGAACATGAGCTTCAGTTGCT   3720 
  3721 ACTCGGAGCATTGAGAGGGAGGCCTAAGAATAATAACAATCCAGTGCTTAAGAGTCAGGC   3780 
  3781 CCGTCCTTAGTATGTTTTTTTGTTTTTTGTTTTTTAAGATGGAGTTTCTCTCTTGTCACC   3840 
  3841 CAGGCTGGAGTGCAATGGAGTGATCTTCGGTCACTGCAACCTCCGCCTCCCGGGTTCAAG   3900 
  3901 CAACTCTCCTGCCTCAGTCTCCCAGGTAGCTGGGATTACAGGTACCTGCCACCATGCCCC   3960 
  3961 GTGAATTTTTTGTATTTTTAGTAGAGAAGGGGTTTCACCATGTTGGCCAGGCTGGTCTCG   4020 
  4021 AACTCCTGACCTCAAGTGATCCTCCAGCCTTGGCCTCCCAAAGTGCTGGGATTAGAGGCA   4080 
  4081 TGTGCCACCACGCCCAGCCCATTCTTAGTATTTCACATGATGTGTTTAGCATGTCCTAGC   4140 
  4141 AGCCTCATCTACCCAGGTTCGAATCCTGATGCCACCACTTATTAGCTGTCTAATCATGTG   4200 
  4201 CATGTTAACCCAGCTCTGAGATCTCAGTTTCCTCATCTGTAAAGTGGGACTGATGATCCC   4260 
  4261 AAAGGGTCATTGGGAAGATTAAATGACTTAATATATGAAAATT  
 
..          SNP GA (no amino acid change: Gly) 
…..       Original outer primers 
…..       Original inner primers 
…..       Extensions to inner primers used by Cartron as single primers (unpublished) 
GGGCCꜜC      Potential Apa1 restriction sites  
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 Appendix 9:    C3 gene sequence – Selected section showing primer annealing and 
polymorphic sites. 
 
 12241 GAGACTCCTCCCCTTCTGAGTCCCTCCCTTCCCTGAGACCCCACCCCTTCTGAGGTTCCT  12300 
 12301 CCCCTTCTCTGAGACTCCACCCCTTCTGAGTCTCCTCCCCCTCTAAGTCCCTCCCACTGA  12360 
 12361 ATTCCTTTTCCAAGCCCCTCCCCCTCGAAGTCTCCTCTTCTGAACTCCTCCCCTCTTAGT  12420 
 12421 CTCCATCACTTTCTAAGTTCCCTCACCTGAGTCCCTCCCCCTTTCTGAGCCCCTCCCATG  12480 
 12481 TCAGCCCCTTCCCTTTCTGAGTCCCCGCCCCTTCTGAGCCCCTCCTCCTATAAGCTCTCT  12540 
 12541 CCTCCTTGTGAGCTCTTCTTTTTGAGTTCCCTCCCTGGTCCCCCCTCTCCCCTCGCACCT  12600 
 12601 CCTTCACATGCCCCTCCCTCCCCAAAACGGCCACCTCGGAAGACCAAGAATAATGGGCAG  12660 
 12661 GCAAGGAGGGACCCAGCCCAAGATCCGGAAGCTGGACCGTGGGCATGGGGCCTTGGAACA  12720 
 12721 GACCCCTGACAATGCCCTGCCCACGCCTAGATCCCAGCCAACAGGGAGTTCAAGTCAGAA  12780 
 12781 AAGGGGCGCAACAAGTTCGTGACCGTGCAGGCCACCTTCGGGACCCAAGTGGTGGAGAAG  12840 
 12841 GTGGTGCTGGTCAGCCTGCAGAGCGGGTACCTCTTCATCCAGACAGACAAGACCATCTAC  12900 
 12901 ACCCCTGGCTCCACAGGTGAGGCTGGGGGCGGCTGGAGAGGGCGGGGCACCGGCGTGGGC  12960 
 12961 GGGCTAGGGTCTCACGAGGCCTCTTTGTCTCTCCCCAGTTCTCTATCGGATCTTCACCGT  13020 
 13021 CAACCACAAGCTGCTACCCGTGGGCCGGACGGTCATGGTCAACATTGAGGTGCCAGCCAG  13080 
 13081 AGGGGGCCCCAGGGGAAGCAGGGGCACAGGCTTAGGAGAGGCAAAGAGATCGAGAGAGAC  13140 
 13141 AGAGAAAGACACACCGGAAGGGGTGCAGTGGCAGAGACACAGAGGCAAAGAGATATGCAG  13200 
 13201 ACACACACCCACACAACACACACACATACAGCACACAACATGCACACACACAGCACACAA  13260 
 13261 TACACACACAGAGGCAAAGAGATATGCAGACACATGTGCACACACAATGCACACACACAA  13320 
 13321 TGCAACACACACAAACACACAACATACACGACCACACAACACACACAACACAACACACAA  13380 
 13381 CACAATACACACAGCACAACGTGCATGACCACACACACAACACACAACACACACAACACA  13440 
 13441 ATACACAACATACACAACCACGCAATACACACAAAACACACACAACACAACACAACATAC  13500 
 
..  SNP CG (predicting ArgGly) 
..... published primers 
..... unpublished primers 
GCGꜜC Potential HhaI restriction site 
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Appendix 10: Reagents 
 
EDTA (Ethylenediaminetetraacetic acid) – a ligand and chelating agent which sequesters 
metal ions in solution, such that they are much less reactive. 
 
TBE (Tris/Borate/EDTA) - a buffer solution containing a mixture of Tris 
(trishydroxymethylaminomethane; (HOCH2)3CNH2), boric acid (H3BO3) and EDTA (ethylene 
diamine tetraacetic acid; (HO2CCH2)2NCH2CH2N(CH2CO2H)2). Tris-acid solutions are 
effective buffers for slightly basic conditions, which keep DNA deprotonated and soluble in 
water. EDTA is a chelator of divalent cations, which are necessary co-factors for many 
enzymes. 
Procedure: Add 9.3 g EDTA, 55 g Boric Acid and 108 g Tris to 1L ddH20.  Mix with a 
magnetic stirrer for about 10 minutes then put in a 10 L tank with a further 9 L of ddH2O.  
 
DTAB (Dodecyltrimethylammonium bromide) – widely used lysing reagent 
 
Trizol is a mono-phasic solution of phenol and guanidine isothiocyanate which disrupts cells 
and dissolves cellular components whilst maintaining the integrity of RNA.   
 
Chloroform 
 
Ethanol 
 
Taq 2x - QIAquick Kits contain a silica membrane assembly for binding of DNA in high-salt 
buffer and elution with low-salt buffer or water. The purification procedure removes primers, 
nucleotides, enzymes, mineral oil, salts, agarose, ethidium bromide, and other impurities 
from DNA samples 
 
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) is an organic compound 
consisting of galactose linked to a substituted indole. It is used test for the presence of an 
enzyme, β-galactosidase.  Bacteria which express β-galactosidase cleave X-Gal, leading to 
a colour change 
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Appendix 11: Results of FCGR3A-V158F polymorphism testing in patients randomised 
to arm A (watch and wait).   
 
The 87 patients were ranked according to assessed tumour bulk at baseline.  The number in 
each quartile for tumour bulk is presented here, with Q1 representing lowest bulk through to 
Q4 representing highest bulk.  
 
 Polymorphism result in 87 patients not treated with rituximab 
Tumour bulk      FF (n=39)     VF (n=38)      VV (n=10) 
Q1 10 (26%)  10 (26%)  2 (20%)  
Q2 12 (31%)  8 (21%)  2 (20%)  
Q3 8 (20%)  11 (29%)  3 (30%)  
Q4 9 (23%)  9 (24%)  3 (30%)  
 
